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The aim of this thesis was to explore the impact of the common sleep-related breathing 
disorder, obstructive sleep apnoea (OSA); specifically for people with a bipolar disorder 
(BD) diagnosis but also the wider experience of the first-line treatment for OSA, positive 
airway pressure (PAP).  
 Chapter 1 is a systematic literature review and thematic synthesis of experiences 
using PAP to treat OSA. Twenty-five papers were reviewed and included in the thematic 
synthesis. The quality of each paper was appraised and considered in relation to contribution 
to the resultant analytical themes. The metasynthesis gave voice to user experiences of PAP 
and revealed barriers to PAP use at a healthcare service level. The findings highlight the need 
for a biopsychosocial approach and long-term person-centred support to enhance PAP use.  
 Chapter 2 is a primary empirical research paper on an investigation as to whether 
people with suspected-OSA and a BD diagnosis experience more sleep and affect instability 
when “inter-episode” compared to people with a BD diagnosis alone. Ecological momentary 
assessment was utilised. Eighteen participants (twelve with suspected-OSA) wore an 
acitgraph for two weeks whilst completing an affect questionnaire twice daily. Measures of 
instability were calculated using the mean squared successive difference and probability of 
acute change indices. The groups were not found to significantly differ other than reduced 
sleep efficiency in the suspected-OSA group. However, only 48% of the intended sample was 
successfully recruited due to the COVID-19 pandemic. Important avenues for further 
research are highlighted.  
 Chapter 3 is a critical appraisal of the thesis. Salient issues relevant to future research 
and clinical practice are discussed, in addition to the under recognised clinical issue of sleep 
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Abstract 
Purpose 
Sub-optimal use of positive airway pressure (PAP) to treat obstructive sleep apnoea (OSA) continues to be a 
major challenge to effective treatment. Meanwhile, the individual and societal impacts of untreated OSA 
make effective treatment a priority. Although extensive research has been conducted into factors that impact 
PAP use, it is estimated that at least half of users do not use it as prescribed. However, the voice of users is 
notably minimal in the literature. A systematic review and qualitative metasynthesis of PAP user experience 
was conducted to contribute to understandings of how PAP is experienced and to inform how usage could be 
improved.  
Methods 
PsycINFO, MEDLINE, CINAHL and EMBASE databases were systematically searched. Primary research 
findings of adult experiences using PAP that had been inductively analysed were included. Inclusion papers 
were critically appraised using the CASP qualitative checklist to generate a “hierarchy of evidence”. 
Thematic synthesis was then conducted to generate analytical themes.  
Results 
Results are presented in accordance with Preferred Reporting Items for Systematic Reviews and Meta-
Analysis (PRISMA). 25 papers reporting on over 398 people’s experiences were analysed to generate 4 
themes: Journey to PAP, Discomfort from and around PAP, Adapting to and using PAP, and Benefits from 
PAP. Author reflexivity and vulnerability to bias is acknowledged. 
Conclusion 
This metasynthesis gave voice to user experiences of PAP, revealing barriers to PAP use at a healthcare 
service level across the world. The findings highlight the need for a biopsychosocial approach and long-term 
person-centred support to enhance PAP use.  
PROSPERO registration number: CRD42020157767 
Keywords: Obstructive sleep apnoea (OSA); positive airway pressure; experience; metasynthesis 
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Experiences of Using Positive Airway Pressure for Treatment of Obstructive Sleep Apnoea: A 
Systematic Review and Thematic Synthesis 
Obstructive sleep apnoea (OSA), the most common sleep-related breathing disorder, involves the 
upper airway repeatedly obstructing airflow during sleep. Estimated prevalence ranges from 1-19% for 
females, 2-33% for males [1–4], and up to 49% for people of advanced age [4]. OSA is linked to serious 
physical, mental, cognitive and social difficulties [5–11] and reduced sleep and quality of life for bed 
partners [12]. Many cases are believed to go unrecognised [1, 13], and prevalence is increasing as obesity is 
a significant risk factor [4, 14]. It is considered that untreated OSA doubles healthcare expenses, largely due 
to increased cardiovascular risk [15]. Effective treatment is crucial to reducing the individual and societal 
impacts [16]. However, evidence suggests that substantial barriers to effective treatment exist which 
psychological understandings may help address.  
Positive airway pressure (PAP or CPAP for continuous) is the first-line treatment for OSA [17–20]. 
Recent developments include bilevel (BiPAP), auto-adjusting and flexible PAP [21]. All involve connection 
to an air supply, covering at least the nostrils and sometimes mouth, to keep the airway inflated overnight. 
PAP can significantly reduce symptoms and improve heath outcomes for people with OSA [22–24]. 
However, whilst prescribed usage is at least 4 hours every night, it is estimated that 46-83% of users do not 
achieve this [25], referred to as a lack of “adherence” and/or “compliance”. These usage rates haven’t 
changed since the introduction of PAP in 1981 [26], presenting a significant challenge to effective OSA 
treatment.  
Suboptimal usage of PAP is not well understood. Much research focuses on biomedical factors and 
has linked usage with body mass index, OSA severity, age and blood oxygen levels [27, 28]. Meanwhile, 
some research has established links with psychological factors such as health value and beliefs, self-efficacy, 
coping strategies, low mood and perceived partner support [29–34]. Further research has also found lower 
PAP use to be associated with ethnic minority status, less education, lower socioeconomic status, living 
alone, and employment [35–40]. PAP side effects, such as mask leakage, nasal stuffiness and feeling 
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claustrophobic, also affect use [41–43]. No individual factor has been able to account for all the variance in 
PAP use [29, 44, 45], indicating the need for a biopsychosocial understanding [46].  
Previous reviews have proposed a biopsychosocial approach, advocating holistic assessment and a 
person-centred approach to identifying and addressing risks for sub-optimum use [44, 47]. There has been a 
more recent focus on person-centred care [48–51] and the development of educational and supportive 
interventions to improve PAP use [52–55]. Despite the suggested efficacy of these interventions, few have 
progressed beyond research trials as further understanding is still considered necessary to determine feasible 
and cost-effective interventions [52, 56]. Meanwhile, there is relatively little research into psychosocial 
variables that may affect PAP use [44]. A review [57] concluded that user perspectives within the literature 
are minimised by medical research paradigms of “compliance” as the ultimate outcome measure, placing 
users in a non-expert position and silencing their experiences. This review reflected the dominance of 
quantitative methodology around experiences in the PAP literature and recommended further exploration of 
qualitative user experiences to determine how PAP use can be improved.  
Therefore, a systematic review and metasynthesis of qualitative research detailing first-person 
experiences was conducted to explore what people’s reported experiences are of using PAP. To the author’s 
knowledge, this is the first metasynthesis of its kind. Synthesis of qualitative experiences make important 
contributions to healthcare innovation and policy [58]. This review aimed to increase awareness of PAP 
users’ experiences to help understandings of how to support PAP use.  
Method 
 
This review followed The Preferred Reporting Items for Systematic Reviews and Meta-Analyses 
[59] (Appendix A) and Enhancing Transparency in Reporting the Synthesis of Qualitative Research [60] 
(Appendix B) guidelines. The protocol was pre-registered on PROSPERO (CRD42020157767). 
Metasynthesis 
This metasynthesis was informed by pragmatism where the contribution of research to improving 
healthcare and people’s lives is prioritised over other considerations [61]. Thematic synthesis [62] was 
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developed to answer healthcare questions and can be used to synthesise qualitative findings generated from 
different methodologies and epistemologies. This inclusive methodology was befitting to the review’s 
multidisciplinary scope.  
Search  
 The author independently searched PsycINFO, MEDLINE, CINAHL and EMBASE databases from 
inception on January 16th 2020. The PEO framework [63], papers found through a scoping search, and 
relevant previous systematic search terms [57] informed pre-planned free-text search terms. Free-text terms 
and any relevant thesaurus terms for each PEO framework category were combined with Boolean operator 
“OR” and these groups were combined with “AND”. Table 1 depicts the full search used in MEDLINE 
alongside differing database-specific thesaurus terms and limits. Due to being the first review of its kind, no 
date limits were applied. The search strategy was developed in consultation with a subject-specific librarian.  
Insert Table 1 here 
Eligibility 
 Primary research papers reporting first-person qualitative experiences of adults (aged 18 or older) 
using PAP to treat OSA were included. As the first review of its kind, experiences were limited to adult 
users and accounts from adolescents, caregivers and partners were not included [64–66]. Included papers 
must have used an inductive analytic method as thematic synthesis involves further inductive analysis [62, 
67]. Papers also had to be in English and published in a peer-reviewed journal. Papers were excluded if (i) 
other participants (e.g. partners) contributed data and these findings were not separable; (ii) participants had 
additional health concerns/needs that are not typical of people with OSA and (iii) discourse analysis was 
used such that the results focussed on the language used rather than the experiences.  
Appraisal  
 Papers were appraised on their contribution to answering the research question using the Critical 
Appraisal Skills Programme [CASP] Qualitative Checklist [68] (Appendix C). Aligning with the proposed 
methodology for thematic synthesis [62], answers of “yes” to the CASP checklist beyond the screening 
items were considered “1 point”, generating a “hierarchy of evidence” and determining each paper’s 
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“value”. Therefore, the CASP checklist was revised to omit the question, “how valuable is this research?”. 
The “hierarchy of evidence” was used to monitor the contribution of differently appraised papers to the 
review findings. The author’s appraisal of a random subset of three papers was peer-reviewed by a trainee 
clinical psychologist.  
Data Extraction and Synthesis 
 Data extraction and analysis were conducted in keeping with thematic synthesis methodology [62]. 
All papers were entered into QSR’s NVivo 12 software. The author selected all content under 
“findings/results” within each paper and novel findings or interpretations presented elsewhere (e.g. 
discussion).  
 The author coded selected content inductively following Braun and Clarke’s principles of thematic 
analysis [69]. The “hierarchy of evidence” was consulted to ensure more poorly appraised papers did not 
largely inform final analytical themes. Analytical themes were generated by “going beyond” the primary 
findings to create novel interpretations that answered the review question [62]. 
Reflexivity 
 Prior to analysis the author noted that they had no personal experiences of PAP or close relationships 
with anyone who had. However, repeated readings of negative experiences during the literature search had 
informed an expectation to read further negative experiences. The author was mindful of this when 
conducting the metasynthesis [68, 70]. The process and emerging themes were discussed in supervision to 
minimise the influence of such expectations on the results.  
Results 
 The search retrieved 6398 papers; 586 were duplicates. The author first reviewed titles and abstracts 
against inclusion/exclusion criteria, eliminating 5,714 papers, and then a further 78 through full text review 
(eliminated papers largely reported on entirely quantitative research or were narrative reviews; see Figure 1). 
Five papers were identified through “snowballing” and “reverse snowballing” [71] using the 20 inclusion 
papers retrieved from the systematic search. 
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Insert Figure 1 here 
 
 Table 2 summarises the 25 inclusion papers. Papers S1-S3 reported on one dataset, as did V1 and V2. 
Supplementary material available with paper E was included. Table 3 details the critical appraisal outcome. 
The papers reported on over 398 people’s experiences from across the world, but largely from Western 
cultures (see Table 2). Experiences were synthesised into 2898 codes and sorted into four analytical themes: 
Journey to PAP, Discomfort from and around PAP, Adapting to and using PAP, and Benefits from PAP. 
These themes are explored with supporting direct quotations from participants. Table 4 shows the papers that 
contributed to each theme. 
Insert Tables 2-4 here 
 
Journey to PAP – The Context Into Which Diagnosis and PAP Must Be Assimilated 
 People’s experiences of PAP were relative to their experiences with OSA. Journeys to learning about 
and acquiring PAP were often difficult and long.  
Difficulties Before PAP 
 Prior to PAP, participants’ fatigue impacted their social life, relationships, mood, and functioning. 
Some slept poorly and disturbed bed partners. Apnoeas could be traumatic and stressful for the whole 
family. Similar symptoms affected participants differently but difficulties motivated participants to seek 
help.   
Delays to Getting Treatment 
 A lack of public and professional awareness caused delays. Participants received misdiagnoses and 
misattribution of their fatigue, “The answer I got was: ‘It is because you are going to an all girl school.’” (P, 
p.187). General Practitioners’ unawareness made sleep service referrals inaccessible and only possible 
through specialists. Services also felt inaccessible due to long waiting times, no transparent funding routes, 
and existing tiredness.  
Participants were also largely unaware of OSA. Snoring was embarrassing to talk about, particularly 
for females, and OSA was difficult to recognise without the testimony of loved ones. Some people denied 
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having a problem due to the stigma of snoring and being overweight, not believing others or avoiding the 
consequences, “I don’t need a doctor, I don’t need to bill this to my insurance.” (I, p.53). Some participants 
suffered for up to 30 years and were often encouraged to seek help by others.  
Experiences of Assessment and Diagnosis 
Some participants found their referral and assessment satisfactory. Others were too uncomfortable on 
their diagnostic night to sleep much, and felt staff lacked skills and confidence, which made them question 
their diagnosis. The OSA diagnosis was a surprise for some and experienced as threatening, “He [the MD] 
really scared me.” (M, p.1240). Despite fears, taking on PAP was not a decision made lightly and sometimes 
partners influenced choices. Some people struggled with the trial and recommended that a better fitting mask 
and humidifier would increase comfort.  
Discomfort From and Around PAP – Affects Relationships, Generating More Discomfort and 
Affecting PAP Use 
 The discomfort accompanying PAP affected multiple relationships, including the users’ relationship 
with PAP. 
Relationship With PAP  
PAP was described as uncomfortable. The mask was a common complaint due to poor fit and 
difficulties adjusting, resulting in noisy air leaks. “The first six months or so was challenging. . . (…) it was 
all to do with the masks” (S1, p.375). The straps, tube and pressure were also uncomfortable; some felt hot 
or unable to breathe. PAP was described as a foreign body unable to synchronise with the human body, “like 
having a Hoover on backwards and someone's shoved the hose in your mouth.” (S3, p.8). Some removed 
PAP during the night due to discomfort whilst others discontinued altogether.  
 PAP negatively impacted users’ bodies, causing dry/sore/bleeding airways, congestion, irritated eyes, 
aerophagia, facial sores/swelling, and back pain. Meanwhile, PAP was reported to be more uncomfortable 
psychologically. Fears of the machine and mask, being unable to breathe and claustrophobia were barriers. 
Participants also felt foolish and humiliated by PAP. 
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 PAP was not an ideal solution, especially as participants were already struggling with OSA 
symptoms, “[The diagnosis] didn’t bother me all that much until I got the machine” (K, p.1725). Some 
desperately sought alternative solutions, “If there were anything that could be done to be free of that 
machine, I’d do it right now” (I, p.54). Participants were reluctant to accept a lifelong solution over a cure 
and expressed anger at the medical profession for not developing something better.  
PAP was not always felt to be worth the discomfort and was abandoned, “It’s a no-win battle.” (I, 
p.54). Some hoped that PAP would reduce symptoms and improve quality of life. However, some did not 
experience this benefit, or not to the extent they had imagined or experienced from the trial. Others were 
conflicted; some were unsure of the benefit or their need for PAP and found reasons not to use it. Others 
struggled to accept the device, experiencing a “love hate relationship” (H, p.145), or were grateful for the 
benefits but not happy with PAP, despite feeling they shouldn’t complain.  
 Relationship With Life 
The addition of PAP was “extraordinarily intrusive” (B, p.233), impacting on both users and 
partners. Cleaning PAP was described as “a pain in the butt” (D, p.245). The necessary daily ritual was an 
obstacle to every day life; participants missed being able to just “go and jump into bed” (G, p.117) and fall 
asleep reading. The mask was annoying to apply and reapply if the user got up in the night.  
 Difficulties travelling with PAP restricted freedom. Users have to consider transporting PAP safely 
and accessing a compatible electricity supply. Some people avoided moving PAP, reducing their 
independence.  
 Lastly, PAP is expensive. For some, the cost exceeded their average monthly salary. Participants 
were “burdened” (J, p.274) by the expense and lack of support from insurance and public health systems. 
Having to consider the cost of replacing the device if necessary further reduced financial freedom.  
 Relationship With Self 
PAP required users to adapt their identity, often towards one they stigmatised. For some, they shifted 
towards feeling disabled. The lifelong support was likened to a prosthesis or assistive technology, making 
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OSA a visible disability. The lifelong nature also made participants feel old and unwell. Some knew older 
people who used PAP. The device resembled hospital equipment and wearing it at home felt like losing 
control as a submissive patient, “Makes you think I am sicker, in the ER or a nursing home” (U, p.7). Others 
struggled to identify as having OSA due to perceptions that OSA only affects overweight men. Women 
reported feeling less feminine due to snoring and PAP, “we’re supposed to be dainty when we sleep” (I, 
p.54). 
  PAP users felt unattractive in the bedroom, a place where some wished to feel desirable. Others “felt 
ashamed” (L, p.77) or “ridiculous” (F, p.247) and angry with themselves for needing PAP. Moreover, they 
felt guilty for unconsciously removing PAP during the night, forgetting, or struggling to use it, “I tried and 
tried and I just couldn’t make the grade.” (H, p.145).  
 Relationship With Others 
Users described being embarrassed and caring what others thought, especially partners, “I have to 
make sure that all the lights are off, (…) It makes me very, very uncomfortable” (B, p.233). Users worried 
PAP made them scary or unattractive, “You don’t start a relationship with somebody because of the CPAP.” 
(E, supplementary material). PAP impeded intimacy and co-sleep with bed partners, deterring use, “It’s had 
an impact on our relationship; you’ve got a frickin’ snorkel thing across your marriage bed” (I, p.54). Some 
users “didn’t want anybody to see” (Q, p.323) and kept PAP secret. Others shared their PAP use but 
experienced stigma and ridicule, feeling they had to join in the mockery of themselves to fit in. 
 Relationship With Sleep 
Some participants felt PAP prevented sleep from being a “refuge from the burden of life” (V2, 
p.232). For some this was because it is “not natural to wear something to sleep” (J, p.273) and “proper sleep” 
(S3, p.7) could only be achieved without the restrictions of PAP. PAP also demanded a different sleeping 
position and sometimes interrupted rather than improved sleep, “I spend a lot of my night doing these little 
adjustments” (A, p.662).  
Adapting To and Using PAP – A Journey Not Destination 
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 This theme illustrates the journey of adapting to PAP and how support is crucial.  
Importance of Support and Information 
Reports illustrated the importance of professional and personal support to adapting to PAP. The 
benefit of contact with the PAP community was similar across different opportunities. Participants felt part 
of an encouraging community whilst they learned from others’ experiences and had their difficulties 
normalised. Experienced users wished to help others, “I would really like to be part of something that might 
prevent other people from going through what I have” (P, p.189) and did so through being a role model, 
promoting PAP, and encouraging self-advocacy, “Don’t feel that it’s your fault. Get it straightened out” (G, 
p.118).  
Some participants found support came from people around them. Working “together as a couple” (U, 
p.5) to integrate PAP, absence of a negative reaction, and reassurance was described as helpful. Others 
described a lack of encouragement, assistance and support as being barriers to use, alongside conflicted 
priorities and partner scepticism, “It’s not easy to counter the effect of your wife saying, ‘[CPAP] is not 
going to work for you!’” (B, p.233). 
 Helpful professional relationships involved trust, consideration and dependability. Participants 
stressed the benefits of a straightforward accessible process, ongoing support, sufficient information, and 
“the possibility to try the CPAP at the hospital.” (E, supplementary data). This support provided relief and 
facilitated acceptance and integration of PAP. Information on both OSA and PAP was reported to be 
powerful in equipping people, “gave me a strong motivation and I think I was comfortable and well prepared 
to meet all possible problems.” (D, p.108). 
Individualised care and sufficient provision were commonly lacking. Participants struggled to use 
PAP without information on OSA, PAP and how to access support. Follow up support was often unavailable 
or inaccessible due to working hours and staff availability. Some found providers unknowledgeable, which 
led some to view PAP as “just another way for the medical establishment to make money.” (P, 188).  
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“When I first went to get the machine, unfortunately it’s a salesman talking to you.… So I had to sit 
and listen to an hourlong sales spiel.... I’m going—okay just tell me how to use the machine.… I 
didn’t even get a manual. I called a few times, and they had to call you back because they are 
salespeople; you get lost and overlooked.” (F, 246) 
Meanwhile, insurance companies were unwilling to pay for PAP creating the impression that some people 
“just have apnoeas and die” (H, p.143). Participants felt alone and unable to request help. Users 
recommended that services be personalised and provide more information, coordinated care, and a chance to 
try different equipment. Follow up support was deemed necessary for empowerment and assistance with 
inevitable difficulties, “I wanted to know how I was doing. (…) why doesn’t somebody call me and say, 
‘You’re doing pretty good, lady. You’re keeping this thing on for eight hours.’” (L, p.78).   
Effort Necessary to Adapt 
Adapting to PAP was described as “trial and error” (S1, p.375). Trialling the benefits, creative 
problem solving and “learning by doing” (M, p.1240) occurred in the absence of professional support. Some 
users sought additional information on PAP through online research, support groups and family and friends. 
Users became experts in their own care by learning how to maintain, adapt and repair their machines, 
monitor their OSA and self-advocate, “I am battling the insurance company because they are saying I 
shouldn’t have one [CPAP].” (F, p.247).  
PAP required compromise. The home environment was adapted; from buying a bedside table to 
drilling a hole in the wall so the machine could live in the next room. Users’ bodies also had to compromise: 
“I trained myself to sleep on my back and hold the hose with my left hand so it doesn’t move.” (G, p.118). 
Meanwhile, partners had to compromise alongside users, “This hoover-head made the wrong choice buying 
a bed. (….) We literally wake up sore in the morning!”. (O, p.106).  
Users also had to “stay with it.”(G, p.118). Perseverance was important to grow accustomed, time is 
required to establish PAP as routine, “Persevere for a while, and then you'll get used to it and then you won't 
ever want to be without it.” (S3, p.8).  
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Attitude, Belief and Context 
PAP use was initially influenced by mindset but then by the journey of adaptation. Acceptance 
seemed key to use, mostly through accepting the compromise, “hideous, but you feel more hideous if you 
don’t use it.” (S1, p.375). Some accepted the compromise through “relief that we were finally going to get 
something done” (C, p.226). Others were desperate and willing to do and “pay for anything that would 
help.” (A, p.664). Some reported to “accept it [the CPAP] with love.” (V2, p.230) and encouraged others’ 
acceptance by telling them about PAP, “I’m not ashamed anymore, (…) I tell as many people as I can” (C, 
p.226).  
Humour was depicted to buffer some discomfort, “My grandchildren have seen me in mine, and I’m 
not the slightest bit worried...I gave them very clear instructions about ‘grandpa’s elephant nose!’” (H, 
p.145). This buffering perhaps resembles acceptance, but it might be unhelpful for some, “he tries to make 
light by cracking jokes, but it doesn’t necessarily make me feel any better” (S2, p.85). Avoidance over 
acceptance seemed a barrier to use. Some participants felt their OSA wasn’t as bad as others’, that losing 
weight would be better than PAP, or were sceptical about PAP’s importance, “you just think of it as a 
snoring thing. You don’t think of it as, I’ve got cancer and I’m going to die” (Q, p.322).  
 Some believed in PAP, “I was sure that it should work, and it does.” (E, supplementary data) and 
others were committed regardless, “there was no way around it, it was just getting on with it” (M, p.1240). 
Many used PAP as protection from negative social, vocational or physical health consequences, such as 
losing their driver’s license. Others were not motivated for themselves but wanted to benefit others, “If you 
love her [the partner], use it.” (U, p.7). Positivity, confidence, and the users’ belief in their abilities also 
helped PAP use. Ultimately, context influenced users’ motivations and attitudes, which were susceptible to 
change.  
PAP Use a Journey Not Destination 
Participants portrayed PAP use as an evolving relationship, not an end to suffering. Most papers 
reported all early experiences to be difficult, regardless of outcome. PAP use was a battle not always won. 
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Some participants had managed to grow accustomed to PAP despite challenges, and some were still 
struggling. Even after the battle, PAP use was fluid not fixed; even committed users reported exceptions, “If 
I am going someplace special, I will just not wear it that night.” (F, p.247). Others seemed uncertain about 
their commitment and deciding daily felt more comfortable than lifelong commitment. Few people were 
fully satisfied with PAP. Users described continually evaluating their compromise and potentially changing 
their minds. Non-users also reported ambivalence, with some reporting big fluctuations in their usage over 
time.  
Meanwhile, PAP experience changed over time. Small changes for the user or machine affected the 
relationship. Changes in PAP due to repair or replacement required a process of readjustment. Meanwhile, 
“so many different issues” (H, p.145) affected sleep. Changes in peer group opinion and other health 
conditions also impacted use. Assessment of ongoing needs was indicated; the benefits of PAP receded for 
some whilst others were unsure of their continued need for PAP after losing weight. 
However, PAP was sold as a destination rather than a journey. Device settings were fixed and not 
reviewed. As bodies are not fixed entities, users tried to adjust their equipment to fluctuating needs and 
struggled to use devices that no longer helped. Usage was monitored but not users’ experience or mental 
wellbeing, “I have to send it [compliance card] to make sure you use it like a big brother; I don’t like being 
watched.” (F, p.247). Even the information provided portrayed a ‘one size fits all’ solution:  
“there wasn’t a lot of personal stuff in there, like people that have actually used machines. So when I 
was on the net I was just basically looking at people’s experiences with the machines and their own 
journeys with it.” (Q, p.322) 
Participants proved largely autonomous in their care, wished to be more involved in treatment decisions and 
wanted to work towards personal goals rather than optimal usage, “We [people with OSA] cannot be 
pigeonholed. Each of us has to be looked at as an individual.” (P. p.191).  
Desired Outcomes 
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Some participants described PAP becoming “a ritual and a new normality, almost like brushing your 
teeth” (M, p.1240). This seemed a comfortable position, suggesting some users may reach a desirable 
destination. Some reported, “there aren’t really any difficulties with the machine. It’s really too easy.” (B, 
p.233). This report’s contrast to others highlights how influential context is, and perhaps how an easy PAP 
experience is expected, “I don’t understand anybody that doesn’t do good on it because it makes you feel so 
much better.” (K, p.1726). 
Benefits From PAP – Engender Motivation and Positive Relationships With PAP 
 Most papers reported benefits that motivated use and facilitated a positive relationship with PAP.   
PAP Effects on OSA 
PAP relieved snoring, apnoeas and daytime sleepiness, bringing OSA “under control” (S1, p.374). 
Participants described a better quality of sleep that was more satisfying and refreshing for them and their 
partners, “Now in the mornings, it’s so much easier to get up” (L, p.77). Some hadn’t fully appreciated their 
symptoms before and noticed a real difference when they didn’t use PAP. Users felt more alert, “I’m safe on 
the road now” (Q, p.323) and energetic which helped them reduce lifestyle contributors to OSA, “I’m in the 
gym, losing weight” (C, p.225).  
PAP Effects on Wider Life 
The benefits generated a “better quality of life” (U, p.5). It was “nice to be able to go to places and 
not have to worry about falling asleep.” (B, p.233). Physical and psychological wellbeing improved. 
Participants reported feeling less irritable and anxious and more “able to relax” (T, p.169). Some felt PAP 
had returned them to their former selves. PAP reportedly “helps the whole house” (C, p.225) through 
improving sleep, mood and relationship quality. Some couples were able to sleep in the same room again. 
Relationship of Improvements to PAP Use 
Benefits motivated use, “you get a much better life.” (M. p.1240). Some experienced immediate and 
notable differences, “I haven’t felt this good in years. It was like night and day; it saved my life.” (G, 117). 
Maintaining PAP use was harder alongside subtle improvements, unless these matched expectations, “I 
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wanted to keep trying because he had told me it might take a while, and then I did notice gradual changes.” 
(F, p.246). 
Bonded to PAP 
Different bonds motivated PAP use. Some reported to “depend on it” (J, p.276) and would take it 
when travelling. PAP was trusted to keep users well and provided a sense of hope, “I feel so secure with it” 
(C, p.225). Others found PAP “soothing” (K, p.1728) and felt thankful for the benefits.  
Discussion 
 The findings highlight the applicability of a biopsychosocial understanding to PAP use. The theme 
“Journey to PAP” depicts biological influences. Participants largely struggled with OSA symptoms but had 
difficulty obtaining the diagnosis or wouldn’t seek help; consistent with findings of an average of up to ten 
years between symptom onset and diagnosis [72, 73]. Limited public and professional awareness presented a 
barrier. Findings suggest symptom severity influences PAP use more than OSA severity [25]. Perhaps 
people experiencing greater symptoms are more motivated to overcome barriers to acquire and use PAP.  
 The theme “Discomfort from and around PAP” emerged from prevalent reports that PAP generates 
psychological as well as physical discomfort [41, 42], impacting use. PAP use required an often-
uncomfortable shift in identity, generating stigma from individual and cultural prejudices. Older age is 
associated with PAP use [74], potentially reflecting higher acceptability of lifelong treatment in later life. 
The stigma experienced by PAP users from themselves and others is not well documented [75, 76] and 
warrants further research as stigma is known to impact other treatments [77–79].  
 People who have not tried PAP report wanting to avoid reliance [80]. However, users depicted 
dependence as a positive bond within “Benefits of PAP”, highlighting the role of psychological factors such 
as attitude and belief within “Adapting to and using PAP”. Early attachment patterns may influence 
relationships with healthcare services [81] and may similarly affect relationships with PAP, perhaps 
explaining why dependence is soothing for some and avoided by others. Such psychological influences on 
PAP use are conceivably complex and require further research.  
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 Benefits were infrequently reported and highlighted the influence of expectation. Some experienced 
drastic changes from PAP use, which outweighed any discomfort experienced. It is possible that these ideal 
yet infrequent experiences have informed expectations. Subtle changes were less motivating, highlighting 
the importance of realistic expectations and ongoing professional input.   
The users’ social context was also reported to affect PAP use. Support was overwhelmingly cited as 
important. Most accounts suggested that services provided little initial and ongoing support, meaning PAP 
use relied on the individual or their personal networks. Information on OSA and PAP emerged as crucial. 
Research suggests that professionals underestimate the importance of information and overestimate the 
impact of side effects [82]. These findings suggest that professionals may overemphasise discomfort at the 
expense of other information, potentially increasing user experience of discomfort through confirmation bias 
[83]. Moreover, it may reflect professional beliefs, similar to the current findings of user frustration, that 
PAP is not an ideal solution and warrants further research. 
Some included studies enabled participants to connect with other users. Group sessions were 
recommended as helpful whilst experienced users wanted to help others use PAP. Connecting users is an 
inexpensive way for services to provide ongoing support. Moreover, the benefit reported of involving people 
around the user in PAP treatment, particularly considering their role in initially recognising OSA, supports 
other findings [64, 84]. Again, it is a low-cost solution to utilise existing support networks. Meanwhile, it 
may provide services the opportunity to understand and mitigate personal relationship difficulties that the 
current findings, alongside others, suggest hinder PAP use [34, 85].  
However, services should not rely on personal networks to support users. Although personal support 
was largely reported as readily available, participants’ PAP usage was still reported as suboptimal, 
suggesting sufficient professional support is also imperative. The findings also suggested that PAP is sold to 
users as a destination whilst user experiences conveyed a lifelong journey that is especially difficult in the 
early stages. To assist this journey, participants described needing ongoing support and wanting to share 
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decision-making, goals and monitoring around their treatment. The focus on objective PAP use was 
experienced as impersonal and unhelpful.  
The needs highlighted here match The World Health Organisation’s 2003 recommendations on 
working collaboratively with people and their families to support long-term treatment use [86]. The 
recommendations detail that users should not be blamed for non-optimal use and that service level factors, 
such as absent holistic ongoing support, have a major effect. However, the PAP literature continues the user 
blaming narrative, despite the emergence of research discrediting focus on objective measures of use [87–
89]. PAP use is considered to threaten the reputation of sleep medicine and the utility of OSA as a diagnosis, 
making investment towards supporting PAP use crucial [90].   
Given the reported role of acceptance, it is thought that Acceptance and Commitment Therapy (ACT) 
[91] principles may help contextualise PAP use as supportive of user values. ACT is an evidence-based 
biopsychosocial approach used to support management of other long-term conditions [92]. However, as PAP 
use is an individual, context dependent, lifelong journey, no supportive or educational interventions will 
likely be effective for all PAP users at once. Instead, users may benefit from a range of support across their 
lifetime. Therefore, PAP services should expand the information and support available, making use of a 
range of evidence-based interventions [52–55, 93, 94] and facilitate collaborative decisions, goals and 
monitoring between professionals, users and their networks [95]. 
Despite reflexive efforts to reduce bias within the findings and interpretations, all systematic reviews 
contain bias, particularly those conducted by one author [96]. Whilst experiences of PAP seemed fairly 
consistent across different countries and healthcare systems, the White British author may have incorrectly 
interpreted different cultural experiences. Seven papers contained translated experiences, increasing 
opportunities for misunderstanding and misrepresentation. Many papers had only recruited current PAP 
users, potentially reducing the inclusion of more difficult experiences of PAP. Meanwhile, the current 
review excluded narratives of significant others. Based on the reported role of others in recognising OSA 
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and supporting PAP use, future research is recommended to include these perspectives to corroborate and 
enhance the current understandings. 
This metasynthesis hoped to address the absence of user’s voices within the PAP literature. The 
findings support a biopsychosocial conceptualisation of PAP use and highlight the limitations of the 
literature’s emphasis on individual factors. Collaborative, person-centred and holistic ongoing support is 
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Tables and Figures in Order of Reference in the Paper 
Table 1 
Full Search Strategy for MEDLINE Database and Database Specific Alternatives 
Database: MEDLINE Search fields 
Population 





MeSH terms “Sleep Apnea, Obstructive” N/A 
                           AND 
Exposure 
Free text keywords positive airway pressure OR CPAP OR BiPAP OR 
(obstructive sleep apnoea OR OSA) N4 (treatment) OR 




MeSH terms “Continuous positive airway pressure” N/A 
                            AND 
Outcome 
Free text keywords experience* OR preference* OR report OR perspective* 
OR perception* OR influenc* OR barrier* OR facilitator* 
OR acceptance OR choice* OR attitude* OR adapt* OR 
cop* OR point of view* OR opinion* OR qualitative OR 
narrative* OR grounded theory OR focus group OR 
theme* OR thematic 
Title OR 
abstract 
MeSH terms “Treatment Adherance and Compliance+” N/A 
Limits applied Journal article, English language and Human 
Database specific alternatives to above search strategy 
Database  Thesaurus terms used Limits applied 
PsycINFO 




O: “Client Attitudes” 
CINAHL 
P: “Sleep Apnea, Obstructive” Journal article  
English language  
Human 
E: “Continuous Positive Airway Pressure” 
O: “Patient Satisfaction+” OR “Patient Compliance+” 
EMBASE 
P: “exp sleep disordered breathing” Article 
English language  
Human 
E: “exp positive and expiratory pressure” 
O: “exp patient attitude” OR  “exp patient compliance” 
* denotes a truncation 
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Figure 1 
PRISMA Flow Diagram [59]  
6398 papers identified 
through database searching 
PsycINFO = 364, MEDLINE 
= 2,766, CINAHL = 586, 

























7 additional papers 
identified  
586 duplicates removed 
5812 papers screened by 
title and abstract 
 
5,714 papers excluded 
 
98 full-text articles assessed 
for eligibility 
78 papers excluded 
Entirely quantitative papers, n=44 
Narrative reviews, n=16 
Not empirical papers, n=4 
Experiences around PAP intervention programme only, n=3 
Health needs not typical of OSA population, n=3 
Deductive analyses, n=3 
Full-text not available in English, n=2 
Discourse analysis, n=1 
No qualitative analysis conducted, n=1 






25 total papers included in 
metasynthesis 
 
20 full-text papers included 
in the metasynthesis 
2 papers excluded  
 Full-text not available in 
English, n=1 
Not qualitative analysis, n=1 
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Table 2 





Data provided on participants with first-hand 




































What are the experiences of CPAP and oral appliance 
users? 















Thematic analysis What are the perceived factors that facilitate CPAP use? 
What are the perceived factors that prevent CPAP use and 
















Focus groups Thematic analysis What are Maori, Pacific and New Zealand European 







1 1 male 33 92 40 Semi-
structured 
interview 
Phenomenographic What are the experiences of CPAP treatment of a young 














Content analysis What are the in-depth experiences associated with 
adherence to CPAP treatment in patients with OSA? 
 


















What are the experiences of individuals with 
sleep apnoea who use CPAP devices from diagnosis to 3 
months?  
What is the usefulness and appropriateness of the Calgary 
sleep apnea quality of life 





















What are the support group experiences of individuals with 














Focus groups Thematic analysis What is the experience of diagnosis and management of 
OSA for older patients? 
What are the factors affecting acceptance of the current 














Content analysis What is the significance of gender and partner-reporting in 















Grounded theory What are OSA patients’ feelings and perceptions in dealing 















Thematic analysis What are OSA patients’ preferences, partner experiences, 
barriers and facilitators to PAP adherence? 
What is the understanding of the educational content 











Focus groups Content analysis What are both patients’ and partners’  
experiences of CPAP and the facilitators and barriers to 





















Narrative analysis How do patients with 


































Analytic induction How do users establish and maintain workable 
relationships between CPAP and other 

















Interviews Grounded theory What are the experiences of individuals 

















Thematic analysis What are the experiences of people with OSA, who have 
sourced their CPAP supply through a pharmacy? 
 
R 
















Grounded theory How do clients' experiences of sleep studies 













Grounded theory What are experiences of living with continuous positive 
airway pressure? 



















Grounded theory What is it like to live with CPAP 






























Content analysis What are personal experiences with CPAP in individuals 

















Content analysis What are couples’ experiences with CPAP treatment? 
What are the facilitators and barriers to incorporating 




































Grounded theory What happens to agency in the context of sleep? 
How is agency exchanged from body to technology in 
sleep? 
aTwo averages are given when average age is presented for two separate groups (e.g. males and females), not the entire participant cohort.  
bApnoea hypopnea index (AHI) is used as a measure of OSA severity, it indicates the average number of apnoeas (cessation of breathing) and hypopneas 
(partial cessation of breathing) for >10 seconds per hour of sleep. 5-14 is considered mild, 15-30 moderate and 30+ severe OSA [118].  
cA body mass index (BMI) of above 35 kg/m2 is considered a risk indicator for OSA [14]. 
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Table 3 
Results of Critical Appraisal  
  Paper 
CASP Question A B C D E F G H I J K L M N O P Q R S1 S2 S3 T U V1 V2 
Was there a clear statement of the aims of 
the research?  
 
Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y 
Is a qualitative methodology appropriate?  
 
Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y 
Was the research design appropriate to 
address the aims of the research? 
 
1 1 0* 1 1 1 0* 1 0* 1 1 1 1 0* 1 1 1 1 1 1 1 1 1 1 0* 
Was the recruitment strategy appropriate to 
the aims of the research? 
 
1 1 1 1 1 0* 1 1 0* 1 0* 1 1 0* 1 0* 1 1 1 1 1 0* 1 1 0* 
Was the data collected in a way that 
addressed the research issue? 
 
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
Has the relationship between researcher and 
participants been adequately considered? 
 
0 0 0 0 0 0 0 1 0 1 0 1 1 0 0 0 0 1 0 0 0 0 0 1 0 
Have ethical issues been taken into 
consideration? 
 
1 1 1 1 1 0* 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
Was the data analysis sufficiently rigorous? 
 
1 1 1 1 1 1 1 1 0* 1 1 1 1 0* 1 1 1 1 1 1 1 1 1 1 1 
Is there a clear statement of findings? 
 
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
Total score  6 6 5 6 6 4 5 7 3 7 5 7 7 3 6 5 6 7 6 6 6 5 6 7 4 
Note. A score out of 7 was assigned to each article based on the number of criteria it met beyond the first two screening criteria (which all articles met). 
No value was assigned for criteria where the answer was either “no” or “can’t tell”. 1 indicates an answer of “yes”, 0* indicates an answer of “can’t tell” 
and 0 indicates an answer of “no”. 
 
 




Contribution of Papers to Each Analytical Theme and Subtheme  
    Paper 
Theme/subtheme A B C D E F G H I J K L M N O P Q R S1 S2 S3 T U V1 V2 
Journey to PAP X X X X X X X X X X X X X  X X X X X X X X X X X 
Difficulties before PAP X X   X X X X X X  X X   X X X X X X X  X X 
Delays to getting treatment   X  X X X X X X X X X   X X X X X X  X X X 
Experiences of assessment and diagnosis X X  X X   X  X   X    X X X  X    X 
Discomfort from and around PAP X X X X X X X X X X X X X X X X X X X X X X X X X 
Relationship with PAP X X X X X X X X X X X X X X X X X X X  X X X X X 
Relationship with life X X X X X X X X X X X X X  X  X X X   X X X X 
Relationship with self  X X X X X X X X  X X X  X X X X X X  X X X X 
Relationship with others X X X X  X X X X  X X X   X X  X X  X X X X 
Relationship with sleep X X  X X X X X  X X X   X X  X X  X  X X X 
Adapting to and using PAP X X X X X X X X X X X X X X X X X X X X X X X X X 
Importance of support   X X X X X X X X X X X X X X X X X X X X X X X  
Attitude, belief, and context X X X X X X X X X X X X X X X X X X X X X X X X X 
Effort necessary to adapt X  X X X X X X  X X X X X X X X X X X X X  X X 
PAP use a journey not destination X X X X X X X X X X X X X X X X X X X X X X  X X 
Desired outcomes  X X X  X X X  X X X X X X  X  X X X X    
Benefits from PAP X X X X X X X X X X X X X  X X X X X X X X X X X 
PAP effects on OSA  X X X X X X X X X X X X  X  X X X X X X X X X 
PAP effects on wider life X X X X X X X X X X X X X   X  X X X X X X  X 
Relationship of improvements to PAP use X  X X X X X X X X X X X   X X X X  X X X X X 
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Appendix D 
Submission Guidelines (Instructions for Authors) for Sleep and Breathing  
Instructions for Authors 
Types of Articles 
SLBR publishes articles in different categories: 
• Original research – with a maximum length of 3000 words, 8 figures and/or tables, and 
not more than 30 references. Abstracts (mandatory) must be structured and have a 
maximum length of 250 words. 
• Editorials – with a maximum length of 1500 words, 2 figures and/or tables, and not 
more than 10 references. 
• Review and series articles – with a maximum length of 5000 words, 5 figures and/or 
tables, and not more than 150 references. Abstracts (mandatory) have a maximum 
length of 250 words. 
• Short communications – with a maximum length of 1,500 words, and 4 figures and/or 
tables. Abstracts (mandatory) have a maximum length of 250 words. Short 
communications must focus on timely and significant findings. Sleep and Breathing is 
not currently considering the publication of case reports. 
• Letters to the editor - with a maximum length of 1200 words, 1 figure and/or table, 
and not more than 5 references. 
Please note: 
• Case Reports – the journal will implement an open call for case reports in the future, 
however please note that currently Sleep and Breathing does not consider case 
reports. Authors may wish to consider submitting their case reports to the Journal of 
Medical Case Reports or to SN Comprehensive Clinical Medicine. 
• Abstracts for Original Articles and Short Communications must be 150 to 250 words 
in length and structured with the following sections: Purpose (stating the main 
purpose and research question); Methods; Results; Conclusions. 
Meta-analyses and systematic reviews 
Must follow PRISMA guidelines (interventional research) , or MOOSE guidelines 
(observational studies). Authors must confirm that their manuscript adheres to the relevant 
guidelines during the submission stage. Manuscripts deemed not to adhere to the guidelines 
will be returned to the author immediately. 
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Editorial Procedure 
If you have any questions please contact: 
• Editors-in-Chief 
Arn H. Eliasson (USA and Rest of World) 
aheliasson@aol.com 
Thomas Penzel (Europe) 
thomas.penzel@charite.de 





Submission of a manuscript implies: that the work described has not been published before; 
that it is not under consideration for publication anywhere else; that its publication has been 
approved by all co-authors, if any, as well as by the responsible authorities – tacitly or 
explicitly – at the institute where the work has been carried out. The publisher will not be 
held legally responsible should there be any claims for compensation. 
Permissions 
Authors wishing to include figures, tables, or text passages that have already been published 
elsewhere are required to obtain permission from the copyright owner(s) for both the print 
and online format and to include evidence that such permission has been granted when 
submitting their papers. Any material received without such evidence will be assumed to 
originate from the authors. 
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Online Submission 
Please follow the hyperlink “Submit online” on the right and upload all of your manuscript 
files following the instructions given on the screen. 
Please ensure you provide all relevant editable source files. Failing to submit these source 
files might cause unnecessary delays in the review and production process. 
Title page 
Title Page 
Please use this template title page for providing the following information. 
The title page should include: 
• The name(s) of the author(s) 
• A concise and informative title 
• The affiliation(s) of the author(s), i.e. institution, (department), city, (state), country 
• A clear indication and an active e-mail address of the corresponding author 
• If available, the 16-digit ORCID of the author(s) 
If address information is provided with the affiliation(s) it will also be published. 
For authors that are (temporarily) unaffiliated we will only capture their city and country of 
residence, not their e-mail address unless specifically requested. 
Abstract 
Please provide a structured abstract of 150 to 250 words which should be divided into the 
following sections: 




For life science journals only (when applicable) 
Trial registration number and date of registration 
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Trial registration number, date of registration followed by “retrospectively registered” 
Keywords 
Please provide 4 to 6 keywords which can be used for indexing purposes. 
Declarations 
All manuscripts must contain the following sections under the heading 'Declarations'. 
If any of the sections are not relevant to your manuscript, please include the heading and 
write 'Not applicable' for that section. 
To be used for non-life science journals 
Funding (information that explains whether and by whom the research was supported) 
Conflicts of interest/Competing interests (include appropriate disclosures) 
Availability of data and material (data transparency) 
Code availability (software application or custom code) 
Authors' contributions (optional: please review the submission guidelines from the journal 
whether statements are mandatory) 
To be used for life science journals + articles with biological applications 
Funding (information that explains whether and by whom the research was supported) 
Conflicts of interest/Competing interests (include appropriate disclosures) 
Ethics approval (include appropriate approvals or waivers) 
Consent to participate (include appropriate statements) 
Consent for publication (include appropriate statements) 
Availability of data and material (data transparency) 
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Code availability (software application or custom code) 
Authors' contributions (optional: please review the submission guidelines from the journal 
whether statements are mandatory) 
Please see the relevant sections in the submission guidelines for further information as well 
as various examples of wording. Please revise/customize the sample statements according to 
your own needs. 
Text 
Text Formatting 
Manuscripts should be submitted in Word. 
• Use a normal, plain font (e.g., 10-point Times Roman) for text. 
• Use italics for emphasis. 
• Use the automatic page numbering function to number the pages. 
• Do not use field functions. 
• Use tab stops or other commands for indents, not the space bar. 
• Use the table function, not spreadsheets, to make tables. 
• Use the equation editor or MathType for equations. 
• Save your file in docx format (Word 2007 or higher) or doc format (older Word 
versions). 
Manuscripts with mathematical content can also be submitted in LaTeX. 
LaTeX macro package (Download zip, 188 kB)  
Headings 
Please use no more than three levels of displayed headings. 
Abbreviations 
Abbreviations should be defined at first mention and used consistently thereafter. 
Footnotes 
Footnotes can be used to give additional information, which may include the citation of a 
reference included in the reference list. They should not consist solely of a reference 
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citation, and they should never include the bibliographic details of a reference. They should 
also not contain any figures or tables. 
Footnotes to the text are numbered consecutively; those to tables should be indicated by 
superscript lower-case letters (or asterisks for significance values and other statistical data). 
Footnotes to the title or the authors of the article are not given reference symbols. 
Always use footnotes instead of endnotes. 
Acknowledgments 
Acknowledgments of people, grants, funds, etc. should be placed in a separate section on the 
title page. The names of funding organizations should be written in full. 
Scientific style 
Please always use internationally accepted signs and symbols for units (SI units). 
References 
Citation 
Reference citations in the text should be identified by numbers in square brackets. Some 
examples: 
1. Negotiation research spans many disciplines [3]. 
2. This result was later contradicted by Becker and Seligman [5]. 
3. This effect has been widely studied [1-3, 7]. 
Reference list 
The list of references should only include works that are cited in the text and that have been 
published or accepted for publication. Personal communications and unpublished works 
should only be mentioned in the text. Do not use footnotes or endnotes as a substitute for a 
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One quarter of people with a bipolar disorder (BD) diagnosis may have obstructive sleep apnoea (OSA), 
which may exacerbate, or be misattributed to, difficulties diagnosed as BD. Little is known about how OSA 
manifests when people also have a BD diagnosis. This study investigated whether people with suspected-
OSA and a BD diagnosis experience more sleep and affect instability when “inter-episode” compared to 
people with a BD diagnosis alone.  
Methods 
The study utilised ecological momentary assessment. Participants were screened for signs of OSA and seven 
were tested overnight. Eighteen participants (twelve with suspected-OSA) wore an acitgraph for two weeks 
whilst completing an affect questionnaire twice daily. Measures of instability were calculated using the mean 
squared successive difference and probability of acute change indices.  
Results 
No statistically significant differences were found other than reduced sleep efficiency in the suspected-OSA 
group (d=-1.15). The suspected-OSA group were diagnosed younger on average and proportionately more 
with a type 1 BD diagnosis. Only 48% of the intended sample was recruited due to the COVID-19 
pandemic. However, high data capture was achieved. 
Limitations 
Due to the small sample, the findings must be interpreted with caution.  
Conclusions 
The findings suggest OSA may further reduce sleep efficiency, and exacerbate the longer wake after sleep 
onset with increased instability, previously observed for people with a BD diagnosis when “inter-episode”. 
However, OSA may constrain total sleep time instability. A strong rationale remains for future research to 
enhance clinical recognition and treatment of OSA for people with a BD diagnosis. 
Key words: Obstructive sleep apnea; bipolar disorder; circadian rhythms; affect; actigraphy; instability. 
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Impact of Obstructive Sleep Apnoea for People with a Bipolar Disorder Diagnosis 
Obstructive sleep apnoea (OSA) involves repetitive upper airway collapse during sleep and is 
believed to affect 9-38% of the general population (Senaratna et al., 2017). The reduced airflow and blood 
oxygen levels disrupt sleep, causing fatigue and daytime sleepiness and are linked to low mood and chronic 
health difficulties (Chervin, 2000; El-Ad and Lavie, 2005; Jordan et al., 2014; Shamsuzzaman et al., 2003). 
OSA may be six to twelve times more prevalent in people with a bipolar disorder (BD) diagnosis, meaning 
that approximately a quarter of people with a BD diagnosis may have OSA (Kelly et al., 2013; Steier et al., 
2014; Stubbs et al., 2016). Similarly, around 20% of people with a diagnosis of OSA have been found to 
meet diagnostic criteria for BD or other mood difficulties (BaHammam et al., 2016; Schröder and O’Hara, 
2005; Sharafkhaneh et al., 2005).  
People with OSA and people with a BD diagnosis often share difficulties of reduced quality of life, 
difficulties socialising, reduced cognitive abilities and heightened emotional responses (“affect lability”; 
Beebe and Gozal, 2002; Henry et al., 2008; Kelly et al., 2013). Therefore, it is believed that OSA may either 
be misdiagnosed as BD or exacerbate difficulties considered to be BD (Pandi-Perumal et al., 2020). 
Meanwhile, prescribed pharmaceutical interventions may also increase the risk and severity of OSA in 
people with a BD diagnosis through causing sedation and weight gain (Gupta and Simpson, 2015; Kelly et 
al., 2013).  
Little is known about the relationship between OSA, sleep and mood for people with a BD diagnosis, 
impeding clinical recognition and management. The little literature surrounding the potential impact of OSA 
for people with a BD diagnosis only comprises of case reports, which do not present a consistent picture 
(Blazer, 1981; Fleming et al., 1985; Strakowski et al., 1991; Szaulińska et al., 2017). Whilst the high co-
morbidity between OSA and mood difficulties have informed routine evaluations of mood within assessment 
and treatment for OSA (Hamilton and Chai-Coetzer, 2019; National Institute for Health and Care Excellence 
(NICE), 2015), OSA is not routinely considered when assessing and supporting people with a BD diagnosis 
(NICE, 2014; Pandi-Perumal et al., 2020; Schröder and O’Hara, 2005). Therefore, research investigating the 
IMPACT OF OSA FOR PEOPLE WITH A BD DIAGNOSIS 2-4	
relationship between OSA and experiences diagnosed as BD is important to inform clinical recognition, 
particularly given the difficulties accessing sleep laboratory assessments (Flemons et al., 2004).   
People with a BD diagnosis are believed to be more vulnerable to circadian rhythm dysregulation 
than others in the general population (Alloy et al., 2017; Frank et al., 2000; Takaesu, 2018). The majority of 
psychological and pharmacological interventions for BD target circadian rhythms either directly or indirectly 
(Geddes and Miklowitz, 2013). For example, Interpersonal and Social Rhythms Therapy (IPSRT; Frank et 
al., 2000) uses a biopsychosocial approach to support people with a BD diagnosis to regulate their sleep-
wake cycle and mood stability to increase functioning. However, these interventions do not yet account for 
OSA potentially affecting a quarter of people with a BD diagnosis. OSA can deregulate circadian rhythms 
through disrupting the sleep cycle (Noda et al., 1998; Pandi-Perumal et al., 2020), further demonstrating the 
need to ascertain the relationship between OSA and difficulties diagnosed as BD.  
Sleep disturbance is a characteristic of periods of acutely elevated and low mood experienced by 
people with a BD diagnosis (Belmaker, 2004; Grande et al., 2016; Harvey et al., 2009). Research has also 
found that up to 70% of people with a BD diagnosis not currently experiencing acutely high or low mood 
(“inter-episode”) still exhibit clinically relevant sleep disturbance. People with a BD diagnosis were 
measured to have lower sleep efficiency and longer periods awake after sleep onset, with more instability 
around this, compared to controls (Gershon et al., 2012; Harvey et al., 2005; Sylvia et al., 2012). Crucially, 
increased instability in sleep and affect (emotional reaction), and more extreme experiences of negative 
affect, have also been consistently observed in this population when “inter-episode” (Depue, 1981; Gershon 
et al., 2012; Gershon and Eidelman, 2015; Harvey et al., 2005; Havermans et al., 2010; Henry et al., 2008; 
Knowles et al., 2007; Lovejoy and Steuerwald, 1995; Sylvia et al., 2012). However, less consistent evidence 
is available around the heightened experience of positive affect (Havermans et al., 2010; Knowles et al., 
2007; Lovejoy and Steuerwald, 1995).  
Heightened affect instability and intensity are considered defining characteristics of mood difficulties 
such as BD (Geddes and Miklowitz, 2013; Grande et al., 2016; Jahng et al., 2008). These fluctuations are 
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believed to be due to disrupted and variable circadian rhythms, even whilst “inter-episode”, leading to 
further acute mood difficulties due the bi-directional relationship between sleep and mood (Geddes and 
Miklowitz, 2013; Grandin et al., 2006; Harvey et al., 2009; Konjarski et al., 2018; Pandi-Perumal et al., 
2020; Takaesu et al., 2018). Conceivably, the presence of OSA is likely to increase this “inter-episode” 
affect instability through OSA’s impact on circadian rhythms, potentially further impacting on longer-term 
mood experiences. Investigating the sleep and affect instability present for people with a BD diagnosis when 
they are “inter-episode” is considered important as this instability may maintain and trigger further 
difficulties (Gershon et al., 2012; Melo et al., 2017; Saunders et al., 2013; Scollon et al., 2003). Therefore, 
measurement of sleep variables at this time, alongside investigation of affect instability through ecological 
momentary assessment (EMA; Shiffman et al., 2008), is an appropriate way to begin to understand how 
OSA may impact people with a BD diagnosis.  
This study aimed to investigate sleep and affect instability of people with a BD diagnosis and 
suspected-OSA. Specifically, the study intended to answer whether people with suspected-OSA and a BD 
diagnosis demonstrate more instability in sleep characteristics and positive and negative affect when “inter-
episode” than those with a diagnosis of BD alone. The research hypothesis predicted that people with 
suspected OSA and a BD diagnosis would experience more sleep and affect instability and greater extremes 
of negative and positive affect change. 
Method 
Design 
We conducted an EMA study to evaluate potential differences in instability of quantitative sleep and 
affect measures between a group of participants with a BD diagnosis and suspected-OSA and a group with a 
BD diagnosis alone. Each participant wore an acitgraph (a watch-like device that measures movement) for 
two weeks (15 consecutive nights) whilst completing a questionnaire on affect twice daily for 14 days. There 
is no consensus on the length of measurement necessary to accurately capture sleep variables (Aili et al., 
2017; Knutson et al., 2007). As night to night variability in sleep characteristics is high, even in the general 
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population (Dillon et al., 2014; Wohlgemuth et al., 1999), two weeks of data collection was considered 
appropriate to balance accuracy of sleep measurement with participant commitment. Meanwhile, twice daily 
EMA of affect for this period heightened the ecological validity around capturing affect instability (Trull et 
al., 2008).  
The study took place across England, United Kingdom. Approval was obtained from the National 
Health Service (NHS) ethics committee and Health Research Authority (reference: 19/SC/0487) and all 
participants provided informed and written consent to participate. Recruitment and data collection began in 
November 2019 and had to conclude in March 2020 due to restrictions around the COVID-19 pandemic 
(Bavel et al., 2020). Participants who completed the study were entered into a prize draw. 
Materials 
REDCap (Research Electronic Data Capture; Harris et al., 2019), a secure online software platform 
licenced by Lancaster University, was used to host online study information and to collect the research data. 
However, participants were also provided with paper versions of study materials where preferred. 
Participants initially provided demographic information via a questionnaire informed by the Duke 
Structured Interview Schedule for Sleep Disorders (DSI; Edinger et al., 2004), a very detailed sleep 
assessment tool (Taylor et al., 2018) containing demographic questions relevant to sleep. These questions 
produced baseline data and informed participant screening. For instance, information was collected on 
prescribed medications. It was anticipated that there would be no significant difference between groups in 
terms of medication as it is the first line treatment for difficulties diagnosed as BD (NICE, 2014). Therefore, 
attempting to recruit participants with a diagnosis of BD not taking medication, or attempting to control for 
medication, was likely to be unfeasible and unrepresentative (Harvey et al., 2009, 2005). 
Participants were asked to complete a further three questionnaires to characterise groups. The 
Epworth Sleepiness Scale (ESS; Johns, 1991), a measure of daytime sleepiness which people with OSA have 
been found to score significantly more highly on, and the Pittsburgh Sleep Quality Index (PSQI; Buysse et 
al., 1989) are two of the most frequently used subjective measures of sleep quality (Buysse et al., 2008). 
IMPACT OF OSA FOR PEOPLE WITH A BD DIAGNOSIS 2-7	
Although these measures have not been found to be predictive of OSA alone (Nishiyama et al., 2014), each 
has previously been used to characterise groups with confirmed OSA (Tufik et al., 2010; Vana et al., 2013) 
but not for those with a BD diagnosis (Soreca et al., 2015). Participants also completed the 7 Up 7 Down 
Inventory (Youngstrom et al., 2013; internal reliability: .83 for 'mania' and .95 for 'depression') as it is a brief 
measure of the severity of experiences relating to a diagnosis of BD. Fourteen participants completed these 
initial questionnaires online whilst five chose to complete paper copies.  
Sections A, C and I-J of the Mini International Psychiatric Interview (MINI; Sheehan, 2016) were 
administered during a telephone screening to ensure participants met current criteria for a BD diagnosis 
(American Psychiatric Association, 2013), were between episodes of extreme mood, and did not meet 
criteria for alcohol or substance misuse.  
To determine groups, participants also completed the STOP-Bang (Chung et al., 2016) questionnaire. 
The OSA section of Structured Clinical Interview for DSM-5 Sleep Disorders (SCISD; Taylor et al., 2018) 
was also administered during the telephone screen. Participants who scored ≥2 (clinical criteria) on the 
SCISD (Taylor et al., 2018; reliability: .73) and ≥3 on the STOP-Bang (Chung et al., 2016, 2008; sensitivity: 
84%-100% and specififity: 56%-37% for detecting mild-severe OSA) met criteria for the suspected-OSA 
group. A subset of these participants (those who lived in the North West of England) were invited to undergo 
an overnight OSA test using a WatchPATTM 200U (Itamar Medical, 2015) oximeter in their own home. 
Whilst the gold standard assessment for OSA is polysomnography (Jordan et al., 2014), evidence also 
supports the use of an oximeter in detecting OSA (Mulgrew et al., 2007; Yuceege et al., 2013). 
GENEActivTM Original (Activinsights, 2015) actigraphs were used to collect accelerometry data to 
then estimate total sleep time, sleep efficiency and wake after sleep onset. Actigraphy has been found to 
facilitate the estimation of these sleep variables with reasonable accuracy (Martin and Hakim, 2011). The 
GGIR package in R was used to estimate sleep variables from the actigraph data (van Hees et al., 2020).  
Participants also provided subjective estimates of their sleep onset and wake times throughout the 
data collection period. The Positive and Negative Affect Scale (PANAS; Watson et al., 1988) was used to 
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capture affect twice a day (after waking and before 1pm, and after 1pm and before sleep). Participants were 
asked to rate how they felt in that moment against the ten positive and ten negative affect items (0-4; very 
slightly or not at all - extremely). The PANAS has been shown to have good psychometric properties and 
has been used in the previous research measuring affect instability in participants with a diagnosis of BD 
(Gershon et al., 2012; Gershon and Eidelman, 2015; Lovejoy and Steuerwald, 1995).  
Participants 
 Participants contacted the first author directly in response to an advertisement shared through local 
services, Twitter and the Spectrum Centre for Mental Health Research mailing list. Participants had to have 
a self-reported BD diagnosis and meet current diagnostic criteria as screened for using sections A and C of 
the MINI (Sheehan, 2016). Participants also needed to live in the United Kingdom and be aged between 30 
and 65. This age range intended to capture people most at risk of OSA (Jordan et al., 2014; NICE, 2015; 
Stubbs et al., 2016), whilst minimising the presence of other extraneous sleep variables known to increase 
with age (Crowley, 2011; Edwards et al., 2010). People living in an environment or with a medical condition 
likely to disrupt sleep (e.g. traumatic brain injury, neurodegenerative condition or substance addiction 
(Hasler et al., 2012; Lee and Thomas, 2011; Ouellet et al., 2015)) were excluded at the screening stage.  
 We aimed to recruit a total of 40 participants (20 with suspected-OSA and 20 without). This aim was 
informed by participant cohort sizes in previous relevant studies (Gershon et al., 2012; Gershon and 
Eidelman, 2015), balanced with pragmatic considerations. Studies utilising EMA require fewer participants 
to achieve statistical power compared to cross-sectional design studies (Lu et al., 2013) yet there is no agreed 
method of calculating the necessary participant cohort size required to achieve statistical power (Scherbaum 
and Ferreter, 2009). 
Analysis 
To address the hypotheses, we aggregated daily sleep and affect data from across the data collection 
period to calculate means, medians and instability. Instability was calculated using the mean square of 
successive differences (MSSD) index whilst the probability of acute change (PAC) index was used to detect 
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extreme changes in affect variables. MSSD and PAC are recommended measures as they account for both 
variability and temporal dependency across a time series and have been found to capture affective instability 
better than other indices (Jahng et al., 2008). Moreover, MSSD is recommended for use in calculating affect 
instability for people with mood cycling condition diagnoses such as BD (Ebner-Priemer et al., 2009) and 
has been used in prior relevant research (Gershon et al., 2012; Gershon and Eidelman, 2015). To 
operationalise PAC, both one and two standard deviations from the sample mean of affect scores were used 
as cut points to define acute change in PAC calculations.  
The data was eyeballed using box plots and line graphs. Independent t-tests were used to compare 
means, MSSD and PAC indices between groups and Cohen’s d effect sizes were calculated. The Wilcoxon 
signed-rank test was used as a sensitivity analysis to confirm statistically significant t-test findings as the 
data was generated from a small sample. Analyses were conducted using SPPS version 26 (IBM, 2019) and 
R (R Core Team, 2013). 
Results 
Nineteen people (10 female; mean age = 49.26) consented to participate and 18 (9 female; mean age 
= 49.56) completed the study. One set of actigraph data could not be retrieved due to circumstances around 
the COVID-19 pandemic (Bavel et al., 2020). Twelve participants (6 female; mean age = 46.92) met criteria 
for the suspected-OSA group. Two people in this group reported existing diagnoses of OSA but that they 
were not currently using treatment. Seven people in the OSA group, without previous diagnoses of OSA, 
underwent the overnight oximeter test. Due to the recruitment period being shorter than intended, just under 
50% of the intended participant cohort size was successfully recruited. 
Demographics and Baseline Clinical Data 
Exploration of demographic and baseline clinical data was approached descriptively so as not to 
attempt to draw statistical inferences from such a small cohort (Grimes and Schulz, 2002). As can be seen in 
Table 1, 50% of participants in both groups identified as female, and the other half as male. The majority of 
participants (72%) overall reported to either be retired, currently unable to work or that they were a carer. 
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Fewer of the suspected-OSA group proportionally were currently working despite being younger on average. 
Proportionally more participants suspected of having OSA had type 1 or unspecified BD diagnoses whereas 
half of the non-OSA group had type 2 BD diagnoses. The suspected-OSA group reported having their BD 
diagnoses for longer, suggesting they received their diagnoses earlier in life as this group were also younger 
on average. Participants in the suspected-OSA group also endorsed more past and present sleep disturbances 
on average (e.g. night terrors), in addition to signs of OSA, had a higher average PSQI score and 
proportionally more (75% vs. 50%) met the PSQI criteria (>5) for being “poor sleepers” (Buysse et al., 
1989). Despite this, more suspected-OSA participants had a current bed partner than participants in the non-
OSA group. Suspected-OSA participants had a higher average ESS score but the average scores for both 
groups registered within the same scoring category of “higher normal daytime sleepiness” (Johns, 1991), 
with only 17% of participants in each group scoring above the clinical range (>10). All but one participant 
was taking at least one medication relating to a psychiatric diagnosis. 
Insert Table 1 here 
Oximeter Test 
 From the seven overnight oximeter tests, five Apnoea Hypopnea Index (AHI; mean = 20.16; range = 
1.5 - 53) and all Respiratory Disturbance Index (RDI; mean = 24.33; range = 5.8 - 56) readings met clinical 
OSA criteria (AHI or RDI ≥5; Guilleminault and Bassiri, 2005; NHS, 2019). Therefore, the presence of 
OSA was supported either by an oximeter test or a self-reported existing diagnosis for 82% of the suspected-
OSA group. 
Sleep Data 
Actigraph data was successfully captured for 99.16% of the data collection period across 17 
participants as two actigraphs only captured 13 days of data. Statistical comparisons were possible within 
sleep data due to the quantity of data points captured. As can be seen in Table 2, only one significant 
difference was found; sleep efficiency (total sleep time/time spent in bed) was significantly lower in the 
suspected-OSA group with the difference reflecting a large effect size (d=-1.15; Wilcoxon signed-rank test 
conducted for sensitivity: Z=53, p=.05).  
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Although not statistically significant, the suspected-OSA group slept for less time on average but 
demonstrated less mean instability (MSSD) in total sleep time, although the median was higher in the 
suspected-OSA group (Figure 1). These group differences reflected medium and small effect sizes 
respectively. As can be seen in Figure 2, the suspected-OSA group also spent more time awake after sleep 
onset, meaning they woke up more often and/or woke up for longer periods during the night, and 
demonstrated more instability around this. These group differences both reflected large effect sizes. 
Meanwhile, notably larger ranges in the data were observed from the suspected-OSA group for these 
variables. 
Insert Table 2 and Figures 1 & 2 here 
 Meanwhile, in addition to a significantly smaller average, participants in the OSA group also 
demonstrated a much greater range in mean sleep efficiency across the data collection period compared to 
the non-OSA group (Figure 3).  
Insert Figure 3 here 
Affect data 
Participants completed 97% of the twice-daily questionnaires, and only 1.3% of these were not fully 
completed. Nine participants completed the questionnaires online, which prevented retrospective recordings 
of missed affect measurements. Ten preferred to complete the questionnaire within a paper booklet and were 
asked to not record missed affect measurements retrospectively.  
Again, statistical comparisons were possible due to the quantity of data captured. None of the 
findings regarding differences in positive or negative affect were statistically significant although group 
differences mostly reflected medium to large effect sizes (Table 3). The non-OSA group recorded greater 
instability and greater extremes of affect change for both positive and negative affect. As can be seen in 
Figure 4, the suspected-OSA group reported a greater range of positive affect scores whilst the non-OSA 
group reported a greater range of negative affect scores.  
Insert Table 3 and Figure 4 here 
 As can be seen in Figure 5, the findings of greater overall instability and extremes of affect change in 
the non-OSA group were likely to have been influenced by one participant demonstrating extreme instability 
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in their affect data (graphs depicting the positive affect scores for this participant and the participant who 
demonstrated the least positive affect instability can be compared in Appendix A, noting the difference in the 
y axes). These data points were not removed due to a preference to present all data captured due to the small 
sample and the possibility that the data reflects genuine levels of affect instability rather than recording error. 
Insert Figure 5 here 
Discussion 
To our knowledge, this is the first study utilising EMA to study sleep and affect instability between 
groups of people with a BD diagnosis with and without suspected-OSA. It was predicted that people with 
suspected OSA and a BD diagnosis would experience more sleep and affect instability and greater extremes 
of negative and positive affect change. Notably, recruitment was limited by the COVID-19 pandemic (Bavel 
et al., 2020) and so conclusions from the study need to be considered with caution. 
Contrary to predictions, greater instability was found in total sleep time (albeit reflecting a small 
effect size) and in positive and negative affect (medium-large effect sizes) for the non-OSA group. This 
group also demonstrated greater extremes of affect change (differences reflecting medium to large effect 
sizes). None of these differences were statistically significant. Although also not statistically significant, the 
suspected-OSA group demonstrated greater instability in wake after sleep onset (large effect size), and 
statistically significant lower levels of sleep efficiency with the difference reflecting a large effect size (d=-
1.15).  
The suspected-OSA group demonstrating significantly reduced sleep efficiency means participants in 
this group spent less time asleep relative to the time they spent in bed. This group also slept for less time on 
average and spent more time awake after sleep onset; although the differences were not statistically 
significant, these differences reflect large effect sizes. It is conceivable that sleep efficiency is likely to be 
reduced for people with OSA by the frequent awakenings caused by apnoeas (Broström et al., 2007; Jordan 
et al., 2014; Redline et al., 2004). However, there is a lack of research around this. Some findings suggest 
even those with severe OSA may be considered to have typical sleep efficiency, and that this doesn’t change 
with OSA treatment (Batool-Anwar et al., 2014; Loredo et al., 1999). Other findings suggest that OSA 
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severity is somewhat linked to reductions in sleep efficiency, increases in wake after sleep onset, and 
reductions in slow wave and rapid eye movement sleep (Redline et al., 2004).  
Meanwhile, less sleep efficiency and total sleep time for people with OSA are linked to the absence 
of excessive daytime sleepiness (EDS) (Mediano et al., 2007; Roure et al., 2008). Although the mechanisms 
behind this are currently unknown, it is suspected that increased sleep efficiency and sleep time may be a 
consequence of EDS. The baseline ESS (Johns, 1991) scores captured suggested that EDS was not 
characteristic of the suspected-OSA group. Whilst EDS is common in populations with OSA, it is not 
invariably present, with prevalence findings ranging from 15.5- 87.2% (Mediano et al., 2007; Seneviratne 
and Puvanendran, 2004; Young et al., 1993). Therefore, it is possible that a suspected-OSA group with 
higher levels of EDS may not have exhibited significantly reduced sleep efficiency. Whilst it is conceivable 
that the presence of OSA may exacerbate circadian rhythm abnormalities in people with a BD diagnosis, 
further research is required to determine how this may manifest. 
The findings may provide preliminary evidence that the presence of OSA exacerbates the reduced 
sleep efficiency and longer wake after sleep onset, with more instability, previously observed in people with 
a BD diagnosis	(Gershon et al., 2012; Harvey et al., 2005; Sylvia et al., 2012). More people in the suspected-
OSA group met PSQI criteria for being “poor sleepers” (Buysse et al., 1989) in addition to demonstrating 
more mean time spent awake after sleep onset and greater instability in this. However, whilst reduced mean 
time asleep and increased mean time awake after sleep onset was expected in the suspected-OSA group, due 
to apnoeas causing frequent awakenings (Broström et al., 2007; Jordan et al., 2014; Redline et al., 2004), 
more instability in average total sleep time in the non-OSA group (albeit reflecting a small effect size) was 
contrary to predictions. This finding could provide preliminary evidence to suggest that the presence of OSA 
may in fact restrict rather than exacerbate instability in total sleep time. Although the median for instability 
in total sleep time was higher in the suspected-OSA group, a much smaller range in instability was observed. 
Perhaps the presence of apnoeas constrains total sleep time such that people with OSA and a BD diagnosis 
consistently sleep for a certain amount of time, which is less than those without OSA. Meanwhile, differing 
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lengths of time in bed would result in the predicted increased instability in time spent awake after sleep onset 
observed in this group. If these preliminary findings were found to be replicable, it would be significant to 
tailoring interventions intending to stabilise circadian rhythms for people with BD and OSA. Therefore, 
further research with a larger cohort is necessary. 
Although involving a similarly small number of people with OSA and a BD diagnosis, Krane-
Gartiser et al. (2016) categorised six people with a BD diagnosis, who also happened to have moderate OSA, 
as demonstrating “stable” circadian rhythms when “inter-episode” based on actigraphy data. Meanwhile, 
three other people with a BD diagnosis, who also happened to have moderate OSA, were categorised in the 
“unstable” group. The study found circadian instability to be significantly related to mood instability, in 
addition to younger age. Their participant groupings suggest that not all people with a BD diagnosis, 
particularly those in the age range of the current study, may demonstrate circadian instability when 
“interepisode”. Moreover, OSA may not exacerbate circadian instability for people with a BD diagnosis. 
Their findings could link to the current study’s findings of no significant differences in instability being 
detected between groups. However, Krane-Gartiser et al. (2016) also acknowledge a small sample size, in 
addition to a short data collection period (1 week), as limitations to application of their findings, highlighting 
the need for further research. 
The current findings are also consistent with previous findings of high levels of sleep disturbance in 
individuals with a BD diagnosis, even between periods of acute mood experience (e.g. Harvey et al., 2005). 
The average PSQI score for both groups was above 5, with 75% of the suspected-OSA group and 50% of the 
non-OSA group meeting this criteria, which is considered indicative of clinically relevant sleep disturbance 
in general populations (Buysse et al., 1989).  
This study’s findings do not suggest that affect instability is exacerbated by the presence of OSA 
when affect is measured using the PANAS. Greater affect instability and extremes of affect change were 
present in the non-OSA group, contrary to predictions. However, the study should be replicated with a larger 
sample to investigate this further, which would allow for enhanced methodology (see future directions). If 
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OSA exacerbates circadian rhythm abnormalities through disrupting the sleep cycle, impacting on sleep 
variables in the ways observed, this will conceivably exacerbate the increased affect instability identified in 
people with a BD diagnosis (Gershon et al., 2012; Gershon and Eidelman, 2015; Lovejoy and Steuerwald, 
1995; Pandi-Perumal et al., 2020). Indeed, Gershon et al., (2012) found greater coupling of negative affect 
with sleep variables, specifically wake after sleep onset, for people with a BD diagnosis. Meanwhile, total 
sleep time was not found to significantly couple with affect variables. These findings are not consistent with 
those of the current study, indicating the need for further research.  
The suspected-OSA group yielded a much greater range of average positive affect scores across the 
data collection period compared to the non-OSA group. However, the non-OSA group showed greater 
instability of positive affect with a large effect size. Therefore, despite the greater range of positive affect 
scores within the suspected-OSA group, scores in this group were detected to have a higher dependency on 
previous scores, suggesting a more stable experience of affect. If this finding were to be replicated this could 
be an avenue that warrants further research towards understanding how OSA may affect people with a BD 
diagnosis.  
Statistical comparisons of baseline demographic and clinical data between groups were not feasible 
due to the small cohort size. However, observations from eyeballing the data suggest that the suspected-OSA 
group received their BD diagnoses earlier in life than the non-OSA group. Earlier recognition of difficulties 
is linked to more life-long difficulties and co-morbidities (Joslyn et al., 2016; Suominen et al., 2007). 
Meanwhile, a greater proportion of the suspected-OSA group were diagnosed with a type 1 BD diagnosis, 
which is also associated with a higher severity of difficulties (Belmaker, 2004). Therefore, these preliminary 
observations should inform future research as they may suggest that difficulties diagnosed as BD present 
earlier and more severely in people who also have OSA. Alternatively, suspected-OSA may have resulted 
from longer exposure to potentially higher doses of medication (Gupta and Simpson, 2015; Kelly et al., 
2013). Future research benefitting from larger cohorts should compare medication history between those 
with OSA and those without.  
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Limitations and Strengths 
The small resultant sample limits the generalisability of the findings. Meanwhile, participants did not 
all complete the study during the same 14-day period. It is therefore possible that the changing climate 
around the COVID-19 pandemic (Bavel et al., 2020) may have acted as a confounding variable as some 
participants, primarily in the suspected-OSA group, needed to shield or remain at home more towards the 
end of the wider data collection period. Increased anxiety is also known to impact sleep and affect variables 
(Egloff et al., 2006; Spoormaker and Van Den Bout, 2005). One participant also reported a family illness 
affecting them during the two weeks they were contributing data. These unavoidable idiosyncrasies in 
circumstance are likely to have had more of a confounding effect on the findings in such a small cohort, 
particularly as it is anticipated that people with a BD diagnosis are more affectively reactive to 
environmental stressors (Myin-Germeys et al., 2003). Lastly, whilst the PANAS (Watson et al., 1988) has 
been used previously in EMA studies with people with a BD diagnosis (Gershon et al., 2012; Gershon and 
Eidelman, 2015; Lovejoy and Steuerwald, 1995), it is arguably a limited measure comprising only 20 items, 
necessitated by the trade-off between breadth of data collection and participant burden (Gershon and 
Eidelman, 2015).   
However, the current study is the first to investigate the impact of OSA on people with a BD 
diagnosis. This was also the first study to utilise the PAC index to investigate extremes of affect change in 
this population. The indices of instability used determined the data’s independence from timing and previous 
and subsequent data. The study provides further evidence of the feasibility of EMA methodology in this area 
as all participants successfully wore an actigraph for two weeks and completion of twice-daily affect 
measures was very high, potentially facilitated by participants being given the option to complete these 
measures on paper or electronically. A further methodological strength was addressing the low levels of 
specificity achieved using the STOP-Bang (Chung et al., 2016, 2008) assessment for suspected-OSA 
through also utilising an oximeter as an objective measure. The overnight oximeter test supported the 
validity of the criteria used to identify participants with suspected-OSA. 
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Clinical implications 
 Despite the acknowledged limitations, the findings suggest OSA may in some way contribute to 
difficulties diagnosed as BD presenting earlier and more severely. Furthermore, OSA may constrain total 
sleep time, potentially impacting on the effectiveness of many interventions intending to regulate circadian 
rhythms, such as IPSRT (Frank et al., 2000). Given the high prevalence of OSA for people with a BD 
diagnosis, it is of great importance that research and practice advances to enhance recognition of OSA in this 
population so that it can be appropriately managed in the context of other difficulties. Positive airway 
pressure (PAP), the first-line treatment for OSA (Engleman et al., 2002), is generally not well tolerated 
(Weaver and Grunstein, 2008). Conceivably, the difficulties around PAP use are likely to be further 
exacerbated by the emotional instability experienced by people with a BD diagnosis without sufficient 
evidence-based support. If tolerated, CPAP treatment is effective (Giles et al., 2006) and therefore may 
reduce difficulties experienced by people with OSA and a diagnosis of BD. 
Future directions 
 The current study has highlighted many relevant avenues for future research to inform research and 
clinical practice. In addition to avenues already mentioned, the current methodology could be enhanced in 
the following ways. Based on the current study’s high levels of data capture, it may be possible to utilise a 
more detailed measure of affect. The PANAS-X (extended version; Watson and Clark, 1994) has been used 
to enhance the measurement of negative affect through creating subscales for hostility, fear and sadness 
(Jahng et al., 2011). Future studies with larger cohorts could utilise similarly enhanced affect measurement 
to formulate the impact of sleep on affect instability utilising statistical multilevel modelling (Jahng et al., 
2008). Furthermore, future studies could advance understanding around the high occurrence of OSA in 
people with a BD diagnosis through comparing participant body mass index, in addition to a more detailed 
medication history than the current study. Meanwhile, future replications should record any major life 
occurrences during data collection so they can be controlled for during analyses. Lastly, a further 
improvement on the current design would be to test for the absence as well as the presence of OSA. 
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Although the overnight oximeter test corroborated the suspected presence of OSA, due to limited resources, 
no participants in the non-OSA group were tested to objectively explore this difference between the groups. 
In conclusion, the study aimed to investigate any difference in sleep and affect instability, and 
extremes of affect change, between a group suspected of having OSA and a group with a BD diagnosis 
alone. The only significant difference between groups was reduced sleep efficiency in the suspected-OSA 
group, which reflected a large effect size. Whilst the small resultant sample size limits the interpretations and 
conclusions that can be drawn from this study, there remains a strong clinical rationale for future replications 
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Table 1 
























Note. SD= standard deviation.  
aEpworth Sleepiness Scale (Johns, 1991).  
bPittsburgh Sleep Quality Index (Buysse et al., 1989).  
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Table 2 




Suspected-OSA	group	(n=11)	 Non-OSA	group	(n=6)	 Statistical	comparison,	t	 Cohen’s	d	
Minutes	slept		 	 	 	 	
Mean		 321.84	(58.85)	316.98		 363.59	(70.08)	364.34	 1.31		 -.62	
MSSDa		 15998.14	(11575.62)	14946.98	 18064.91	(13519.47)	12439.54	 .33		 -.16	
Minutes	awake		 	 	 	 	
Mean	 141.93	(53.68)	148.69	 98.22	(37.35)	102.46	 1.76		 .85	
MSSD		 8638.52	(5418.81)	7804.14	 4361.50	(3624.96)	3485.29	 1.72		 .83	
Sleep	efficiency	 	 	 	 	
Mean	 .71	(.08)	.71	 .80	(.06)	.79	 2.40*		 -1.15	
Note. SD=standard deviation, * indicates p<.05 
aMSSD can be expressed in minutes by calculating the square root (rMSSD; e.g. MSSD=14400, 
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Figure 2 




Line Graph Depicting Individual Sleep Efficiencya and Box Plot Depicting Mean Sleep Efficiency 
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Table 3 





Positive	affect	 	 	 	 	
Mean		 12.30	(7.68)	10.28	 13.29	(6.50)	12.05	 .27		 -.13	
MSSDa		 45.31	(29.40)	41.07	 93.84	(95.83)b1	49.79	 1.65		 -.76	
PAC	(1SD)		 .14	(.07)	.17	 .22	(.12)	.19	 1.80		 -.84	
PAC	(2SD)		 .03	(.03)	.00	 .07	(.09)	.04	 1.43		 -.66	
Negative	affect	 	 	 	 	
Mean		 2.67	(1.85)	2.36	 5.16	(3.55)	4.21	 1.99		 -.92	
MSSD		 13.13	(12.60)	7.28	 32.64	(38.87)b2	20.52	 1.62		 -.75	
PAC	(1SD)		 .15	(.11)	.15	 .20	(.10)	.19	 .93		 -.44	
PAC	(2SD)		 .06	(.08)	.04	 .09	(.09)	.08	 .72		 -.34	
Note. SD=standard deviation, * indicates p<.05 
aMSSD can be interpreted by calculating the square root (rMSSD; e.g. MSSD=49, rMSSD=7 points), if 
=2SD around the mean, this indicates total independence in the series (Neumann et al., 1941).  
b1-2high SD due to very high instability recorded by one participant (see Figure 5 and Appendix A). If 
participant removed b1mean=55.45 and b2mean=17.62 (insignificant differences between groups remain). 
 
Figure 4 
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Figure 5 
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Appendix A 
Figure A1 
Line Graph Depicting the Individual Positive Affect Scores for the Participant who Demonstrated the 











Line Graph Depicting the Individual Positive Affect Scores for the Participant who Demonstrated the Least 
Affect Instability  
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Appendix B 
Submission Guidelines (Guide for Authors) for Journal of Affective Disorders  
Description 
 
The Journal of Affective Disorders publishes papers concerned with affective disorders in the widest 
sense: depression, mania, anxiety and panic. It is interdisciplinary and aims to bring together different approaches 
for a diverse readership. High quality papers will be accepted dealing with any aspect of affective disorders, including 
biochemistry, pharmacology, endocrinology, genetics, statistics, epidemiology, psychodynamics, classification, clinical 
studies and studies of all types of treatment. 
Submission checklist 
 
You can use this list to carry out a final check of your submission before you send it to the journal for review. Please 
check the relevant section in this Guide for Authors for more details. 
Ensure that the following items are present: 
One author has been designated as the corresponding author with contact details: 
• E-mail address 
• Full postal address 
All necessary files have been uploaded: 
Manuscript: 
• Include keywords 
• All figures (include relevant captions) 
• All tables (including titles, description, footnotes) 
• Ensure all figure and table citations in the text match the files provided 
• Indicate clearly if color should be used for any figures in print 
Author Statement Contributors, Role of the Funding Source and Acknowledgements are mandatory and must be 
retained in the Author Statement (submission file type) under their respective headings. 
Graphical Abstracts / Highlights files (where applicable) 
Supplemental files (where applicable) 
Further considerations 
• Manuscript has been 'spell checked' and 'grammar checked' 
• All references mentioned in the Reference List are cited in the text, and vice versa 
• Permission has been obtained for use of copyrighted material from other sources (including the Internet) 
• A competing interests statement is provided, even if the authors have no competing interests to declare 
• Journal policies detailed in this guide have been reviewed 
• Referee suggestions and contact details provided, based on journal requirements 
For further information, visit our Support Center. 
 
Ethics in publishing 
 
Please see our information pages on Ethics in publishing and Ethical guidelines for journal publication. 
Ethical Considerations 
 
Authors of reports on human studies, especially those involving placebo, symptom provocation, drug discontinuation, 
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or patients with disorders that may impair decision-making capability, should consider the ethical issues related to the 
work presented and include (in the Methods and Materials section of their manuscript) detailed information on the 
informed consent process, including the method or methods used to assess the subject's capacity to give informed 
consent, and safeguards included in the study design for protection of human subjects. Specifically, authors should 
consider all ethical issues relevant to their research, and briefly address each of these in their reports. When relevant 
patient follow-up data are available, this should also be reported. Specifically, investigators reporting on research 
involving human subjects or animals must have prior approval from an institutional review board. This approval should 
be mentioned in the methods section of the manuscript. In countries where institutional review boards are not 
available; the authors must include a statement that research was conducted in accordance with the Helsinki 
Declaration as revised 1989. All studies involving animals must state that the authors followed the guidelines for the 
use and care of laboratory animals of the author's institution or the National Research Council or any national law 
pertaining to animal research care. 
Declaration of interest 
 
All authors must disclose any financial and personal relationships with other people or organizations that could 
inappropriately influence (bias) their work. Examples of potential competing interests include employment, 
consultancies, stock ownership, honoraria, paid expert testimony, patent applications/registrations, and grants or other 
funding. Authors must disclose any interests in two places: 1. A summary declaration of interest statement in the title 
page file (if double-blind) or the manuscript file (if single-blind). If there are no interests to declare then please state 
this: 'Declarations of interest: none'. This summary statement will be ultimately published if the article is accepted. 2. 
Detailed disclosures as part of a separate Declaration of Interest form, which forms part of the journal's official records. 
It is important for potential interests to be declared in both places and that the information matches. More information. 
Submission declaration 
 
Submission of an article implies that the work described has not been published previously (except in the form of an 
abstract, a published lecture or academic thesis, see 'Multiple, redundant or concurrent publication' for more 
information), that it is not under consideration for publication elsewhere, that its publication is approved by all authors 
and tacitly or explicitly by the responsible authorities where the work was carried out, and that, if accepted, it will not 
be published elsewhere in the same form, in English or in any other language, including electronically without the 
written consent of the copyright-holder. 
Preprints 
Please note that preprints can be shared anywhere at any time, in line with Elsevier's sharing policy. Sharing your 
preprints e.g. on a preprint server will not count as prior publication (see 'Multiple, redundant or concurrent publication' 
for more information). 
Use of inclusive language 
 
Inclusive language acknowledges diversity, conveys respect to all people, is sensitive to differences, and promotes 
equal opportunities. Content should make no assumptions about the beliefs or commitments of any reader; contain 
nothing which might imply that one individual is superior to another on the grounds of age, gender, race, ethnicity, 
culture, sexual orientation, disability or health condition; and use inclusive language throughout. Authors should 
ensure that writing is free from bias, stereotypes, slang, reference to dominant culture and/or cultural assumptions. We 
advise to seek gender neutrality by using plural nouns ("clinicians, patients/clients") as default/wherever possible to 
avoid using "he, she," or "he/she." We recommend avoiding the use of descriptors that refer to personal attributes 
such as age, gender, race, ethnicity, culture, sexual orientation, disability or health condition unless they are relevant 
and valid. These guidelines are meant as a point of reference to help identify appropriate language but are by no 
means exhaustive or definitive. 
Contributors 
 
Each author is required to declare his or her individual contribution to the article: all authors must have materially 
participated in the research and/or article preparation, so roles for all authors should be described. The statement that 
all authors have approved the final article should be true and included in the disclosure. 
Changes to authorship 
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Authors are expected to consider carefully the list and order of authors before submitting their manuscript and provide 
the definitive list of authors at the time of the original submission. Any addition, deletion or rearrangement of author 
names in the authorship list should be made only before the manuscript has been accepted and only if approved by 
the journal Editor. To request such a change, the Editor must receive the following from the corresponding author: 
(a) the reason for the change in author list and (b) written confirmation (e-mail, letter) from all authors that they agree 
with the addition, removal or rearrangement. In the case of addition or removal of authors, this includes confirmation 
from the author being added or removed. 
Only in exceptional circumstances will the Editor consider the addition, deletion or rearrangement of authors after the 
manuscript has been accepted. While the Editor considers the request, publication of the manuscript will be 
suspended. If the manuscript has already been published in an online issue, any requests approved by the Editor will 
result in a corrigendum. 
Article transfer service 
This journal is part of our Article Transfer Service. This means that if the Editor feels your article is more suitable in 
one of our other participating journals, then you may be asked to consider transferring the article to one of those. If you 
agree, your article will be transferred automatically on your behalf with no need to reformat. Please note that your 
article will be reviewed again by the new journal. More information. 
Copyright 
 
Upon acceptance of an article, authors will be asked to complete a 'Journal Publishing Agreement' (see more 
information on this). An e-mail will be sent to the corresponding author confirming receipt of the manuscript together 
with a 'Journal Publishing Agreement' form or a link to the online version of this agreement. 
Subscribers may reproduce tables of contents or prepare lists of articles including abstracts for internal circulation 
within their institutions. Permission of the Publisher is required for resale or distribution outside the institution and for 
all other derivative works, including compilations and translations. If excerpts from other copyrighted works are 
included, the author(s) must obtain written permission from the copyright owners and credit the source(s) in the article. 
Elsevier has preprinted forms for use by authors in these cases. 
For gold open access articles: Upon acceptance of an article, authors will be asked to complete an 'Exclusive License 
Agreement' (more information). Permitted third party reuse of gold open access articles is determined by the author's 
choice of user license. 
Author rights 
As an author you (or your employer or institution) have certain rights to reuse your work. More information. 
Elsevier supports responsible sharing 
Find out how you can share your research published in Elsevier journals. 
Role of the funding source 
 
You are requested to identify who provided financial support for the conduct of the research and/or preparation of the 
article and to briefly describe the role of the sponsor(s), if any, in study design; in the collection, analysis and 
interpretation of data; in the writing of the report; and in the decision to submit the article for publication. If the funding 
source(s) had no such involvement then this should be stated. 
Open access 
 
Please visit our Open Access page for more information. 
Elsevier Researcher Academy 
Researcher Academy is a free e-learning platform designed to support early and mid-career researchers throughout 
their research journey. The "Learn" environment at Researcher Academy offers several interactive modules, webinars, 
downloadable guides and resources to guide you through the process of writing for research and going through peer 
review. Feel free to use these free resources to improve your submission and navigate the publication process with 
ease. 
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Language (usage and editing services) 
Please write your text in good English (American or British usage is accepted, but not a mixture of these). Authors who 
feel their English language manuscript may require editing to eliminate possible grammatical or spelling errors and to 




Our online submission system guides you stepwise through the process of entering your article details and uploading 
your files. The system converts your article files to a single PDF file used in the peer-review process. Editable files 
(e.g., Word, LaTeX) are required to typeset your article for final publication. All correspondence, including notification 
of the Editor's decision and requests for revision, is sent by e-mail. 
Manuscript Submission 
 
The Journal of Affective Disorders now proceeds totally online via an electronic submission system. Mail submissions 
will no longer be accepted. By accessing the online submission 
system, https://www.evise.com/profile/api/navigate/JAD, you will be guided stepwise through the creation and 
uploading of the various files. When submitting a manuscript online, authors need to provide an electronic version of 
their manuscript and any accompanying figures and tables. 
The author should select from a list of scientific classifications, which will be used to help the editors select reviewers 
with appropriate expertise, and an article type for their manuscript. Once the uploading is done, the system 
automatically generates an electronic (PDF) proof, which is then used for reviewing. All correspondence, including the 
Editor's decision and request for revisions, will be processed through the system and will reach the corresponding 
author by e-mail. 
Once a manuscript has successfully been submitted via the online submission system authors may track the status of 
their manuscript using the online submission system (details will be provided by e-mail). If your manuscript is accepted 
by the journal, subsequent tracking facilities are available on Elsevier's Author Gateway, using the unique reference 
number provided by Elsevier and corresponding author name (details will be provided by e-mail). 
Authors may send queries concerning the submission process or journal procedures to our Editors-in-Chief 
Paolo Brambilla: paolo.brambilla1@unimi.it or Jair Soares: Jair.C.Soares@uth.tmc.edu. 
Please submit your article via https://www.evise.com/profile/api/navigate/JAD. 
Types of Papers 
The Journal primarily publishes: 
Full-Length Research Papers (up to 5000 words, excluding references and up to 6 tables/figures) 
Review Articles and Meta-analyses (up to 8000 words, excluding references and up to 10 tables/figures) 
Short Communications (up to 2000 words, 20 references, 2 tables/figures) 
Correspondence (up to 1000 words, 10 references, 1 table/figure). 
At the discretion of the accepting Editor-in-Chief, and/or based on reviewer feedback, authors may be allowed fewer or 
more than these guidelines. 
Retraction Policy 
It is a general principle of scholarly communication that the editor of a learned journal is solely and independently 
responsible for deciding which articles submitted to the journal shall be published. In making this decision the editor is 
guided by policies of the journal's editorial board and constrained by such legal requirements in force regarding libel, 
copyright infringement and plagiarism. Although electronic methods are available to detect plagiarism and duplicate 
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publications, editors nonetheless rely in large part on the integrity of authors to fulfil their responsibilities within the 
requirements of publication ethics and only submit work to which the can rightfully claim authorship and which has not 
previously been published. 
An outcome of this principle is the importance of the scholarly archive as a permanent, historic record of the 
transactions of scholarship. Articles that have been published shall remain extant, exact and unaltered as far as is 
possible. However, very occasionally circumstances may arise where an article is published that must later be 
retracted or even removed. Such actions must not be undertaken lightly and can only occur under exceptional 
circumstances, such as: 
• Article Withdrawal: Only used for Articles in Press which represent early versions of articles and sometimes contain 
errors, or may have been accidentally submitted twice. Occasionally, but less frequently, the articles may represent 
infringements of professional ethical codes, such as multiple submission, bogus claims of authorship, plagiarism, 
fraudulent use of data or the like. • Article Retraction: Infringements of professional ethical codes, such as multiple 
submission, bogus claims of authorship, plagiarism, fraudulent use of data or the like. Occasionally a retraction will be 
used to correct errors in submission or publication. • Article Removal: Legal limitations upon the publisher, copyright 
holder or author(s). • Article Replacement: Identification of false or inaccurate data that, if acted upon, would pose a 
serious health risk. For the full policy and further details, please refer https://www.elsevier.com/about/publishing-
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The subjects of both the empirical paper and systematic literature review were motivated by the 
wider clinical issue of the impact of sleep arguably being under-recognised in both research and clinical 
practice. This issue is discussed here in relation to the clinical applications of the thesis findings. The 
research is perhaps particularly timely given the anticipated release of a new clinical guidance from the 
National Institute for Health and Care Excellence (2020) around obstructive sleep apnoea (OSA), which has 
been delayed until further notice due to the COVID-19 pandemic (Bavel et al., 2020).  
This critical appraisal also contains further considerations around the research project that informed 
the empirical paper of this thesis. Further evaluation of the study and discussion of the ethical considerations 
that arose for the author during its completion are presented. Therefore, a summary of the findings from both 
the empirical paper research study and systematic literature review are presented below before discussion 
around the following topics: evaluation of the empirical research project, ethical challenges and 
considerations surrounding the empirical project, and the clinical issue of sleep.  
Empirical Paper Summary 
 This study aimed to investigate whether people with suspected-OSA and a bipolar disorder (BD) 
diagnosis experience more sleep and affect instability when “inter-episode” compared to people with a BD 
diagnosis alone. Ecological momentary assessment was used across a two-week data collection period to 
evaluate potential differences between groups in instability of quantitative sleep and affect measures. The 
groups were not found to significantly differ other than suspected-OSA group demonstrating reduced sleep 
efficiency. As only 48% of the intended sample was successfully recruited, much exploration of the data was 
approached descriptively. The findings may provide preliminary evidence to suggest that OSA may in some 
way contribute to difficulties diagnosed as BD presenting earlier and more severely. Furthermore, and 
contrary to predictions, OSA may constrain instability in total sleep time. Despite the limitations presented 
by the small resultant sample size, the protocol achieved high data capture and the findings highlight many 
relevant avenues for future research to inform clinical practice. 
Systematic Literature Review Summary 
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 The aim of the review was to synthesise user experience of PAP to address the notable absence of 
users’ voices in the literature and to inform how PAP usage could be improved. PAP is the first-line 
treatment of OSA (Engleman et al., 2002) but sub-optimal use continues to be a major challenge to effective 
treatment. Although extensive quantitative research has been conducted into factors that impact PAP use, it 
is estimated that at least half of users do not use it as prescribed (Weaver and Grunstein, 2008). Meanwhile, 
the individual, societal and financial impacts of untreated OSA make effective treatment a priority (Knauert 
et al., 2015; Tarasiuk and Reuveni, 2013). Therefore, a systematic review and metasynthesis of qualitative 
experiences of using PAP was warranted. Twenty-five papers reporting on global, but largely Western, 
research were appraised and included. The findings highlighted existing barriers to PAP use at a healthcare 
service level, the need for a biopsychosocial approach and that long-term person-centred support is 
necessary to enhance PAP use. 
Evaluation of the Empirical Research Project 
 The research project was the first study to investigate the impact of OSA on people with a BD 
diagnosis with the intention of informing enhanced awareness, assessment and treatment. Although the 
scope of the findings was unfortunately limited due to time constraints and the COVID-19 pandemic, a 
strong clinical rationale for further research remains. The author hopes that the preliminary findings from the 
current study will inform such efforts.  
 One contribution of the study is a study protocol that yielded high levels of data capture. All 
participants wore an actigraph for a total of 14 days (15 nights). Moreover, all except one participant 
contributed to completing 97% of the twice-daily questionnaires and only 1.3% of these were not fully 
completed. Of course the individual reasons for the commitment shown by participants should not be 
reduced to the effectiveness of a protocol. However, participants were invited to give feedback on their 
experience of the study, the results of which suggested that a structure of “checking in” on feelings twice a 
day was experienced as helpful. Moreover, despite suggestions that the Positive and Negative Affect Scale 
(PANAS; Watson et al., 1988) may be too lengthy for participants to complete frequently and/or over long 
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periods (Gershon and Eidelman, 2015; Thompson, 2007), participants reported that they did not find the 
measure too onerous. Furthermore, the option to complete the PANAS electronically via an email link, 
enabling participants to complete it on their preferred device, was cited as convenient for participants. It 
seems important to note that the majority of participants did not have employment responsibilities 
throughout the data collection period, which may have facilitated data capture. However, these informal 
findings support the feasibility of high data capture through replicating the protocol, or perhaps even through 
enhancing affect measurement. For instance, the PANAS-X (extended version; Watson and Clark, 1994), 
which comprises of an additional 40 items to the PANAS, has been used to enhance the measurement of 
negative affect through creating subscales for hostility, fear and sadness (Jahng et al., 2011). Utilising a 
similar methodology to this in future research with a larger cohort would not only enable use of more 
complex analytical models to further explore the relationship between sleep and affect instability, but 
respond to feedback. Participants reported that they did not always feel their current feelings could be fully 
captured by the 20 feelings included in the PANAS (Watson et al., 1988), particularly when they were 
feeling low or sad. Moreover, some participants wished to be able to provide qualitative information on their 
identified reason(s) for their current feelings. Providing this opportunity to participants in future replications 
would somewhat, albeit analytically challenging, enable controlling for the impact of extraneous life events 
during the data collection period when not doing so was identified as a limitation of the current study.  
 A further perceived strength of the protocol was the multiple opportunities to develop a rapport with 
participants. Firstly, due to the relative complexity of the study, a video version of the participant 
information sheet was made available online (https://youtu.be/yFb1jPqsvso) to convey details of the study in 
an accessible and engaging manner. Additionally, it was hoped that participants might feel more of a 
connection with the study and the chief investigator, increasing participant uptake. The author, and chief 
investigator, found the video facilitative of adding enthusiasm and engagement to the recruitment process. 
Secondly, all participants were screened over the phone, providing a further opportunity to develop a 
rapport. Lastly, the chief investigator personally delivered and collected the overnight test equipment, and 
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actigraphs in some cases, to participants who lived in the North West of England. It is believed that these 
opportunities to develop a rapport with participants may also have contributed to the high data capture 
through participants feeling connected to the study. Indeed, participant feedback included positive comments 
about the information video, interactions with the chief investigator and enjoyment of taking part in the 
study. The author also felt these interactions with participants added an aspect of human connection to the 
study. Participants were found to be very passionate about “putting BD on the map” in terms of research, 
increasing awareness of the link between OSA and a BD diagnosis, and keen to discuss this with similarly 
motivated people. The author gained the impression that this was an area in which participants had wanted to 
see increased awareness for some time, leading to them being highly motivated to participate. It is 
recommended that similar opportunities for rapport building with participants be maintained in future 
replications. However, the time commitment this will require if intending to recruit a larger sample is also 
worth considering.  
Necessary considerations for future replications also include recruitment strategy and necessary 
ethical approval procedures. The current study received ethical approval through the National Health Service 
(NHS) and Health Research Authority so the study could be advertised through a local mental health service 
commissioned specifically for people with a BD diagnosis, in addition to other methods. It was considered 
that the increased recruitment opportunities arising from advertising the study through the NHS would 
compensate for any reduction in the length of the possible recruitment period resulting from the more 
detailed ethical approval procedure. However, only one participant was successfully recruited through 
advertisement in local services, the reason for which is unclear. All other participants responded to an email 
advert sent to the Spectrum Centre for Mental Health Research mailing list. No participants were recruited 
through advertisement via social media. This finding suggests that potential research participants in this 
population are most successfully recruited when they have previously expressed an interest in participating 
in research. Moreover, the majority of participants’ pre-existing interest in participating in research may also 
have contributed to the high levels of data capture.  
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Finally, participant responses in the current research potentially highlighted a need for future 
research to carefully consider the interpretation of the last question on the STOP-Bang questionnaire (Chung 
et al., 2016) if using to screen for risk of OSA. Participants are asked if their gender is male as affirmative 
answers to this question have been linked to a higher risk of OSA (Chung et al., 2016, 2008). Previous 
research has not differentiated biological sex with gender identification due to the terms gender and sex 
being used synonymously (Jordan et al., 2014; Pillar et al., 2000). However, one participant in the current 
study provided different answers to the question around sex included in the demographic questionnaire and 
the gender question of the STOP-Bang. Fortunately, this participant’s group allocation would not have been 
altered by different interpretations of the gender question on the STOP-Bang questionnaire and so further 
consideration was not required in this instance. However, as biological sex and gender identity are not 
synonymous (Unger, 1979), future research should ensure to clarify the intended interpretation of this 
question for standardisation.  
Ethical Challenges and Considerations Arising from the Research Study 
 The following ethical considerations arose for the author when undertaking the study that also should 
be considered prior to replications. The author noticed that although participants had provided informed 
consent, it sometimes felt uncomfortable administering the Mini International Psychiatric Interview (MINI; 
Sheehan, 2016) over the telephone upon speaking to participants for the first time due to the sensitive nature 
of the questions. All participants but one chose to conduct the screening interview over the phone, and the 
one attempt to videoconference was unsuccessful and phone had to be used instead. However, it was 
considered that conducting the screening interview over videoconference might enable a faster development 
of a comfortable rapport with clients. On the other hand, although participants were assured they did not 
need to answer all questions if they did not feel comfortable to do so, only one participant conveyed 
discomfort at answering some of the questions. In this instance, the participant described the questions in 
section I of the MINI as vague and difficult to answer, which was being used to ensure participants’ alcohol 
intake was not likely to be affecting their sleep. The author noticed a reluctance to ask participants all the 
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questions in sections I if participants had answered “yes” to I1 (“In the past 12 months, have you had 3 or 
more alcoholic drinks, - within a 3 hour period, - on 3 or more occasions?”) but “no” to the first few 
questions in the next section, I2 (e.g. “During the times when you drank alcohol, did you end up drinking 
more than you planned when you started?” and “On the days that you drank, did you spend substantial time 
obtaining alcohol, drinking, or recovering from the effects of alcohol?”). The author reflected that culturally, 
an affirmative answer to I1 is likely to be considered a social norm, yet then being asked a further 12 follow 
up questions may challenge this norm, potentially generating discomfort for participants. No potential 
participants had to be excluded based on the outcome of the screening process. Therefore future replications 
may instead consider simply asking participants if they have a diagnosis of, or consider themselves to have, 
a substance use difficulty, or if they consider their substance use will likely impact their sleep during the data 
collection period. Alternatively, to ensure scientific rigour, researchers can assure participants of the 
standardised nature of the screen and that every question needs to be asked regardless of previous answers in 
some cases.  
 The author was also aware of “pulls” towards the position of a clinician over a researcher during the 
telephone screen. As discussed above, the administration of the MINI (Sheehan, 2016) involved asking 
participants for sensitive information that was sometimes accompanied by understandable levels of distress. 
These situations required the author to use their clinical skills in sitting with and containing distress. 
However, it was noted that these skills and the instinct that accompanies them, e.g. not to move the 
conversation away from difficult emotions, often juxtaposed with the research agenda of continuing with the 
screening questions. Therefore, some telephone screenings were much lengthier than others to allow for 
what felt like an appropriate balance of these positions and skills in order to maintain rapport with 
participants.  
Moreover, the author also noticed discomfort around informing participants in the suspected-OSA 
group that they were considered likely to have OSA, particularly when the oximeter results supported this. It 
was stipulated in the participant information sheet that the author was not qualified to diagnose OSA and 
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participants in the suspected-OSA group were provided with a letter detailing the results of the screening 
questionnaires, and oximeter results if applicable, which they were advised to share with their GP. As the 
results did not constitute a diagnosis, the author did not initially consider the communication of the oximeter 
results, and began sending these to participants via email. However, the author reflected that this may be 
difficult news for some participants to receive and considered that it may have been more sensitive to ask 
participants if they would prefer the results to be initially delivered via phone call or email. On the other 
hand, no participants appeared to become distressed by the results, as far as this could be ascertained, as 
many seemed relieved to have evidence that supported their suspicions that they could have OSA. The 
author also reflected on their clinical role rarely involving providing diagnoses, or information suggestive of 
a diagnosis, which may have generated a discomfort for the author not shared by participants.  
Notably, a couple of participants were concerned that they had OSA and expressed surprise and 
disappointment when they did not meet the criteria for the suspected-OSA group. For instance, one 
participant was experiencing waking up in the night and not breathing, yet did not endorse any further signs 
of OSA. These participants were also offered GP letters with their screening results and were advised to 
consult with their GP if they were concerned. These experiences suggested to the author that participants 
were perhaps more likely to take part in the study if they suspected they had OSA, and perhaps hoped that 
the study may confirm their suspicions and facilitate formal investigation by their GP. Research has found 
that access to sleep clinic assessments of OSA in the UK is incredibly limited (Flemons et al., 2004). 
Moreover, the thematic synthesis conducted as part of this thesis revealed that GPs can have limited 
awareness of OSA, limiting the accessibility of referrals to sleep clinics. The author had noticed being 
surprised at recruiting more people meeting the criteria for the suspected-OSA group, as they had expected 
around the estimated 25% of people with a BD diagnosis (Stubbs et al., 2016) to meet the criteria. However, 
anecdotal information from participants supported the finding from the thematic synthesis; the study 
potentially provided participants with recognition of their potential OSA that they were struggling to receive 
elsewhere. This advantage provided by the study may explain why more participants with suspected-OSA 
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were recruited. These findings are therefore worth bearing in mind when recruiting for future replications as 
it is possible that there is less incentive for people who do not suspect they have OSA.  
Providing reimbursement that reflects the time commitment requested of participants may reduce the 
imbalance in incentive to take part for people with and without suspected-OSA, in addition to facilitating 
recruitment generally. The author noticed feeling very uncomfortable asking participants for the necessary 
time commitment for the study without being able to offer representative reimbursement. Most participants 
appeared eager to contribute their time because they were committed to furthering research in the area. Only 
one participant raised the issue of the imbalance between participant time and the only reimbursement being 
a prize draw for a £50 Amazon voucher. However, this participant was happy to participate when the limited 
funding for the study was explained. It is therefore difficult to know if recruitment outcomes would have 
been altered by more proportionate participant reimbursement but it is hoped that future replications may not 
have to rely so much on participant’s personal motivation and commitment to the subject.  
  The last ethical consideration that arose for the author was noticing an imbalance in disclosure 
between themselves and some participants. Both the paper and electronic versions of the PANAS appeared 
to lead some participants to wish to contextualise their scores with the author. Some participants enclosed 
letters within the paper diary, offering more information about their personal circumstances. Meanwhile 
others, who were providing their responses online, sent emails or texts to the researcher to contextualise their 
scores that day, as though they anticipated the author was receiving and interpreting the scores live. These 
experiences made the author reflect on the potential perceived intimacy of the design for some participants 
and that this requires sensitive consideration and management. For instance, one participant continued to 
contact the author intermittently after their data collection period to provide updates on their wellbeing, 
reflect on their perceived value of the study and enquire about progress towards the study’s findings. The 
author wondered if this was perhaps due to the participant feeling a loss following perceived disclosure and 
interest in their feelings twice a day for two weeks, or due to the context of the COVID-19 pandemic 
lockdown (Bavel et al., 2020) and the participant’s understandable interest in how this had affected the 
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study. These increased interactions from what the study design intends may also result from the rapport 
established between researcher and participants. It is felt that it is therefore important to assure participants 
in future replications that PANAS scores are not interpreted individually and therefore do not need to be 
contextualised in the hopes this will prevent unnecessary effort and disclosure on behalf of participants.  	
The Clinical Issue of Sleep 
 The topics of both the empirical paper and systematic literature review were informed by the current 
clinical issue that the contribution of sleep to clinical presentations is under recognised in both research and 
practice. Sleep difficulties, OSA and insomnia being the most common, are believed to be some of the most 
prevalent complaints in primary health care settings (Chai-Coetzer et al., 2015; Morin and Benca, 2012; 
Morphy et al., 2007; Shochat et al., 1999). Meanwhile, sleep difficulties have been linked to most mental 
health difficulties (Baglioni et al., 2016), a plethora of physical health conditions (Barone and Menna-
Barreto, 2011; Shamsuzzaman et al., 2003; Shi et al., 2018) and have even been found to mediate the impact 
of socioeconomic status on wellbeing (Demakakos et al., 2008). However, it is recognised that sleep 
complaints are under recognised and poorly understood by healthcare professionals worldwide (Fuhrman et 
al., 2012; Gibson, 2004; Kapur et al., 2002; Tufan et al., 2017; Wilson et al., 2019).  
This lack of awareness is perhaps unsurprising given the extremely limited training on sleep 
difficulties provided. Romiszewski et al. (2020) found that an average of only 3.2 hours were dedicated to 
teaching around sleep during UK medical courses and that sleep is not considered a core topic. Meanwhile, 
coverage of sleep and sleep difficulties during clinical psychology training is similarly limited, despite the 
role of psychology in treating sleep difficulties now being recognised as integral (Meltzer et al., 2009). The 
author became aware of this gap in teaching provision during their own training, alongside noticing a 
reluctance of their supervisors to support them to work with clients around their sleep on clinical placements.  
It is the author’s perception that as sleep is a universal human need, with recommended human sleep 
time comprising over a third human lifetimes (Hirshkowitz et al., 2015), the clinical significance of poor 
sleep is hugely under considered and under researched. Indeed, as there is still much that scientific enquiry is 
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yet to conclude about the purpose of sleep (Eidelman, 2002), perhaps this leads to the general avoidance of 
the topic in clinical fields. However, it can be argued that our understandings around mental health are far 
less established than the conclusion that a lack of quality sleep detriments both physical and mental health 
(Baglioni et al., 2016; Barone and Menna-Barreto, 2011; Grandner, 2012; Shamsuzzaman et al., 2003; Shi et 
al., 2018). Meanwhile, as the field of “sleep medicine” is arguably still in its infancy due to being under 
recognised and under resourced for many years (Romiszewski et al., 2020), the existing literature is 
predominantly medical. Therefore, the author was motivated to contribute research to further clinical 
recognition and management of sleep difficulties whilst also promoting the value of psychological principles 
in the area. 
The thematic synthesis and empirical paper have generated both formal and informal findings that 
can inform clinical psychological practice. The thematic synthesis highlighted the importance of 
biopsychosocial understandings to improving PAP use. Therefore, psychological skills and understandings 
could be utilised at an individual and consultation level to achieve this. As current guidance around PAP 
does not detail psychological consultation or input (National Institute for Health and Care Excellence, 2008), 
this is an area of practice that needs to be targeted through further recognition and research. Anecdotally, the 
author is aware that very few (~40) clinical psychologists are commissioned to work into UK sleep clinics. 
Moreover, whilst the majority of sleep clinics are specifically commissioned to assess and treat respiratory 
sleep disorders, such as OSA, these services have even less psychological input than others.  
Meanwhile, informal findings from the empirical project, as detailed above, support the findings 
from the thematic synthesis that people with suspected OSA can struggle to have their symptoms recognised 
and formally assessed. Furthermore, only two out of twelve people identified as having suspected-OSA had 
previously received investigation and a diagnosis. One of the participants with an existing diagnosis even 
reported that they had received their diagnosis following taking part in previous research around OSA. 
Therefore, there is certainly the clinical implication that OSA is under recognised in people with a BD 
diagnosis. Psychological practice can seek to improve recognition of OSA through biopsychosocial 
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assessment and formulation, which should include an individual’s experiences of sleep. Meanwhile, 
biopsychosocial formulation can then inform holistic understandings and psychological intervention around 
the incorporation of PAP into people’s lives as indicated by the results of the thematic synthesis. The 
identified difficulties around PAP use are likely to be further exacerbated by the emotional instability 
experienced by people with a BD diagnosis. It is notable that both participants who had previously received 
a diagnosis of OSA reported to be no longer using PAP, although the reasons for this were unexplored. 
Finally, it is hoped that the findings provide evidence that it is not beneficial for sleep to be a 
“specialist” subject and only dealt with by specialist services that are very difficult to access (Flemons et al., 
2004). The author feels the findings of the thesis suggest that it would be more beneficial for clinicians to 
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Psychopharmacol. 33, 923–947. https://doi.org/10.1177/0269881119855343 
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25 September 2019 
 
Miss Amy Brown 
Trainee Clinical Psychologist 
Lancashire Care NHS Foundation Trust 
Department of Clinical Psychology 




Dear Miss Brown  
 
Study title: Impact of obstructive sleep apnoea for people with a 
bipolar disorder diagnosis 
REC reference: 19/SC/0487 
Protocol number: N/A 
IRAS project ID: 240867 
 
The Proportionate Review Sub-committee of the South Central - Oxford C Research Ethics 




On behalf of the Committee, the sub-committee gave a favourable ethical opinion of the above 
research on the basis described in the application form, protocol and supporting documentation, 
subject to the conditions specified below. 
 
Conditions of the Favourable Opinion 
 
The REC favourable opinion is subject to the following conditions being met prior to the start of 
Please note: This is the 
favourable opinion of the 
REC only and does not allow 
you to start your study at 
NHS sites in England until 
you receive HRA Approval  
 





1 Increase the prominence of the information resource on OSA 2. When advising 
participants to attend their GP, suggest that the researcher ensures that the 
person has appropriate information to show to the GP about the study. This 
may take the form of a GP letter. 
 
Number Recommendation 
1 Omit any mention of the Samaritans. 
 
You should notify the REC once all conditions have been met (except for site approvals 
from host organisations) and provide copies of any revised documentation with updated 
version numbers. Revised documents should be submitted to the REC electronically 
from IRAS. The REC will acknowledge receipt and provide a final list of the approved 
documentation for the study, which you can make available to host organisations to 
facilitate their permission for the study. Failure to provide the final versions to the REC 
may cause delay in obtaining permissions. 
 
Confirmation of Capacity and Capability (in England, Northern Ireland and Wales) or NHS 
management permission (in Scotland) should be sought from all NHS organisations involved in 
the study in accordance with NHS research governance arrangements. Each NHS organisation 
must confirm through the signing of agreements and/or other documents that it has given 
permission for the research to proceed (except where explicitly specified otherwise). 
 
Guidance on applying for HRA and HCRW Approval (England and Wales)/ NHS permission for 
research is available in the Integrated Research Application System. 
 
For non-NHS sites, site management permission should be obtained in accordance with the 
procedures of the relevant host organisation. 
 
Sponsors are not required to notify the Committee of management permissions from host 
organisations. 
 
Registration of Clinical Trials 
 
It is a condition of the REC favourable opinion that all clinical trials are registered on a publicly 
accessible database. For this purpose, clinical trials are defined as the first four project 
categories in IRAS project filter question 2. For clinical trials of investigational medicinal 
products (CTIMPs), other than adult phase I trials, registration is a legal requirement. 
 
Registration should take place as early as possible and within six weeks of recruiting the first 
research participant at the latest. Failure to register is a breach of these approval conditions, 
unless a deferral has been agreed by or on behalf of the Research Ethics Committee ( see here 




As set out in the UK Policy Framework, research sponsors are responsible for making 
information about research publicly available before it starts e.g. by registering the research 
A Research Ethics Committee established by the Health Research Authority 
 




You should notify the REC of the registration details.  We routinely audit applications for 
compliance with these conditions.  
 
Publication of Your Research Summary 
 
We will publish your research summary for the above study on the research summaries section 
of our website, together with your contact details, no earlier than three months from the date of 
this favourable opinion letter.  Should you wish to provide a substitute contact point, make a 




It is the responsibility of the sponsor to ensure that all the conditions are complied with 
before the start of the study or its initiation at a particular site (as applicable). 
 
After ethical review: Reporting requirements 
 
The attached document “After ethical review – guidance for researchers” gives detailed 
guidance on reporting requirements for studies with a favourable opinion, including: 
 
• Notifying substantial amendments 
• Adding new sites and investigators 
• Notification of serious breaches of the protocol 
• Progress and safety reports 
• Notifying the end of the study, including early termination of the study 
• Final report 
 
The latest guidance on these topics can be found at 
https://www.hra.nhs.uk/approvals-amendments/managing-your-approval/.  
 
Ethical review of research sites 
 
The favourable opinion applies to all NHS sites taking part in the study, subject to management 
permission being obtained from the NHS/HSC R&D office prior to the start of the study (see 




The documents reviewed and approved were: 
 
Document   Version   Date   
Copies of advertisement materials for research participants [Twitter 
adverts]  
Version 0.1  28 June 2019  
Copies of advertisement materials for research participants [Poster 
advert]  
Version 0.1  28 June 2019  
Covering letter on headed paper [Cover letter for paper 
questionnairea]  
Version 0.1  28 June 2019  
A Research Ethics Committee established by the Health Research Authority 
 
Evidence of Sponsor insurance or indemnity (non NHS Sponsors 
only) [Evidence of sponsor indemnity insurance]  
Version 0.1  18 July 2019  
Instructions for use of medical device [Actigraph manual]  Version 0.1  28 June 2019  
Instructions for use of medical device [Oximeter manual]  Version 0.1  28 June 2019  
IRAS Application Form [IRAS_Form_28082019]    28 August 2019  
IRAS Application Form XML file [IRAS_Form_28082019]    28 August 2019  
IRAS Checklist XML [Checklist_28082019]    28 August 2019  
Letter from sponsor [Sponsorship letter]  Version 0.1  13 August 2019  
Non-validated questionnaire [Paper demographics questionnaire]  Version 0.1  28 June 2019  
Other [Instructions for participants around calculating BMI for 
STOP-Bang questionnaire]  
Version 0.1  28 June 2019  
Other [Online questionnaire emails]  Version 0.1  28 June 2019  
Other [Paper questionnaire booklet (PANAS questionnaires)]  Version 0.1  28 June 2019  
Participant consent form [Paper participant consent form]  Version 0.1  28 June 2019  
Participant information sheet (PIS) [Paper participant information 
sheet]  
Version 0.1  28 June 2019  
Research protocol or project proposal [Research protocol]  Version 0.1  28 June 2019  
Summary CV for Chief Investigator (CI) [Summary CV for CI]  Version 0.1  28 June 2019  
Summary CV for supervisor (student research) [Prof Steven Jones 
CV]  
Version 1  28 June 2019  
Summary CV for supervisor (student research) [Dr Guillermo Perez 
Algorta CV]  
Version 1  28 June 2019  
Validated questionnaire [Epworth Sleepiness Scale (paper copy)]  Version 1  28 June 2019  
Validated questionnaire [STOP-Bang Questionnaire (paper copy)]  Version 1  28 June 2019  
Validated questionnaire [Pittsburgh Sleep Quality Index (paper 
copy)]  
Version 1  28 June 2019  
Validated questionnaire [The 7 Up 7 Down Inventory (paper copy)]  Version 1  28 June 2019  
Validated questionnaire [Paper questionnaire booklet (PANAS 
questionnaires)]  
  28 June 2019  
 
Membership of the Proportionate Review Sub-Committee 
 
The members of the Sub-Committee who took part in the review are listed on the attached 
sheet. 
 
Statement of compliance  
 
The Committee is constituted in accordance with the Governance Arrangements for Research 
Ethics Committees and complies fully with the Standard Operating Procedures for Research 




The Health Research Authority is continually striving to provide a high quality service to all 
applicants and sponsors. You are invited to give your view of the service you have received and 
the application procedure. If you wish to make your views known please use the feedback form 
available on the HRA website: 
http://www.hra.nhs.uk/about-the-hra/governance/quality-assurance/    





We are pleased to welcome researchers and research staff to our HRA Learning Events and 
online learning opportunities– see details at: 
https://www.hra.nhs.uk/planning-and-improving-research/learning/  
 
With the Committee’s best wishes for the success of this project. 
 





Dr Linda Cartwright 




Enclosures: List of names and professions of members who took part in the review  
 
“After ethical review – guidance for researchers” 
 
Copy to: Ms Becky Gordon 
 
A Research Ethics Committee established by the Health Research Authority 
 
South Central - Oxford C Research Ethics Committee 
 
Attendance at PRS Sub-Committee of the REC meeting on 20 September 2019 
 
Committee Members:  
 
Name   Profession   Present    Notes   
Mr David Carpenter (Co-optee) Retired Social Scientist  Yes     
Dr Linda Cartwright (Alternate 
Vice Chair and Meeting Chair) 
Retired Consultant 
Epidemiologist  
Yes     
Mrs Vivienne Laurie (Vice Chair) Barrister  Yes     
  
Also in Attendance:  
 
Name   Position (or reason for attending)   
Miss Charlotte Ferris  Approvals Officer  
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South Central - Oxford C Research Ethics Committee 
Level 3, Block B  
Whitefriars Building 














02 October 2019 
 
Miss Amy Brown 
Department of Clinical Psychology 




Dear Miss Brown 
 
Study title: Impact of obstructive sleep apnoea for people with a 
bipolar disorder diagnosis 
REC reference: 19/SC/0487 
Protocol number: N/A 
IRAS project ID: 240867 
 
Thank you for your letter of 26 September 2019. I can confirm the REC has received the 
documents listed below and that these comply with the approval conditions detailed in our letter 




The documents received were as follows: 
 
Document   Version   Date   
GP/consultant information sheets or letters [Letter to show to GP]  Version 0.1  26 September 2019  
IRAS Checklist XML [Checklist_26092019]    26 September 2019  
Other [Conditions of favourable opinion and response table]  Version 0.1  26 September 2019  
Please note: This is an 
acknowledgement letter from 
the REC only and does not 
allow you to start your study 
at NHS sites in England until 
you receive HRA Approval  
 
A Research Ethics Committee established by the Health Research Authority 
 
Participant information sheet (PIS) [Paper participant information 
sheet]  
Version 0.2  26 September 2019  




The final list of approved documentation for the study is therefore as follows: 
 
Document   Version   Date   
Copies of advertisement materials for research participants [Twitter 
adverts]  
Version 0.1  28 June 2019  
Copies of advertisement materials for research participants [Poster 
advert]  
Version 0.1  28 June 2019  
Covering letter on headed paper [Cover letter for paper 
questionnairea]  
Version 0.1  28 June 2019  
Evidence of Sponsor insurance or indemnity (non NHS Sponsors 
only) [Evidence of sponsor indemnity insurance]  
Version 0.1  18 July 2019  
GP/consultant information sheets or letters [Letter to show to GP]  Version 0.1  26 September 2019  
Instructions for use of medical device [Actigraph manual]  Version 0.1  28 June 2019  
Instructions for use of medical device [Oximeter manual]  Version 0.1  28 June 2019  
IRAS Application Form [IRAS_Form_28082019]    28 August 2019  
IRAS Application Form XML file [IRAS_Form_28082019]    28 August 2019  
IRAS Checklist XML [Checklist_26092019]    26 September 2019  
Letter from sponsor [Sponsorship letter]  Version 0.1  13 August 2019  
Non-validated questionnaire [Paper demographics questionnaire]  Version 0.1  28 June 2019  
Other [Instructions for participants around calculating BMI for 
STOP-Bang questionnaire]  
Version 0.1  28 June 2019  
Other [Online questionnaire emails]  Version 0.1  28 June 2019  
Other [Paper questionnaire booklet (PANAS questionnaires)]  Version 0.1  28 June 2019  
Other [Conditions of favourable opinion and response table]  Version 0.1  26 September 2019  
Participant consent form [Paper participant consent form]  Version 0.1  28 June 2019  
Participant information sheet (PIS) [Paper participant information 
sheet]  
Version 0.2  26 September 2019  
Research protocol or project proposal [Research protocol]  Version 0.2  26 September 2019  
Summary CV for Chief Investigator (CI) [Summary CV for CI]  Version 0.1  28 June 2019  
Summary CV for supervisor (student research) [Prof Steven Jones 
CV]  
Version 1  28 June 2019  
Summary CV for supervisor (student research) [Dr Guillermo Perez 
Algorta CV]  
Version 1  28 June 2019  
Validated questionnaire [Epworth Sleepiness Scale (paper copy)]  Version 1  28 June 2019  
Validated questionnaire [STOP-Bang Questionnaire (paper copy)]  Version 1  28 June 2019  
Validated questionnaire [Pittsburgh Sleep Quality Index (paper 
copy)]  
Version 1  28 June 2019  
Validated questionnaire [The 7 Up 7 Down Inventory (paper copy)]  Version 1  28 June 2019  
Validated questionnaire [Paper questionnaire booklet (PANAS 
questionnaires)]  
  28 June 2019  
 
A Research Ethics Committee established by the Health Research Authority 
 
You should ensure that the sponsor has a copy of the final documentation for the study.  It is 
the sponsor's responsibility to ensure that the documentation is made available to R&D offices 
at all participating sites. 
 









Copy to: Miss Amy Brown 




Miss Amy Brown 
Trainee Clinical Psychologist 
Lancashire Care NHS Foundation Trust 
Department of Clinical Psychology 







17 October 2019 
 





Study title: Impact of obstructive sleep apnoea for people with a 
bipolar disorder diagnosis 
IRAS project ID: 240867  
Protocol number: N/A 
REC reference: 19/SC/0487   
Sponsor Lancaster University 
 
I am pleased to confirm that HRA and Health and Care Research Wales (HCRW) Approval 
has been given for the above referenced study, on the basis described in the application form, 
protocol, supporting documentation and any clarifications received. You should not expect to 
receive anything further relating to this application. 
 
Please now work with participating NHS organisations to confirm capacity and capability, in 
line with the instructions provided in the “Information to support study set up” section towards 
the end of this letter. 
 
How should I work with participating NHS/HSC organisations in Northern Ireland and 
Scotland? 
HRA and HCRW Approval does not apply to NHS/HSC organisations within Northern Ireland 
and Scotland. 
 
If you indicated in your IRAS form that you do have participating organisations in either of 
these devolved administrations, the final document set and the study wide governance report 
(including this letter) have been sent to the coordinating centre of each participating nation. 
The relevant national coordinating function/s will contact you as appropriate. 
HRA and Health and Care 






Please see IRAS Help for information on working with NHS/HSC organisations in Northern 
Ireland and Scotland.  
 
How should I work with participating non-NHS organisations? 
HRA and HCRW Approval does not apply to non-NHS organisations. You should work with 
your non-NHS organisations to obtain local agreement in accordance with their procedures. 
 
What are my notification responsibilities during the study?  
  
The document “After Ethical Review – guidance for sponsors and investigators”, issued with 
your REC favourable opinion, gives detailed guidance on reporting expectations for studies, 
including: 
x Registration of research 
x Notifying amendments 
x Notifying the end of the study 
The HRA website also provides guidance on these topics, and is updated in the light of 
changes in reporting expectations or procedures. 
 
Who should I contact for further information? 
Please do not hesitate to contact me for assistance with this application. My contact details 
are below. 
 





HRA Approvals Manager 
 
 
Email: hra.approval@nhs.net      
  
Copy to: Ms Becky Gordon (Sponsor Contact) 
 
 





List of Documents 
 
The final document set assessed and approved by HRA and HCRW Approval is listed below.   
 
Document   Version   Date   
Copies of advertisement materials for research participants [Twitter 
adverts]  
Version 0.1  28 June 2019  
Copies of advertisement materials for research participants [Poster 
advert]  
Version 0.1  28 June 2019  
Covering letter on headed paper [Cover letter for paper 
questionnairea]  
Version 0.1  28 June 2019  
Evidence of Sponsor insurance or indemnity (non NHS Sponsors 
only) [Evidence of sponsor indemnity insurance]  
Version 0.1  18 July 2019  
GP/consultant information sheets or letters [Letter to show to GP]  Version 0.1  26 September 2019  
Instructions for use of medical device [Actigraph manual]  Version 0.1  28 June 2019  
Instructions for use of medical device [Oximeter manual]  Version 0.1  28 June 2019  
IRAS Application Form [IRAS_Form_28082019]    28 August 2019  
IRAS Checklist XML [Checklist_26092019]    26 September 2019  
Letter from sponsor [Sponsorship letter]  Version 0.1  13 August 2019  
Non-validated questionnaire [Paper demographics questionnaire]  Version 0.1  28 June 2019  
Other [Conditions of favourable opinion and response table]  Version 0.1  26 September 2019  
Other [Sponsor email confirmation re: insurance]    17 October 2019  
Other [Instructions for participants around calculating BMI for STOP-
Bang questionnaire]  
Version 0.1  28 June 2019  
Other [Online questionnaire emails]  Version 0.1  28 June 2019  
Other [Paper questionnaire booklet (PANAS questionnaires)]  Version 0.1  28 June 2019  
Participant consent form [Paper participant consent form]  Version 0.1  28 June 2019  
Participant information sheet (PIS) [Paper participant information 
sheet]  
Version 0.2  26 September 2019  
Research protocol or project proposal [Research protocol]  Version 0.2  26 September 2019  
Summary CV for Chief Investigator (CI) [Summary CV for CI]  Version 0.1  28 June 2019  
Summary CV for supervisor (student research) [Prof Steven Jones 
CV]  
Version 1  28 June 2019  
Summary CV for supervisor (student research) [Dr Guillermo Perez 
Algorta CV]  
Version 1  28 June 2019  
Validated questionnaire [Paper questionnaire booklet (PANAS 
questionnaires)]  
  28 June 2019  
Validated questionnaire [Epworth Sleepiness Scale (paper copy)]  Version 1  28 June 2019  
Validated questionnaire [STOP-Bang Questionnaire (paper copy)]  Version 1  28 June 2019  
Validated questionnaire [Pittsburgh Sleep Quality Index (paper 
copy)]  
Version 1  28 June 2019  
Validated questionnaire [The 7 Up 7 Down Inventory (paper copy)]  Version 1  28 June 2019  
 
 
IRAS project ID 240867 
 
Information to support study set up 
 
The below provides all parties with information to support the arranging and confirming of capacity and capability with participating NHS 






Expectations related to confirmation of 
capacity and capability 
















is only one site 
type. 
Organisations will not be required to formally 
confirm capacity and capability, and research 
activities may begin 35 days after provision of 
the local information pack, provided the 
following conditions are met.  
x You have contacted participating NHS 
organisations (see below for details) 
x The NHS organisation has not 
provided a reason as to why they 
cannot participate 
x The NHS organisation has not 
requested additional time to confirm. 
 
You may start the research prior to the above 
deadline if the PIC organisation positively 
confirms that the research may proceed.  
The sponsor should 
ensure that 
appropriate 






























undertaken by local 
staff, it is unlikely 
that letters of 
access or honorary 
research contracts 




not already in 
place, researchers 
undertaking any of 
the research 
activities listed in 
A18 of the IRAS 
form would be 
expected to obtain 





Other information to aid study set-up and delivery 
This details any other information that may be helpful to sponsors and participating NHS organisations in England and Wales in study set-up. 




Health Research Authority, England  NIHR Clinical Research Network, England 
NHS Research Scotland  NISCHR Permissions Co-ordinating Unit, Wales 
HSC Research & Development, Public Health Agency, Northern Ireland 
Notification of non-substantial / minor amendments; version 1.0; November 2014     Page 1 of 4 
 
 
Notification of Non-Substantial/Minor Amendments(s) for NHS Studies 
 
This template must only be used to notify NHS/HSC R&D office(s) of amendments, which are NOT 
categorised as Substantial Amendments.  
If you need to notify a Substantial Amendment to your study then you MUST use the appropriate 
Substantial Amendment form in IRAS.  
 
Instructions for using this template 
• For guidance on amendments refer to http://www.hra.nhs.uk/research-community/during-your-research-
project/amendments/ 
• This template should be completed by the CI and optionally authorised by Sponsor, if required by sponsor 
guidelines.  
• This form should be submitted according to the instructions provided for NHS/HSC R&D at 
http://www.hra.nhs.uk/research-community/during-your-research-project/amendments/which-review-
bodies-need-to-approve-or-be-notified-of-which-types-of-amendments/ . If you do not submit your 
notification in accordance with these instructions then processing of your submission may be significantly 
delayed.  
 
1. Study Information 
 
Full title of study: 
 
Impact of obstructive sleep apnoea for people with a 




IRAS Project ID: 
 
240867 




Sponsor Amendment Notification 
date: 
 
Details of Chief Investigator: 
Name [first name and surname] Amy Brown 
Address:  
Department of Clinical Psychology, 
Division of Health Research, 
Lancaster University  
 
Postcode: LA1 4YW 
Contact telephone number: 07769187413 
Email address: a.brown21@lancaster.ac.uk 
 
Details of Lead Sponsor: 
Name: Becky Gordon 
Contact email address: sponsorship@lancaster.ac.uk 
Details of Lead Nation: 
 
 
Name of lead nation 
delete as appropriate 
England  
If England led is the study going 
through CSP? 
delete as appropriate 
No 
Name of lead R&D office: Lancashire & South Cumbria NHS Foundation Trust 
Partner Organisations: 
Health Research Authority, England  NIHR Clinical Research Network, England 
NHS Research Scotland  NISCHR Permissions Co-ordinating Unit, Wales 
HSC Research & Development, Public Health Agency, Northern Ireland 




Health Research Authority, England  NIHR Clinical Research Network, England 
NHS Research Scotland  NISCHR Permissions Co-ordinating Unit, Wales 
HSC Research & Development, Public Health Agency, Northern Ireland 
Notification of non-substantial / minor amendments; version 1.0; November 2014     Page 3 of 4 
 
2. Summary of amendment(s)  
This template must only be used to notify NHS/HSC R&D office(s) of amendments, which are NOT categorised as Substantial Amendments.  





Brief description of amendment 
(please enter each separate amendment in a new row) 
Amendment applies to  
(delete/ list as appropriate) 
List relevant supporting document(s), 
including version numbers 
(please ensure all referenced supporting documents are 
submitted with this form) 
R&D category 
of amendment  
(category A, B, C) 
For office use only 
Nation Sites Document Version  
1 Addition of Lancashire & South Cumbria NHS 
Foundation Trust as a research site.  
 
This is following liaison with Lancashire & South 
Cumbria NHS Foundation Trust R&D who have 
advised that the advertisement activities described 
on the IRAS form to be conducted through 
Lancashire & South Cumbria NHS Foundation Trust 
(formerly Lancashire Care NHS Foundation Trust) 
Community Mental Health Team constitutes the 
activity of a research site rather than a PIC.  









2      
3      
4      
5      
[Add further rows as required] 
Partner Organisations: 
Health Research Authority, England  NIHR Clinical Research Network, England 
NHS Research Scotland  NISCHR Permissions Co-ordinating Unit, Wales 
HSC Research & Development, Public Health Agency, Northern Ireland 
Notification of non-substantial / minor amendments; version 1.0; November 2014     Page 4 of 4 
 
3. Declaration(s)  
 
 
Declaration by Chief Investigator 
 
• I confirm that the information in this form is accurate to the best of my knowledge and I take full responsibility 
for it. 
 
• I consider that it would be reasonable for the proposed amendment(s) to be implemented. 
 
 
Signature of Chief Investigator:      …….……………………………… 
 
 
Print name:  Amy Brown                                  …….……………………………… 
 
 





Optional Declaration by the Sponsor’s Representative (as per Sponsor Guidelines) 
The sponsor of an approved study is responsible for all amendments made during its conduct.  
The person authorising the declaration should be authorised to do so. There is no requirement for a particular 
level of seniority; the sponsor’s rules on delegated authority should be adhered to. 
• I confirm the sponsor’s support for the amendment(s) in this notification. 
 
 


















Health Research Authority, England  NIHR Clinical Research Network, England 
NHS Research Scotland  NISCHR Permissions Co-ordinating Unit, Wales 
HSC Research & Development, Public Health Agency, Northern Ireland 
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Notification of Non-Substantial/Minor Amendments(s) for NHS Studies 
 
This template must only be used to notify NHS/HSC R&D office(s) of amendments, which are NOT 
categorised as Substantial Amendments.  
If you need to notify a Substantial Amendment to your study then you MUST use the appropriate 
Substantial Amendment form in IRAS.  
 
Instructions for using this template 
• For guidance on amendments refer to http://www.hra.nhs.uk/research-community/during-your-research-
project/amendments/ 
• This template should be completed by the CI and optionally authorised by Sponsor, if required by sponsor 
guidelines.  
• This form should be submitted according to the instructions provided for NHS/HSC R&D at 
http://www.hra.nhs.uk/research-community/during-your-research-project/amendments/which-review-
bodies-need-to-approve-or-be-notified-of-which-types-of-amendments/ . If you do not submit your 
notification in accordance with these instructions then processing of your submission may be significantly 
delayed.  
 
1. Study Information 
 
Full title of study: 
 
 
Impact of obstructive sleep apnoea for people with a 
bipolar disorder diagnosis 
 
IRAS Project ID: 
 
240867 




Sponsor Amendment Notification 
date: 
 
Details of Chief Investigator: 
Name [first name and surname] Amy Brown 
Address:  
Department of Clinical Psychology, 
Division of Health Research, 
Lancaster University  
 
Postcode: LA1 4YW 
Contact telephone number: 07769187413 
Email address: a.brown21@lancaster.ac.uk 
 
Details of Lead Sponsor: 
Name: Becky Gordon 
Contact email address: sponsorship@lancaster.ac.uk 
Details of Lead Nation: 
 
 
Name of lead nation 
delete as appropriate 
England  
If England led is the study going 
through CSP? 
delete as appropriate 
No 
Name of lead R&D office: 
 
Lancashire & South Cumbria NHS Foundation Trust 
Partner Organisations: 
Health Research Authority, England  NIHR Clinical Research Network, England 
NHS Research Scotland  NISCHR Permissions Co-ordinating Unit, Wales 
HSC Research & Development, Public Health Agency, Northern Ireland 
Notification of non-substantial / minor amendments; version 1.0; November 2014     Page 2 of 4 
 
Partner Organisations: 
Health Research Authority, England  NIHR Clinical Research Network, England 
NHS Research Scotland  NISCHR Permissions Co-ordinating Unit, Wales 
HSC Research & Development, Public Health Agency, Northern Ireland 
Notification of non-substantial / minor amendments; version 1.0; November 2014     Page 3 of 4 
 
2. Summary of amendment(s)  
This template must only be used to notify NHS/HSC R&D office(s) of amendments, which are NOT categorised as Substantial Amendments.  





Brief description of amendment 
(please enter each separate amendment in a new row) 
Amendment applies to  
(delete/ list as appropriate) 
List relevant supporting document(s), 
including version numbers 
(please ensure all referenced supporting documents are 
submitted with this form) 
R&D category 
of amendment  
(category A, B, C) 
For office use only 
Nation Sites Document Version  
1 Inclusion criteria to be expanded to people living 
across the UK and to people aged up to 65.  
England All sites     
   
2      
3      
4      
5      
[Add further rows as required] 
Partner Organisations: 
Health Research Authority, England  NIHR Clinical Research Network, England 
NHS Research Scotland  NISCHR Permissions Co-ordinating Unit, Wales 
HSC Research & Development, Public Health Agency, Northern Ireland 
Notification of non-substantial / minor amendments; version 1.0; November 2014     Page 4 of 4 
 
3. Declaration(s)  
 
 
Declaration by Chief Investigator 
 
• I confirm that the information in this form is accurate to the best of my knowledge and I take full responsibility 
for it. 
 
• I consider that it would be reasonable for the proposed amendment(s) to be implemented. 
 
 
Signature of Chief Investigator:      …….……………………………… 
 
 
Print name:   Amy Brown                           …….……………………………… 
 
 





Optional Declaration by the Sponsor’s Representative (as per Sponsor Guidelines) 
The sponsor of an approved study is responsible for all amendments made during its conduct.  
The person authorising the declaration should be authorised to do so. There is no requirement for a particular 
level of seniority; the sponsor’s rules on delegated authority should be adhered to. 
• I confirm the sponsor’s support for the amendment(s) in this notification. 
 
 

















 Welcome to the Integrated Research Application System
 IRAS Project Filter
The integrated dataset required for your project will be created from the answers you give to the following questions. The
system will generate only those questions and sections which (a) apply to your study type and (b) are required by the
bodies reviewing your study. Please ensure you answer all the questions before proceeding with your applications. 
Please complete the questions in order. If you change the response to a question, please select ‘Save’ and review all the
questions as your change may have affected subsequent questions. 
Please enter a short title for this project (maximum 70 characters) 
Obstructive sleep apnoea and a bipolar disorder diagnosis. Version 0.1
1. Is your project research?
 Yes  No
2. Select one category from the list below:
 Clinical trial of an investigational medicinal product
 Clinical investigation or other study of a medical device
 Combined trial of an investigational medicinal product and an investigational medical device
 Other clinical trial to study a novel intervention or randomised clinical trial to compare interventions in clinical practice
 Basic science study involving procedures with human participants
 Study administering questionnaires/interviews for quantitative analysis, or using mixed quantitative/qualitative
methodology
 Study involving qualitative methods only
 Study limited to working with human tissue samples (or other human biological samples) and data (specific project
only)
 Study limited to working with data (specific project only)
 Research tissue bank
 Research database
If your work does not fit any of these categories, select the option below:
 Other study
2a. Will the study involve the use of any medical device without a CE Mark, or a CE marked device which has been
modified or will be used outside its intended purposes?
 Yes       No
2b. Please answer the following question(s):
a) Does the study involve the use of any ionising radiation?  Yes       No
b) Will you be taking new human tissue samples (or other human biological samples)?  Yes       No
c) Will you be using existing human tissue samples (or other human biological samples)?  Yes       No
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d) Will the study involve any other clinical procedures with participants (e.g. MRI, ultrasound,
physical examination)?
 Yes  No










 This study does not involve the NHS
4. Which applications do you require?
 IRAS Form
 Confidentiality Advisory Group (CAG)
 Her Majesty's Prison and Probation Service (HMPPS)
Most research projects require review by a REC within the UK Health Departments' Research Ethics Service. Is
your study exempt from REC review? 
 Yes       No
5. Will any research sites in this study be NHS organisations?
 Yes       No
5a. Are all the research costs and infrastructure costs (funding for the support and facilities needed to carry out
research e.g. NHS Support costs) for this study provided by a NIHR Biomedical Research Centre, NIHR Collaboration for
Leadership in Health Research and Care (CLAHRC), NIHR Patient Safety Translational Research Centre or Medtech and
In Vitro Diagnostic Cooperative in all study sites? 
Please see information button for further details.
 Yes       No
Please see information button for further details.
5b. Do you wish to make an application for the study to be considered for NIHR Clinical Research Network (CRN)
Support and inclusion in the NIHR Clinical Research Network Portfolio? 
Please see information button for further details.
 Yes       No
The NIHR Clinical Research Network provides researchers with the practical support they need to make clinical studies
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happen in the NHS e.g. by providing access to the people and facilities needed to carry out research “on the ground". 
If you select yes to this question, you must complete a NIHR Clinical Research Network (CRN) Portfolio Application Form
(PAF) immediately after completing this project filter question and before submitting other applications. Failing to complete
the PAF ahead of other applications e.g. HRA Approval, may mean that you will be unable to access NIHR CRN Support for
your study.
6. Do you plan to include any participants who are children?
 Yes       No
7. Do you plan at any stage of the project to undertake intrusive research involving adults lacking capacity to consent
for themselves?
 Yes       No
Answer Yes if you plan to recruit living participants aged 16 or over who lack capacity, or to retain them in the study following
loss of capacity. Intrusive research means any research with the living requiring consent in law. This includes use of
identifiable tissue samples or personal information, except where application is being made to the Confidentiality Advisory
Group to set aside the common law duty of confidentiality in England and Wales. Please consult the guidance notes for
further information on the legal frameworks for research involving adults lacking capacity in the UK.
8. Do you plan to include any participants who are prisoners or young offenders in the custody of HM Prison Service or
who are offenders supervised by the probation service in England or Wales?
 Yes       No
9. Is the study or any part of it being undertaken as an educational project? 
 Yes       No
Please describe briefly the involvement of the student(s): 
Please note that in this application the student is purposefully listed as the chief investigator in this study. This is
because the student is an experienced care practitioner undertaking doctoral-level study while employed by a health
care provider, and in such circumstances the UK Policy Framework for Health and Social Care explicitly permits
students to take the chief investigator role (p17 of the Framework contains this specific provision).
9a. Is the project being undertaken in part fulfilment of a PhD or other doctorate?
 Yes       No
10. Will this research be financially supported by the United States Department of Health and Human Services or any of
its divisions, agencies or programs?
 Yes       No
11. Will identifiable patient data be accessed outside the care team without prior consent at any stage of the project
(including identification of potential participants)?
 Yes       No
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Integrated Research Application System
Application Form for Basic science study involving procedures with human participants
 IRAS Form (project information)
Please refer to the E-Submission and Checklist tabs for instructions on submitting this application.
The Chief Investigator should complete this form. Guidance on the questions is available wherever you see this
symbol displayed. We recommend reading the guidance first. The complete guidance and a glossary are available by
selecting Help. 
Please define any terms or acronyms that might not be familar to lay reviewers of the application.
Short title and version number: (maximum 70 characters - this will be inserted as header on all forms)   
Obstructive sleep apnoea and a bipolar disorder diagnosis. Version 0.1
Please complete these details after you have booked the REC application for review.
REC Name:
REC Reference Number:      Submission date:   
 PART A: Core study information
 1. ADMINISTRATIVE DETAILS
A1. Full title of the research:
Impact of obstructive sleep apnoea for people with a bipolar disorder diagnosis
A2-1. Educational projects
Name and contact details of student(s): 
Student 1
 
 Title   Forename/Initials  SurnameMiss Amy  Brown
Address Department of Clinical Psychology
 Division of Health Research
 Lancaster University




Give details of the educational course or degree for which this research is being undertaken:
Name and level of course/ degree: 
Doctorate in Clinical Psychology
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Name and contact details of academic supervisor(s): 
Academic supervisor 1
 
 Title  Forename/Initials  SurnameDr  Guillermo  Perez Algorta
Address Spectrum Centre and Department of Clinical Psychology
 Division of Health Research
 Lancaster University
Post Code LA1 4YW
E-mail g.perezalgorta@lancaster.ac.uk




 Title   Forename/Initials  SurnameProfessor Steven  Jones
Address Spectrum Centre
 Division of Health Research
 Lancaster University
Post Code LA1 4YW
E-mail s.jones7@lancaster.ac.uk
Telephone +44 1524 593382
Fax 0
 
Please state which academic supervisor(s) has responsibility for which student(s): 
Please click "Save now" before completing this table. This will ensure that all of the student and academic supervisor
details are shown correctly. 
Student(s) Academic supervisor(s)
Student 1  Miss Amy Brown  Dr Guillermo Perez Algorta
 Professor Steven Jones
A copy of a current CV for the student and the academic supervisor (maximum 2 pages of A4) must be submitted with the
application.
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 Title   Forename/Initials  SurnameMiss Amy  Brown
Post Trainee Clinical Psychologist
Qualifications MSci Psychology and Psychological Practice
ORCID ID 0000 0002 6768 4692
Employer Lancashire Care NHS Foundation Trust
Work Address Department of Clinical Psychology
 Division of Health Research
 Lancaster University
Post Code LA1 4YW
Work E-mail a.brown21@lancaster.ac.uk
* Personal E-mail amibrown@hotmail.co.uk
Work Telephone 07769187413
* Personal Telephone/Mobile 07769187413
Fax 0
* This information is optional. It will not be placed in the public domain or disclosed to any other third party without prior
consent.
A copy of a current CV (maximum 2 pages of A4) for the Chief Investigator must be submitted with the application.
A4. Who is the contact on behalf of the sponsor for all correspondence relating to applications for this project?
This contact will receive copies of all correspondence from REC and HRA/R&D reviewers that is sent to the CI.
     
 Title  Forename/Initials  SurnameMs  Becky  Gordon
Address Head of Research Quality and Policy
 
 Lancaster University




A5-1. Research reference numbers. Please give any relevant references for your study:





Funder's reference number (enter the reference number or state not
applicable): N/A
Project website: http://www.tinyurl.com/OSA-BDresearch/
Registry reference number(s):    
The UK Policy Framework for Health and Social Care Research sets out the principle of making information about
research publicly available. Furthermore: Article 19 of the World Medical Association Declaration of Helsinki adopted
in 2008 states that "every clinical trial must be registered on a publicly accessible database before recruitment of the
first subject"; and the International Committee of Medical Journal Editors (ICMJE) will consider a clinical trial for
publication only if it has been registered in an appropriate registry. Please see guidance for more information.
International Standard Randomised Controlled Trial Number (ISRCTN):
ClinicalTrials.gov Identifier (NCT number):
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Additional reference number(s):
Ref.Number Description Reference Number
N/A N/A
A5-2. Is this application linked to a previous study or another current application?
 Yes       No
Please give brief details and reference numbers.
N/A
 2. OVERVIEW OF THE RESEARCH  
 
To provide all the information required by review bodies and research information systems, we ask a number of
specific questions. This section invites you to give an overview using language comprehensible to lay reviewers and
members of the public. Please read the guidance notes for advice on this section.
A6-1. Summary of the study.   Please provide a brief summary of the research (maximum 300 words) using language
easily understood by lay reviewers and members of the public. Where the research is reviewed by a REC within the UK
Health Departments’ Research Ethics Service, this summary will be published on the Health Research Authority (HRA)
website following the ethical review. Please refer to the question specific guidance for this question.
Obstructive sleep apnoea (OSA) is a sleeping difficulty where the throat muscles relax and block airflow. The sleeper’s
brain comes out of a deep sleep to restart breathing between five and thirty times an hour, causing extreme tiredness
and low mood during the day. Research in the general population suggests that OSA is related to reduced quality of
life and mood difficulties. Whilst OSA is estimated to affect 2-4 people out of 100 in the UK general population, as
many as one in four of people with a bipolar disorder (BD) diagnosis may have OSA. BD is a diagnostic term that can
be used to describe experiencing fluctuating mood, experiencing very low periods (often termed “depressive”) and
extremely elevated, euphoric periods (often termed “manic”). It is believed that people with a BD diagnosis experience
fluctuations in mood due to also having irregular sleep-wake patterns. OSA is likely to further disrupt sleep-wake
patterns for people with a BD diagnosis, however, no research to date has investigated this. This study intends to look
at the relationship between OSA and sleep and affect (short-term mood experience) variability for people who also
have a BD diagnosis. People with a BD diagnosis will be invited to participate, one group without suspected OSA and
one group with. The study will look to confirm that a smaller group of people within the suspected OSA group do show
symptoms that could be diagnosed as OSA. Information about participants’ sleep (measured by a watch-like device
and self-report) and affect (measured by self-report) will be collected on a daily basis across a fortnight. Comparisons
will be made between the groups. It is predicted that people with suspected OSA will experience more variability in
sleep and affect and will experience more extreme affect changes compared to the group without suspected OSA.
A6-2. Summary of main issues. Please summarise the main ethical, legal, or management issues arising from your study
and say how you have addressed them.
Not all studies raise significant issues. Some studies may have straightforward ethical or other issues that can be identified
and managed routinely. Others may present significant issues requiring further consideration by a REC, HRA, or other
review body (as appropriate to the issue). Studies that present a minimal risk to participants may raise complex




The research team will not have access to potential participant's personal details without their consent (e.g. prior
agreement to be on a mailing list). Potential participants recruited through NHS services will be approached by a
member of their existing care team and participants will need to respond to the research advert before any direct
correspondence with the research team will be able to take place. 
2. Risks, burdens and benefits to participants
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Whilst it is considered that the study should pose little to no risk to participants, contact numbers and websites are
provided to participants in case of distress. 
It is hoped that a benefit of the study is that it may support people of moderate to high risk of OSA to recognise this and
to seek advice from their GP. When participants are identified as having suspected OSA, they will be made aware of
this and encouraged to see their GP. 
It is recognised that the study requires a twice-daily commitment from participants for two weeks in addition to
completing screening measures. Completion of all twice-daily measures during the two weeks is not mandatory and
all participants who wear the actigraph for two weeks (15 nights) and complete at least the first morning questionnaire
will be entered into the prize draw. 
3. Risk to researcher
The chief investigator will need to visit people at home to deliver and explain how to use the oximeter and deliver
actigraphs. The Lancashire Care NHS Foundation Trust lone worker policy will be followed in order to ensure the
safety of the chief investigator. This will involve a risk assessment of each visit based on information gathered during
the participant screening process, time and location of the visit etc. The details of the visit (e.g. date, time, location) will
be shared with one of the two supervisors within the research team who will act as a "buddy" for this visit. The chief
investigator will always carry a fully charged mobile phone during visits. The chief investigator will telephone or text the
supervisor of the team when the visit is concluded. If this telephone call/text does not take place beyond a reasonable
agreed time, the "buddy" will attempt to contact the chief investigator via telephone and text. If contact with the chief
investigator cannot be made within a reasonable time frame, the police will be contacted.
4. Risk to equipment 
The equipment being provided to participants is expensive. Where actigraphs are posted this will be done using
signed for delivery using a private courier. Participants will be asked to confirm that they are prepared to take care of
the equipment and return it at the end of the data collection period. However, it is a recognised risk that equipment may
be damaged or lost. In the event that equipment is damaged or lost, participants will be assured that this is a
recognised risk and their participation will not necessarily be affected. The study has access to 40 actigraphs in total
but it is the intention that not all actigraphs will be used at once to ensure that there are replacements available to
participants in the event of the equipment not working or accidental loss or damage. Participants will not be held liable
for any unintended loss or damage of the equipment. 
5. Data storage
All electronic data will be stored on the secure university server for the duration of the project. This will include the
secure web data collection application, REDCap, which is accessible via the university and are deemed to meet the
university's requirements for secure storage.
Paper data (e.g. consent forms, questionnaires) will be stored in a secure locked location on the University premises.
 3. PURPOSE AND DESIGN OF THE RESEARCH
A7. Select the appropriate methodology description for this research. Please tick all that apply:
 Case series/ case note review
 Case control
 Cohort observation
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 Questionnaire, interview or observation study
 Randomised controlled trial
 Other (please specify)
A10. What is the principal research question/objective? Please put this in language comprehensible to a lay person.
Do sleep characteristics (e.g. time spent asleep) and affect vary more for people with suspected obstructive sleep
apnoea and a bipolar disorder diagnosis compared to those with a bipolar disorder diagnosis alone?
Do people with suspected obstructive sleep apnoea and a bipolar disorder diagnosis experience greater acute
(sudden) affect changes compared to those with BD alone?
A11. What are the secondary research questions/objectives if applicable? Please put this in language comprehensible to
a lay person.
Are the groups of participants identified as having suspected obstructive sleep apnoea significantly different from each
other in terms of demographic information and on their answers to questionnaires on sleep quality, daytime
sleepiness and mood?
A12. What is the scientific justification for the research? Please put this in language comprehensible to a lay person.
Obstructive sleep apnoea (OSA) is a sleeping difficulty where the throat muscles relax and block airflow. The sleeper’s
brain comes out of a deep sleep to restart breathing between five and thirty times an hour, causing extreme tiredness
and low mood during the day.
OSA is believed to be six to twelve times more common for people with a bipolar disorder (BD) diagnosis, which would
mean that approximately one in four (1/4) people with a BD diagnosis have OSA. When people are assessed for OSA,
NICE guidance states that people should be asked about their mood. However, NICE guidance does not currently
suggest that people with a BD diagnosis should be asked about their risk of OSA. 
Not much is known about how having OSA as well as a BD diagnosis might affect people. The disruption to the sleep
cycle that OSA causes very likely disrupts the body's daily rhythms in terms of hormone release. This effect is likely to
impact people with a BD diagnosis more as people with a BD diagnosis are believed to be more vulnerable to a
disruption in their body's daily rhythms. However, the only research that seems to be available are separate
observations of individual people which report different things. Therefore, research into how OSA impacts people with
a BD diagnosis is important to for clinical guidelines and practice. 
The proposed study aims to look at how different sleep and affect (short-term experience of mood) are across a two
week period between a group of people with a BD diagnosis and suspected OSA and a group with a BD diagnosis
alone.
A13. Please summarise your design and methodology. It should be clear exactly what will happen to the research
participant, how many times and in what order. Please complete this section in language comprehensible to the lay person.
Do not simply reproduce or refer to the protocol. Further guidance is available in the guidance notes.
Design
It is predicted that a group of people with suspected OSA and a BD diagnosis will experience more differences in their
sleep and affect across the two weeks and bigger differences in how they feel from one point to the next, compared to
a group of people with a bipolar disorder diagnosis alone. Testing this hypothesis will involve measuring the
differences between two groups of people with a BD diagnosis, one group with suspected OSA and one without. It is
hoped that this will help further understanding of how OSA can be recognised more easily in people with a bipolar
disorder diagnosis so that suitable treatment can be provided. 
Participants
It is intended that 20 people with a BD diagnosis and suspected OSA and 20 people with a diagnosis of BD alone will
be recruited. It is the aim to recruit this many participants as it is similar to the number of participants in previous
studies that have used a similar design to investigate the relationship between sleep and affect variability with people
with a BD diagnosis, and this number will provide enough power to extract a robust conclusion.
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All participants will need to report that they have received a BD (or manic depression) diagnosis and not be currently
experiencing a period of extreme mood (i.e. not experiencing "mania" or "depression", often termed "euthymia").
Participants will be asked about their current and past mood using the Mini International Psychiatric Interview in Step 2
of the study (see below) to ensure that these requirements are met. 
All participants will be aged between 30 and 60 years old. This chosen age range is intended to capture the
demographic identified as most at risk of OSA to maximise recruitment, whilst minimising the risk of other things that
affect sleep, such as sleep fragmentation, the risk of which is known to increase with age. 
Participants will be recruited from the North West due to the locality of the chief investigator and the research protocol
involving the need to visit a subset of participants at home. Furthermore, restricting the geographical area of




Participants can consent to take part online using a laptop or desktop computer, or using a paper consent form that
will be posted to them (with a stamped envelope to return) if they email the chief investigator requesting this. 
Participants who consent to take part will be invited to answer some demographic and screening questions which
ensure that participants meet the requirements for the study. Participants will also be invited to answer 4
questionnaires (STOP-Bang Questionnaire, Pittsburgh Sleep Quality Index, Epworth Sleepiness Scale and 7 Up 7
Down Inventory). Participants' answers to one of these questionnaires (STOP-Bang) will help assign participants to
either the suspected obstructive sleep apnoea or the bipolar disorder diagnosis only group, and provide some
information about these groups that can be compared at the analysis stage. Answering all the questions should take
around 20 minutes in total. Participants can complete these questionnaires in their own time online using a laptop or
desktop computer or on paper forms that will be posted to them with a stamped envelope to return. 
Step 2
Participants will be contacted by the chief investigator either by email or phone (depending on what the participant
responded in Step 1). This will be to arrange a telephone interview with the chief investigator at a time that is
convenient for the participant. 
Where possible, telephone interviews will be conducted over Zoom (https://www.zoom.us/) or Skype to minimise
telephone costs. Zoom is a video call software like Skype that doesn't require a participants to have a login for. A video
call will allow face to face contact with participants, if they are happy to use the video function, which will enable the
chief investigator to be more aware of any signs of distress from the participant during the interview and be able to
adapt the process accordingly. Skype calls can be conducted if participants would prefer this to Zoom. If participants
would prefer to be contacted by telephone, the interview will be conducted using a landline telephone in a private room
at Lancaster University. These interviews will be offered during the day or early evening to fit around participants’
commitments.
During the telephone interview, participants may be asked about answers that they provided to questions during Stage
1 if their answers suggest they do not meet the requirements for the study. All participants will be interviewed using a
structured interview tool (Mini International Psychiatric Interview) to further ensure that they meet the requirements for
the study. If a participant’s responses during Step 1 indicate that they drink alcohol and/or take non-prescribed
substances, questions from the relevant sections of the interview tool will also be asked about participants' alcohol
and/or drug use. Participants will also be interviewed using the Structured Clinical Interview for DSM-5 Sleep
Disorders to contribute to their group allocation. Participants will also be invited to ask any questions about the study
that they may have. Telephone interviews should take no longer than 45 minutes. 
The chief investigator will then contact participants using their preferred method of contact, either to make
arrangements for Step 3 of the study or to explain that the responses they have given suggest that they do not meet the
requirements to continue participating in the study. Everyone who is not able to continue participating in the study will
be invited to leave an email or postal address to be sent a non-scientific report of the study once the study is
completed, and will be invited to withdraw the information they have provided up until this point. People continuing to
participate will be told which group they have been assigned to based on their responses. 
Step 3
Nine participants in the suspected OSA group who are geographically closest to Lancaster University will be invited to
undergo an overnight test using a piece of equipment called an oximeter. This is a device that can be worn overnight to
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test for OSA. It measures oxygen levels in the blood using a infrared light via a tube placed over one finger, and snoring
using a microphone. 
If the participants who are geographically closest to Lancaster University decline, then the next closest participants will
be invited to undergo the test if possible.   For participants who undergo the overnight test, the chief investigator will
deliver the oximeter to the participant’s home, at a time suitable for them, and provide instructions on how to operate it.
The chief investigator will then leave the oximeter with the participant and return the next day to collect it at a convenient
time for the participant. 
The overnight test is optional for nine participants in the suspected OSA group only. This is due to a shortage of
equipment. 
All participants will receive a watch like device called an actigraph, which they will be asked to wear for two weeks (15
nights). Actigraphs will either be delivered by the chief investigator (following a risk assessment and in accordance
with the Lancashire Care NHS Foundation Trust Lone Worker Policy) or posted to a pick up location convenient for the
participant. The actigraph tracks movement and is able to predict when the participant is awake and asleep. During
these two weeks, participants will be asked to complete a short questionnaire on how they are feeling (Positive and
Negative Affect Scale) twice a day. Participants can complete these questionnaires online using a laptop or desktop
computer, a mobile phone or tablet or using a paper questionnaire booklet. If participants choose to complete the
questionnaires online, they will be sent an email twice a day with a link to each questionnaire. As part of the morning
questionnaire, participants will also be asked three questions about their sleep the night before. Answering each
questionnaire, including the three sleep questions, should take participants around two minutes to complete. 
Once participants have worn their actigraphs for two weeks (15 nights), the chief investigator will contact them using
their preferred method of contact to arrange either collection or free postage of the actigraph from where they collected
it (depending on how they received the actigraph). 
Experts by experience 
Consultation from experts by experience suggested that participants would understand what the study was asking of
them from reading the information sheet. The information sheet was improved following consultation with experts by
experience by adding expected timings to each of the steps.
A14-1. In which aspects of the research process have you actively involved, or will you involve, patients, service users,
and/or their carers, or members of the public?
 Design of the research
 Management of the research
 Undertaking the research
 Analysis of results
 Dissemination of findings
 None of the above
 
Give details of involvement, or if none please justify the absence of involvement.
A panel of three experts by experience (people with a bipolar disorder or manic depression diagnosis), organised
through the Spectrum Centre at Lancaster University, were consulted on the advertisement materials, participant
information sheet and methodology of the study. The advertisement materials and participant information sheet have
been adapted according to feedback. This involved specifying more clearly the expected time commitment of
participants in each step and highlighting the benefits that participating in research can have. All three experts by
experience felt that the design of the methodology of the study was acceptable and that they would participate in the
study if they met the requirements.
 4. RISKS AND ETHICAL ISSUES
 RESEARCH PARTICIPANTS
A15. What is the sample group or cohort to be studied in this research?
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 Generic Health Relevance
 Infection
 Inflammatory and Immune System
 Injuries and Accidents
 Mental Health
 Metabolic and Endocrine
 Musculoskeletal
 Neurological
 Oral and Gastrointestinal
 Paediatrics
 Renal and Urogenital




Gender:  Male and female participants
Lower age limit:  30  Years
Upper age limit:  60  Years
A17-1. Please list the principal inclusion criteria (list the most important, max 5000 characters).
Aged between 30 and 60 years old.
Live in North West England.
Report a diagnosis of BD (or manic depression).
Report to being between periods of extreme mood.
A17-2. Please list the principal exclusion criteria (list the most important, max 5000 characters).
If participants:
• work night shifts
• regularly travel overseas
• are currently jet-lagged
• are likely to be disturbed at night (e.g. live with a child under 1 year old)
• have had a brain injury
• have a neurodegenerative condition (e.g. dementia or Parkinson's)
• have received treatment for obstructive sleep apnoea and no longer have symptoms 
• drink alcohol or caffeine or take drugs in a way that may impact on sleep 
• are taking part in a drug trial 
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• are unable to move most of their body
 RESEARCH PROCEDURES, RISKS AND BENEFITS  
A18. Give details of all non-clinical intervention(s) or procedure(s) that will be received by participants as part of the
research protocol. These include seeking consent, interviews, non-clinical observations and use of questionnaires.
Please complete the columns for each intervention/procedure as follows:
1. Total number of interventions/procedures to be received by each participant as part of the research protocol.
2. If this intervention/procedure would be routinely given to participants as part of their care outside the research,
how many of the total would be routine?
3. Average time taken per intervention/procedure (minutes, hours or days)
4. Details of who will conduct the intervention/procedure, and where it will take place.
Intervention or procedure 1 2 3 4
Complete consent form and initial questionnaires 1 20
minutes
Can be completed online or on paper
at participant's homes in their own
time.
Conversation to arrange telephone interview 1 5
minutes
Chief investigator will contact
participant via email or phone
depending on their preference.
Telephone interview 1 30-45
minutes
Chief investigator will contact
participant over Zoom, Skype or phone
depending on their preference at a
time that is convenient for the
participant.
Conversation to confirm possibility of further participation,
group allocation and to arrange delivery of the actigraph.




Chief investigator will contact
participant via email or phone
depending on their preference.
Wear actigraph 1 14 days Chief investigator will deliver or post to
participant. Participants asked to wear
actigraph at all times.
Complete questionnaires (2 per day for 14 days) 28 2
minutes
Can be completed online using
computer/tablet/phone or on paper.
Opportunity to give feedback 1 0-5
minutes
Can be completed online or paper -
opportunity at the end of the last of the
twice daily questionnaires.
Conversation to arrange return of the actigraphs and offer
a non-scientific report of the study
1 5
minutes
Chief investigator will contact
participant via email or phone
depending on their preference.






Chief investigator will contact
participant via email or phone
depending on their preference.
A21. How long do you expect each participant to be in the study in total?
Participants will be involved in the study for approximately 4 weeks. This includes the 2 week observation period and a
total of 2 weeks of time either side for Steps 1 and 2 to be conducted and arrange to return of the actigraphs.
Participants who request a non-scientific report of the findings will receive this from the chief investigator at the end of
the study, which could be as long as 1 year after consenting to participate in the study. This also applies to the
participant who wins the prize draw.
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A22. What are the potential risks and burdens for research participants and how will you minimise them?
For all studies, describe any potential adverse effects, pain, discomfort, distress, intrusion, inconvenience or changes
to lifestyle. Only describe risks or burdens that could occur as a result of participation in the research. Say what steps
would be taken to minimise risks and burdens as far as possible.
There is a risk that participants may become distressed if they learn they are suspected of having obstructive sleep
apnoea. Participants will be provided with resources that they can use in the event of distress at the end of the
participant information sheet. Moreover, participants who are suspected of having obstructive sleep apnoea will be
advised to see their GP. These participants will also be told they are suspected of having obstructive sleep apnoea by
the chief investigator who is trained and experienced in managing distress in others and who will receive supervision
from an experienced clinical researcher in the field. The benefits to participants that present with this risk is that
participants may learn (following a visit to their GP and potential referral to a sleep clinic) that they have obstructive
sleep apnoea which can be treated and this may reduce their mood difficulties. Moreover, participants are being
made aware of the risk factors of obstructive sleep apnoea and therefore how they may be able to prevent or reduce
their risk of obstructive sleep apnoea through life style changes. These risks and benefits were corroborated in
consultation with experts by experience who felt it was valuable to learn about obstructive sleep apnoea and whether
you potentially have the condition.
The study involves a long time commitment (two weeks) and twice-daily input from participants, which may become a
burden on participants. To minimise this, it is not compulsory that participants complete every questionnaire.
Participants are asked to not complete missed questionnaires at a later date and online links to questionnaires
expire after a set number of hours. Participants can also withdraw from the study at any time and email the chief
investigator if they would like to withdraw their data, which will be possible up until the point that data analysis has
begun. Data analysis will not begin for at least 10 days following the last participant completing/withdrawing from the
study so all participants will have at least 10 days to withdraw their data before analysis should they wish to.   All
participants who wear the actigraph for two weeks (15 nights) and complete at least the first morning questionnaire
will be entered into a prize draw for a £50 Amazon voucher. The benefit to participating in the research includes the
opportunity to be entered into the prize draw. Moreover, consultation with experts by experience emphasised the
benefit of participating as potentially benefitting to improving people's lives if obstructive sleep apnoea can be better
recognised for people with a bipolar disorder diagnosis.   
There is a risk of a breach of confidentiality as personal data will be collected. This risk will be minimised as far as
possible by personal data being stored separately from all other data either in a locked cabinet or on the university
secure network. Participant personal contact details will be kept for 6 months following the study finishing and they
will then be deleted or destroyed.
A24. What is the potential for benefit to research participants?
Participants may become aware of their risk of obstructive sleep apnoea and visit their GP about this or make positive
lifestyle changes to reduce their risk. 
All participants may become more aware of any links between their sleep and their mood which may prove helpful in
predicting and even preventing re-occurrences of periods of extreme mood.
All participants regardless of their level of participation will be offered a non-scientific report of the study's findings. 
All participants who wear the actigraph for two weeks (15 nights) and complete at least the first morning questionnaire
will be entered into a prize draw for a £50 Amazon voucher.
 RECRUITMENT AND INFORMED CONSENT
 In this section we ask you to describe the recruitment procedures for the study. Please give separate details fordifferent study groups where appropriate.
A27-1. How will potential participants, records or samples be identified? Who will carry this out and what resources
will be used?For example, identification may involve a disease register, computerised search of GP records, or review of
medical records. Indicate whether this will be done by the direct healthcare team or by researchers acting under
arrangements with the responsible care organisation(s).
Some potential participants who are currently accessing services within Lancashire Care NHS Foundation trust
around their bipolar disorder (or manic depression diagnosis), and who meet the inclusion criteria of the study, will be
told about the study by a member of their existing care team. Alternatively they may see a poster advertisement on the
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service premises. No details of potential participants will be passed to the research team by anyone other than the
participant themselves. To take part in the study participants will need to visit the study website or email the chief
investigator. 
Other potential participants who are on the Spectrum Connect mailing list (through previous involvement with the
Spectrum Centre and Lancaster University) will be sent an advert for the research study. Again, participants will need
to visit the study website or email the chief investigator to take part in the study. The same applies for potential
participants who see the study advertised on social media.
A27-2. Will the identification of potential participants involve reviewing or screening the identifiable personal
information of patients, service users or any other person?
 Yes       No
Please give details below:
Clinicians currently involved in the care of potential participants will signpost participants to the study, if appropriate.
These clinicians work within a service in the North West of England specifically for people with a BD diagnosis and so
they will be already be aware of potential participants' diagnosis and age. 
In most cases, the research team will not have access to the personal information of potential participants until the
participants either contact the chief investigator via email or consent to take part online. 
The only exception to this is the use of the Spectrum Connect mailing list which will be used to advertise the study.
However, this list is comprised of the email addresses of people who have given their consent to be contacted about
upcoming research projects in this way and the list will not be used to identify potential participants according to the
inclusion criteria of this study.
A28. Will any participants be recruited by publicity through posters, leaflets, adverts or websites?
 Yes       No
If Yes, please give details of how and where publicity will be conducted, and enclose copy of all advertising material
(with version numbers and dates).
Poster adverts will be placed in the premises of Lancashire Care NHS Foundation Trust Community Mental Health
Team sites.
An email advertisement will be sent out to people who are on the Spectrum Connect mailing list (following previous
involvement with the Spectrum Centre and Lancaster University).
The study will also be advertised through a professional dedicated Twitter account created specifically to advertise
the study (https://twitter.com/OSA_BDresearch), which will not be used for any other purpose. The account page
redirects any potential participants to the study's webpage.
A29. How and by whom will potential participants first be approached?
Some potential participants will be approached about the study by a member of their existing care team within
Lancashire Care NHS Foundation Trust (LCFT) Community Mental Health Team (CMHT). 
Potential participants on the Spectrum Connect mailing list will be approached via email using the dedicated
Spectrum Centre email address. 
Other potential participants will not be directly approached and may see the study advertised on social media or on a
poster within LCFT CMHT services. 
In all cases interested potential participants will be directed to contact the chief investigator directly or to visit the study
website.
A30-1. Will you obtain informed consent from or on behalf of research participants?
 Yes       No
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If you will be obtaining consent from adult participants, please give details of who will take consent and how it will be
done, with details of any steps to provide information (a written information sheet, videos, or interactive material).
Arrangements for adults unable to consent for themselves should be described separately in Part B Section 6, and for
children in Part B Section 7.
If you plan to seek informed consent from vulnerable groups, say how you will ensure that consent is voluntary and
fully informed.
Potential participants will have access to a written and video version of the participant information sheet. Participants
will also be able to email the chief investigator to ask any questions they may have before consenting to take part. 
Participants can complete an online or paper consent form, if they choose to, in their own time and this will not be
done in the presence of anyone from the research team.
 
If you are not obtaining consent, please explain why not.
N/A
Please enclose a copy of the information sheet(s) and consent form(s).
A30-2. Will you record informed consent (or advice from consultees) in writing?
 Yes       No
A31. How long will you allow potential participants to decide whether or not to take part?
Potential participants will have from when they first find out about the study until six weeks before analysis needs to
begin to decide whether or not to take part (currently estimated as April 2020 but this could change depending on the
success of recruitment). Advertisement within services and active advertisement over Twitter will stop eight weeks
before analysis needs to begin to allow participants at least two weeks to decide whether or not to take part.
A32. Will you recruit any participants who are involved in current research or have recently been involved in any




If Yes, please give details and justify their inclusion. If Not Known, what steps will you take to find out?
Participants who are currently taking part in a drug trial are not able to take part in the study in case the medication
they are taking unknowingly impacts on sleep, a question about this is included in the initial demographics and
screening questionnaire that participants are asked to complete in Step 1 of the study. However, there are not
considered to be any design or safety considerations if participants are taking part in other research alongside this
study so this will be the participant's choice.
A33-1. What arrangements have been made for persons who might not adequately understand verbal explanations or
written information given in English, or who have special communication needs?(e.g. translation, use of interpreters)
Participants need to be able to read and answer a questionnaire in English by themselves or with support to take part
in this study. Due to length and time commitment of this study, it is unfortunately not possible for someone from the
research team to support participants to answer twice-daily questionnaires and so participants with their own support
who are not able to read and answer a questionnaire in English will not be able to take part.   
The participant information sheet is written in simple English and a video version is also available for participants who
find this more accessible than reading the lengthy information sheet.   
The online software (REDCap) that hosts the online materials allows participants to adjust the size of the font and
provides an audio version of all written information. Participants can also be sent a paper version of the participant
information sheet in large font if required.
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A35. What steps would you take if a participant, who has given informed consent, loses capacity to consent during the
study?  Tick one option only.
 The participant and all identifiable data or tissue collected would be withdrawn from the study. Data or tissue which
is not identifiable to the research team may be retained.
 The participant would be withdrawn from the study. Identifiable data or tissue already collected with consent would
be retained and used in the study. No further data or tissue would be collected or any other research procedures carried
out on or in relation to the participant.
 The participant would continue to be included in the study.
 Not applicable – informed consent will not be sought from any participants in this research.




The participant information sheet details that if participants become unwell during the study and they are considered to
lose capacity to consent to continue to take part, they will be withdrawn from the study but their data collected up until that
point will be kept.
If you plan to retain and make further use of identifiable data/tissue following loss of capacity, you should inform
participants about this when seeking their consent initially.
 CONFIDENTIALITY  
 In this section, personal data means any data relating to a participant who could potentially be identified. It includespseudonymised data capable of being linked to a participant through a unique code number.
 Storage and use of personal data during the study
A36. Will you be undertaking any of the following activities at any stage (including in the identification of potential
participants)?(Tick as appropriate)
 Access to medical records by those outside the direct healthcare team
 Access to social care records by those outside the direct social care team
 Electronic transfer by magnetic or optical media, email or computer networks
 Sharing of personal data with other organisations
 Export of personal data outside the EEA
 Use of personal addresses, postcodes, faxes, emails or telephone numbers
 Publication of direct quotations from respondents
 Publication of data that might allow identification of individuals
 Use of audio/visual recording devices
 Storage of personal data on any of the following:
   
 Manual files (includes paper or film)
 NHS computers
 Social Care Service computers
 Home or other personal computers
 University computers
 Private company computers
 Laptop computers
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Further details:
A37. Please describe the physical security arrangements for storage of personal data during the study?
Personal data on paper will be kept in a locked cabinet in a locked office on university premises that can only be
accessed by members of the research team. 
Electronic personal data will be kept securely on the university secure network and only members of the research
team will have access to this.
A38. How will you ensure the confidentiality of personal data?Please provide a general statement of the policy and
procedures for ensuring confidentiality, e.g. anonymisation or pseudonymisation of data.
All personal data will be kept confidential in accordance with the NHS Code of Confidentiality, EU General Data
Protection Regulation (GDPR) and the UK’s Data Protection Act 2018. Published data will not be identifiable.
A40. Who will have access to participants' personal data during the study? Where access is by individuals outside the
direct care team, please justify and say whether consent will be sought.
Only members of the research team will have access to participants' personal data during the study, and this will only
be any information provided by the participants themselves. Primarily it will only be the chief investigator accessing
and using participants' personal data in order to communicate with participants but supervisors within the research
team will also have access in case they need to contact participants in the absence of the chief investigator.
 Storage and use of data after the end of the study
A41. Where will the data generated by the study be analysed and by whom?
Data will be analysed by the research team based at Lancaster University and stored on the university's secure server.
Analysed data will not be identifiable.
A42. Who will have control of and act as the custodian for the data generated by the study?
     
 Title  Forename/Initials  SurnameDr  Guillermo  Perez Algorta
Post Lecturer in Mental Health and Health Researcher
Qualifications PhD.
Work Address Department of Clinical Psychology
 Division of Health Research
 Lancaster University
Post Code LA1 4YW
Work Email g.perezalgorta@lancaster.ac.uk
Work Telephone 01524 594711
Fax 0
A43. How long will personal data be stored or accessed after the study has ended?
 Less than 3 months
 3 – 6 months
 6 – 12 months
 12 months – 3 years
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 Over 3 years
If longer than 12 months, please justify: 
Consent forms will be stored for 10 years. All other personal data will be destroyed within 6 months of the study
completion unless participants have requested a non-scientific report of the study findings, in which case their contact
details will be retained for as long as necessary in order to send them this.
A44. For how long will you store research data generated by the study?
Years: 10 
Months: 0 
A45. Please give details of the long term arrangements for storage of research data after the study has ended.Say
where data will be stored, who will have access and the arrangements to ensure security.
Paper data (e.g. questionnaires) will be kept for 10 years in a secure locked location, with only access from research
team members.
Electronic data will be kept for 10 years on the secure university network. Again, this will only be accessible to the
research team.
This is in accordance with Lancaster University's policies.
 INCENTIVES AND PAYMENTS
A46. Will research participants receive any payments, reimbursement of expenses or any other benefits or incentives
for taking part in this research?
 Yes       No
If Yes, please give details. For monetary payments, indicate how much and on what basis this has been determined.
There will be a prize draw for a £50 Amazon voucher for all participants who wear the actigraph for two weeks (15
nights) and complete at least the first morning questionnaire.
A47. Will individual researchers receive any personal payment over and above normal salary, or any other benefits or
incentives, for taking part in this research?
 Yes       No
A48. Does the Chief Investigator or any other investigator/collaborator have any direct personal involvement (e.g.
financial, share holding, personal relationship etc.) in the organisations sponsoring or funding the research that may
give rise to a possible conflict of interest?
 Yes       No
 NOTIFICATION OF OTHER PROFESSIONALS
A49-1. Will you inform the participants’ General Practitioners (and/or any other health or care professional responsible
for their care) that they are taking part in the study?
 Yes       No
If Yes, please enclose a copy of the information sheet/letter for the GP/health professional with a version number and date.
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 PUBLICATION AND DISSEMINATION
A50. Will the research be registered on a public database?
The UK Policy Framework for Health and Social Care Research sets out the principle of making information about
research publicly available. Furthermore: Article 19 of the World Medical Association Declaration of Helsinki adopted
in 2008 states that "every clinical trial must be registered on a publicly accessible database before recruitment of the
first subject"; and the International Committee of Medical Journal Editors (ICMJE) will consider a clinical trial for
publication only if it has been registered in an appropriate registry. Please see guidance for more information.
 Yes       No
Please give details, or justify if not registering the research.
The study is not a clinical trial and the resulting thesis write up will be publicly available online via Lancaster University.
Please ensure that you have entered registry reference number(s) in question A5-1.
A51. How do you intend to report and disseminate the results of the study?Tick as appropriate:
 Peer reviewed scientific journals
 Internal report
 Conference presentation
 Publication on website
 Other publication
 Submission to regulatory authorities
 Access to raw data and right to publish freely by all investigators in study or by Independent Steering Committee
on behalf of all investigators
 No plans to report or disseminate the results
 Other (please specify)
A non-scientific report will be offered to all participants and anyone else who expresses an interest in receiving the
study findings.
A52. If you will be using identifiable personal data, how will you ensure that anonymity will be maintained when
publishing the results?
Published data will not be identifiable.
A53. Will you inform participants of the results?
 Yes       No
Please give details of how you will inform participants or justify if not doing so.
All participants will be asked if they wish to receive a non-scientific report of the study's findings and this will be sent
once the study has been written up.
 5. Scientific and Statistical Review
A54. How has the scientific quality of the research been assessed?Tick as appropriate:
 Independent external review
 Review within a company
 Review within a multi−centre research group
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 Review within the Chief Investigator's institution or host organisation
 Review within the research team
 Review by educational supervisor
 Other
Justify and describe the review process and outcome. If the review has been undertaken but not seen by the
researcher, give details of the body which has undertaken the review:
The design and methodology has been developed under supervision from two academic supervisors and has been
reviewed and approved by members of the Doctorate in Clinical Psychology Programme team at Lancaster University.
For all studies except non-doctoral student research, please enclose a copy of any available scientific critique reports,
together with any related correspondence.
For non-doctoral student research, please enclose a copy of the assessment from your educational supervisor/ institution.
A56. How have the statistical aspects of the research been reviewed?Tick as appropriate:
 Review by independent statistician commissioned by funder or sponsor
 Other review by independent statistician
 Review by company statistician
 Review by a statistician within the Chief Investigator’s institution
 Review by a statistician within the research team or multi−centre group
 Review by educational supervisor
 Other review by individual with relevant statistical expertise
 No review necessary as only frequencies and associations will be assessed – details of statistical input not
required
In all cases please give details below of the individual responsible for reviewing the statistical aspects. If advice has
been provided in confidence, give details of the department and institution concerned.
     
 Title  Forename/Initials  SurnameDr  Guillermo  Perez Algorta
Department Doctorate in Clinical Psychology
Institution Lancaster University
Work Address Department of Clinical Psychology
 Division of Health Research
 Lancaster University





Please enclose a copy of any available comments or reports from a statistician.
A57. What is the primary outcome measure for the study?
The primary outcome measures for this study are participants' scores across the twice-daily questionnaires and
participants' sleep characteristics (rated quality of sleep, total sleep time and number of awakenings) across the two
week measurement period.
A58. What are the secondary outcome measures?(if any)
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Participants' scores on the Pittsburgh Sleep Quality Index and Epworth Sleepiness Scale.
A59. What is the sample size for the research?  How many participants/samples/data records do you plan to study in
total? If there is more than one group, please give further details below.
Total UK sample size: 40 
Total international sample size (including UK): 40 
Total in European Economic Area: 40 
Further details:
It is intended that a total of 20 participants will be recruited to each group: suspected obstructive sleep apnoea and
bipolar disorder diagnosis alone.
A60. How was the sample size decided upon?  If a formal sample size calculation was used, indicate how this was done,
giving sufficient information to justify and reproduce the calculation.
As data will be collected every day from all participants across two weeks, fewer participants are required to achieve
statistical power than in cross-sectional design studies (Lu et al, 2013). However, there is no agreed method of
calculating the number of participants required to achieve statistical power for this kind of study (Scherbaum &
Ferreter, 2009). Therefore, the intended number of participants has been selected based on the sample sizes of
previous studies and pragmatic considerations. It is the aim to recruit this many participants as it is similar to the
number of participants in previous studies that have used a similar design to investigate the relationship between
sleep and affect variability with people with a BD diagnosis (Gershon et al, 2012; Harvey, Schmidt, Scarnà, Semler &
Goodwin, 2005; Leibenluft, Albert, Rosenthal & Wehr, 1996), and this number will provide enough power to extract a
robust conclusion. Moreover, it is conceivably feasible to recruit this number of participants in the allotted time frame
and with the available resources of the study.
A61. Will participants be allocated to groups at random?
 Yes       No
A62. Please describe the methods of analysis (statistical or other appropriate methods, e.g. for qualitative research) by
which the data will be evaluated to meet the study objectives.
Preliminary analyses of between group comparisons based on demographic and clinical data (questionnaire
responses) collected at baseline will be conducted using descriptive statistics and parametric tests (e.g. t-tests) or
appropriate non-parametric tests if data is not normally distributed. This will be to determine if there are significant
differences between the groups at baseline that may have impacted on sleep and affect variability. 
Descriptive/exploratory analyses will also be conducted to evaluate average characteristics of the sleep (subjective
and objective) and affect data collected for each group. Actigraph data will be analysed using GGIR package in R (van
Hees et al., 2019).
Measures of instability in sleep and affect recordings will be calculated using the mean squared successive difference
(MSSD; Jahng, Wood & Trull, 2008). MSSD differences between groups will be explored using generalised multilevel
modelling (Jahng, Wood & Trull, 2008).
The probability of acute change (PAC; Jahng, Wood & Trull, 2008) index will be calculated and explored between
groups using generalised multilevel modelling. 
Patterns of missing data will be explored and decisions will be made accordingly (e.g. use of multiple imputation if
missing data points are completely random). 
Analysis will be conducted using R software (van Hees et al., 2019) and SPSS.
 6. MANAGEMENT OF THE RESEARCH
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A63. Other key investigators/collaborators. Please include all grant co−applicants, protocol co−authors and other key
members of the Chief Investigator’s team, including non-doctoral student researchers.
 
 Title   Forename/Initials  SurnameProfessor Steven  Jones
Post Professor of Clinical Psychology and Co-Director of the Spectrum Centre for Mental HealthResearch
Qualifications PhD.
Employer Lancaster University
Work Address Spectrum Centre
 Division of Health Research
 Lancaster University





 A64. Details of research sponsor(s)
A64-1. Sponsor
Lead Sponsor
Status:  NHS or HSC care organisation
 Academic
 Pharmaceutical industry
 Medical device industry
 Local Authority
 Other social care provider (including voluntary sector or private
organisation)
 Other
If Other, please specify:  




Name of organisation Lancaster University
Given name Becky
Family name Gordon
Address Head of Research Quality and Policy
Town/city Lancaster University
Post code LA1 4YT
Country  UNITED KINGDOM
Telephone 01524 592981
Fax 0
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E-mail sponsorship@lancaster.ac.uk
A65. Has external funding for the research been secured?
Please tick at least one check box.
 Funding secured from one or more funders
 External funding application to one or more funders in progress
 No application for external funding will be made
What type of research project is this?
 Standalone project
 Project that is part of a programme grant
 Project that is part of a Centre grant
 Project that is part of a fellowship/ personal award/ research training award
 Other
Other – please state: 
A66. Has responsibility for any specific research activities or procedures been delegated to a subcontractor (other
than a co-sponsor listed in A64-1) ?  Please give details of subcontractors if applicable.
 Yes       No
A67. Has this or a similar application been previously rejected by a Research Ethics Committee in the UK or another
country?
 Yes       No
Please provide a copy of the unfavourable opinion letter(s). You should explain in your answer to question A6-2 how the
reasons for the unfavourable opinion have been addressed in this application.
A68-1. Give details of the lead NHS R&D contact for this research:
     
 Title  Forename/Initials  SurnameMs  Beverley  Lowe
Organisation Lancashire Care NHS Foundation Trust
Address The Lantern Centre
 Vicarage Lane, Fulwood
 Preston





Details can be obtained from the NHS R&D Forum website: http://www.rdforum.nhs.uk
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A69-1. How long do you expect the study to last in the UK?
Planned start date: 01/08/2019
Planned end date: 08/05/2020
Total duration:  
Years: 0 Months: 9 Days: 8 
A71-1. Is this study?
 Single centre
 Multicentre





 Other countries in European Economic Area
Total UK sites in study
Does this trial involve countries outside the EU?
 Yes       No
A72. Which organisations in the UK will host the research?Please indicate the type of organisation by ticking the box and
give approximate numbers if known:
 NHS organisations in England  
 NHS organisations in Wales  
 NHS organisations in Scotland  
 HSC organisations in Northern Ireland  
 GP practices in England  
 GP practices in Wales  
 GP practices in Scotland  
 GP practices in Northern Ireland  
 Joint health and social care agencies (eg
community mental health teams)
 
 Local authorities  
 Phase 1 trial units  
 Prison establishments  
 Probation areas  
 Independent (private or voluntary sector)
organisations
 
 Educational establishments 1 
 Independent research units  
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 Other (give details)  
  
Total UK sites in study: 1
A73-1. Will potential participants be identified through any organisations other than the research sites listed above?
 Yes       No
 A76. Insurance/ indemnity to meet potential legal liabilities  
 Note: in this question to NHS indemnity schemes include equivalent schemes provided by Health and Social Care(HSC) in Northern Ireland
A76-1. What arrangements will be made for insurance and/or indemnity to meet the potential legal liability of the
sponsor(s) for harm to participants arising from the management of the research?  Please tick box(es) as applicable.
Note: Where a NHS organisation has agreed to act as sponsor or co-sponsor, indemnity is provided through NHS schemes.
Indicate if this applies (there is no need to provide documentary evidence). For all other sponsors, please describe the
arrangements and provide evidence.
 NHS indemnity scheme will apply (NHS sponsors only)
 Other insurance or indemnity arrangements will apply (give details below)
Lancaster University legal liability cover will apply.
Please enclose a copy of relevant documents.
A76-2. What arrangements will be made for insurance and/ or indemnity to meet the potential legal liability of the
sponsor(s) or employer(s) for harm to participants arising from the design of the research?  Please tick box(es) as
applicable.
Note: Where researchers with substantive NHS employment contracts have designed the research, indemnity is provided
through NHS schemes. Indicate if this applies (there is no need to provide documentary evidence). For other protocol
authors (e.g. company employees, university members), please describe the arrangements and provide evidence.
 NHS indemnity scheme will apply (protocol authors with NHS contracts only)
 Other insurance or indemnity arrangements will apply (give details below)
Lancaster University legal liability cover will apply.
Please enclose a copy of relevant documents.
A76-3. What arrangements will be made for insurance and/ or indemnity to meet the potential legal liability of
investigators/collaborators arising from harm to participants in the conduct of the research? 
Note: Where the participants are NHS patients, indemnity is provided through the NHS schemes or through professional
indemnity. Indicate if this applies to the whole study (there is no need to provide documentary evidence). Where non-NHS
sites are to be included in the research, including private practices, please describe the arrangements which will be made at
these sites and provide evidence.
 NHS indemnity scheme or professional indemnity will apply (participants recruited at NHS sites only)
 Research includes non-NHS sites (give details of insurance/ indemnity arrangements for these sites below)
Lancaster University legal liability cover will apply.
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Please enclose a copy of relevant documents.
A78. Could the research lead to the development of a new product/process or the generation of intellectual property?
 Yes  No  Not sure
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 PART C: Overview of research sites
Please enter details of the host organisations (Local Authority, NHS or other) in the UK that will be responsible for the
research sites.   For further information please refer to guidance.
Investigator





Institution name Lancaster University
Department name Department of ClinicalPsychology
Street address Division of HealthResearch
Town/city Lancaster University
Post Code LA1 4YW








MSci Psychology and Psychological
Practice
Country  UNITED KINGDOM
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 PART D: Declarations
D1. Declaration by Chief Investigator
1. The information in this form is accurate to the best of my knowledge and belief and I take full responsibility for
it.   
2. I undertake to fulfil the responsibilities of the chief investigator for this study as set out in the UK Policy
Framework for Health and Social Care Research.
3. I undertake to abide by the ethical principles underlying the Declaration of Helsinki and good practice
guidelines on the proper conduct of research.
4. If the research is approved I undertake to adhere to the study protocol, the terms of the full application as
approved and any conditions set out by review bodies in giving approval.
5. I undertake to notify review bodies of substantial amendments to the protocol or the terms of the approved
application, and to seek a favourable opinion from the main REC before implementing the amendment.
6. I undertake to submit annual progress reports setting out the progress of the research, as required by review
bodies.
7. I am aware of my responsibility to be up to date and comply with the requirements of the law and relevant
guidelines relating to security and confidentiality of patient or other personal data, including the need to register
when necessary with the appropriate Data Protection Officer. I understand that I am not permitted to disclose
identifiable data to third parties unless the disclosure has the consent of the data subject or, in the case of
patient data in England and Wales, the disclosure is covered by the terms of an approval under Section 251 of
the NHS Act 2006.
8. I understand that research records/data may be subject to inspection by review bodies for audit purposes if
required.
9. I understand that any personal data in this application will be held by review bodies and their operational
managers and that this will be managed according to the principles established in the Data Protection Act
2018.
10. I understand that the information contained in this application, any supporting documentation and all
correspondence with review bodies or their operational managers relating to the application:
Will be held by the REC (where applicable) until at least 3 years after the end of the study; and by NHS
R&D offices (where the research requires NHS management permission) in accordance with the NHS
Code of Practice on Records Management.
May be disclosed to the operational managers of review bodies, or the appointing authority for the REC
(where applicable), in order to check that the application has been processed correctly or to investigate
any complaint.
May be seen by auditors appointed to undertake accreditation of RECs (where applicable).
Will be subject to the provisions of the Freedom of Information Acts and may be disclosed in response
to requests made under the Acts except where statutory exemptions apply.
May be sent by email to REC members.
11. I understand that information relating to this research, including the contact details on this application, may be
held on national research information systems, and that this will be managed according to the principles
established in the Data Protection Act 2018.   
12. Where the research is reviewed by a REC within the UK Health Departments Research Ethics Service, I
understand that the summary of this study will be published on the website of the Health Research Authority
(HRA) together with the contact point for enquiries named below. Publication will take place no earlier than 3
months after the issue of the ethics committee’s final opinion or the withdrawal of the application.   
Contact point for publication(Not applicable for R&D Forms)
HRA would like to include a contact point with the published summary of the study for those wishing to seek further
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 Other – please give details
 None
 
Access to application for training purposes (Not applicable for R&D Forms)
Optional – please tick as appropriate: 
 I would be content for members of other RECs to have access to the information in the application in confidence
for training purposes. All personal identifiers and references to sponsors, funders and research units would be
removed.   
This section was signed electronically by Miss Amy Brown on 27/08/2019 10:11.
Job Title/Post: Trainee Clinical Psychologist
Organisation: Lancashire Care NHS Foundation Trust
Email: a.brown21@lancaster.ac.uk
IRAS Form Reference: IRAS Version 5.13
Date: 240867/1370082/37/17130
D2. Declaration by the sponsor's representative
If there is more than one sponsor, this declaration should be signed on behalf of the co−sponsors by a representative
of the lead sponsor named at A64-1.
I confirm that:
1. This research proposal has been discussed with the Chief Investigator and agreement in principle to
sponsor the research is in place.
2. An appropriate process of scientific critique has demonstrated that this research proposal is worthwhile and
of high scientific quality.
3. Any necessary indemnity or insurance arrangements, as described in question A76, will be in place before
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Introduction 
Obstructive Sleep Apnoea (OSA) describes repetitive pharyngeal obstruction during sleep, which 
reduces airflow, consequently disrupting sleep and leading to fatigue, daytime sleepiness and low mood 
(Akashiba, 2002; Chervin, 2000; Jordan, McSharry & Malhorta, 2014). OSA is believed to be six to twelve 
times more prevalent in people with a bipolar disorder (BD) diagnosis, suggesting that approximately a 
quarter of people with a BD diagnosis have OSA (Kelly, Douglas, Denmark, Brasuell & Lieberman, 2013; 
Steier et al, 2014; Stubbs et al., 2016; Young et al., 1993). Similarly, around 20% of people with a diagnosis 
of OSA have been found to meet diagnostic criteria for BD or other mood difficulties (Schröder & O'Hara, 
2005). People with OSA or a BD diagnosis often share difficulties of reduced quality of life, difficulties 
socialising, fatigue and reduced cognitive abilities and it has been suggested that symptoms of OSA may 
either add to or be misattributed to difficulties diagnosed as BD (Kelly, Douglas, Denmark, Brasuell & 
Lieberman, 2013). Whilst the high co-morbidity between OSA and mood difficulties have informed routine 
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considerations of mood within assessment and treatment for OSA (National Institute for Health and Care 
Excellence (NICE), 2015), OSA is not routinely considered when assessing and supporting people with a 
BD diagnosis (NICE, 2014; Schröder & O'Hara, 2005). Little is known on the relationship between OSA 
and mood for people with a BD diagnosis, impeding clinical recognition and management. Therefore, 
research into the relationship between OSA and experiences diagnosed as BD is important to inform clinical 
guidelines and practice.  
Whilst sleep disturbance is considered characteristic of periods of acutely elevated and low mood 
experienced by people with a BD diagnosis (Belmaker, 2004), research has found increased variations in 
sleep and affect, and more extreme experiences of negative affect, for people with a BD diagnosis compared 
to the general population, even when people are “inter-episode” (not currently experiencing a phase of 
acutely high or low mood; Harvey, Schmidt, Scarnà, Semler & Goodwin, 2005; Lovejoy & Steuerwald, 
1995). Gershon and colleagues (2012) argue the importance of investigating difficulties for people with a 
BD diagnosis when they are “inter-episode” to learn of factors that maintain and trigger further difficulties. 
They measured daily affect and sleep and recorded more variability in sleep for people with a BD diagnosis 
compared to controls, in addition to more variability and extremes in negative affect, recommending further 
research into the reasons for increased affect variability in “inter-episode” periods to inform targets for 
intervention. It is theorised that sleep, and consequently circadian rhythms, for people with a BD diagnosis 
are disrupted and variable, even when “inter-episode” (Grandin, Alloy & Abramson, 2006), leading to 
further acute mood difficulties due the apparent bi-directional relationship between sleep and mood (Geddes 
& Miklowitz, 2013). Interpersonal and social rhythms therapy (IPSRT; Frank, 2007) uses a biopsychosocial 
approach to support people with a BD diagnosis to regulate their sleep-wake cycle and mood stability to 
increase functioning (Frank, Swartz & Kupfer, 2000). Despite evidence for the effectiveness of IPSRT 
(Geddes & Miklowitz, 2013), it does not account for the potential impact of OSA affecting a quarter of 
people with a BD diagnosis, indicating a need for research to ascertain the relationship between OSA and 
difficulties diagnosed as BD. 
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OSA conceivably deregulates circadian rhythms through disrupting the sleep cycle (Noda, Yasuma, 
Okada & Yokota, 1998), potentially having a more disruptive effect on people with a BD diagnosis who are 
believed to be more vulnerable to circadian rhythm disruption (Frank, Swartz & Kupfer, 2000). However, 
the little literature surrounding OSA and a BD diagnosis comprises of case reports that do not present a 
consistent picture of the potential impact of OSA on people who have a BD diagnosis (Blazer, 1981; 
Fleming, Fleetham, Taylor & Remick, 1985; Strakowski et al., 1991; Szaulińska et al., 2017). The proposed 
study aims to investigate sleep and affect variability of people with a BD diagnosis and suspected OSA, 
compared to people with a diagnosis of BD alone. Specifically, the study will intend to answer whether sleep 
characteristics and affect vary more for people with suspected OSA and a BD diagnosis compared to those 
with a diagnosis of BD alone, in addition to whether people with suspected OSA and a BD diagnosis 
experience greater acute affect changes compared to those with a diagnosis of BD alone. It is predicted that 
people with suspected OSA and a BD diagnosis will experience more sleep and affect variability and greater 
extremes of affect change. 
Method 
Design  
The study will be a longitudinal comparison of the variability and relationship between quantitative 
sleep and affect measures, collected over two weeks (15 nights), between a group of participants with a BD 
diagnosis and suspected OSA and a group of participants with a diagnosis of BD alone (control group). 
Sleep data will be captured using objective (actigraphy) and self-report measures of sleep. Affect will be 
captured using a twice-daily self-report measure. This design will allow for comparison of the variability of 
sleep and affect data, and the extent of affect changes, between the control and suspected OSA group. 
Night to night variability in sleep parameters is high, even in the general population (Wohlgemuth, 
Edinger, Fins & Sullivan, 1999) and there is a body of literature around the length of measurement necessary 
to accurately capture sleep variables (e.g. Edinger, Marsh, McCall, Erwin & Lininger, 1991; Knutson, 
Rathouz, Yan, Liu & Lauderdale, 2007; Wohlgemuth et al., 1999). However, there is no agreed length of 
necessary measurement to accurately measure sleep parameters of people with OSA. Therefore, 
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measurement across two weeks (15 nights) is considered appropriate as it strikes a balance between the 
length of time suggested necessary for accurate measurement, based on the age of the participants, and 
considerations of the time commitment for participants. 
Participants 
It is intended that 20 people with a BD diagnosis and suspected OSA (OSA group) and 20 people 
with a diagnosis of BD alone (control group) will be recruited. As data will be collected every day from all 
participants across two weeks, fewer participants are required to achieve statistical power than in cross-
sectional design studies (Lu et al, 2013). However, there is no agreed method of calculating the number of 
participants required to achieve statistical power for this kind of study (Scherbaum & Ferreter, 2009). 
Therefore, the intended number of participants has been selected based on the sample sizes of previous 
studies and pragmatic considerations. It is the aim to recruit this many participants as it is similar to the 
number of participants in previous studies that have used a similar design to investigate the relationship 
between sleep and affect variability with people with a BD diagnosis (Gershon et al, 2012; Harvey, Schmidt, 
Scarnà, Semler & Goodwin, 2005; Leibenluft, Albert, Rosenthal & Wehr, 1996), and this number will 
provide enough power to extract a robust conclusion. Moreover, it is conceivably feasible to recruit this 
number of participants in the allotted time frame and with the available resources of the study.  
Although the ideal protocol would be to match participants by age and biological sex, this is likely to 
be too challenging alongside time and geographical constraints. As age, biological sex and sex steroids are 
known to influence sleep variables (Mong & Cusmano, 2016; Reyner & Horne, 1995), particularly OSA 
(Jordan, McSharry & Malhorta, 2014), participants will be asked to disclose their biological sex and if they 
are currently taking any hormonal drugs so that comparisons can be made between groups. Moreover, all 
participants will be aged between thirty and sixty years old. This chosen age range is intended to capture the 
demographic identified as most at risk of OSA (NHS, 2016; Stubbs et al., 2016; Young et al., 1993) to 
maximise recruitment, whilst minimising the presence of other extraneous sleep variables, such as sleep 
fragmentation, of which the prevalence is known to increase with age (Crowley, 2011). 
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Participants will be recruited from the North West due to the locality of the chief investigator and the 
research protocol involving the need to visit a subset of participants at home. Furthermore, restricting the 
geographical area of recruitment may minimise costs of posting sleep measurement equipment, as it may be 
possible to deliver some devices personally. Therefore, inclusion criteria for all participants will be as 
follows: 
Inclusion criteria for all participants: 
• Aged between thirty and sixty years old. 
• Live in North West England. 
• Report a diagnosis of BD (or manic depression), the difficulties associated with which will be verified 
as being consistent with the current diagnostic criteria for BD through screening using the Mini 
International Psychiatric Interview, (MINI; Sheehan, 2016), sections A and C, which are the sections 
of this brief screening structured interview that are consistent with the DSM-V (American 
Psychological Association, 2013) criteria for BD. It is understood that a diagnosis of BD is commonly 
accompanied with further psychiatric diagnoses (Krishnan, 2005) and so excluding participants with 
any further diagnoses would not likely achieve a representative sample (Harvey, Schmidt, Scarnà, 
Semler & Goodwin, 2005). However, it will be confirmed that BD is participants’ primary diagnosis, 
defined as the diagnosis given to the experiences that are most prominent, distressing and/or disabling, 
to reduce the effects of confounding difficulties on results as much as feasibly possible.  
• Report to being between periods of extreme mood. This will be confirmed through participants not 
affirming current difficulties (in the past two weeks) that meet criteria for a “major depressive” or 
“hypomanic/manic” episode during screening using the MINI (Sheehan, 2016).  
Exclusion criteria for all participants: 
Report of the following: 
• Currently living in an environment that is likely to disrupt sleep, e.g. having no sheltered 
accommodation. 
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• A medical condition that may affect sleep such as a previous traumatic brain injury, current 
neurodegenerative condition or substance addiction (Hasler, Smith, Cousins & Bootzin, 2012; Lee & 
Thomas, 2011; Ouellet, Beaulieu-Bonneau, & Morin, 2015).  
The above exclusion criteria will initially be screened for using initial screening questions that participants 
will answer via an online or paper questionnaire following consenting to participate in the study. These 
questions are based on the demographic information section of the Duke Structured Interview Schedule 
(DSI; Edinger et al., 2009). Whilst this tool has not been validated for the screening of sleep disorders 
according to DSM-V criteria (Taylor et al., 2018), due to its design as a screening tool for sleep disorders, it 
contains demographic questions designed to collect information on wider factors that could impact on sleep. 
Participants’ answers to these initial screening questions will inform questions asked during a later 
telephone-screening interview. Sections I and J of the MINI (Sheehan, 2016) will be administered during the 
telephone-screening interview to assess for “alcohol use disorder” and “substance use disorder (non 
alcohol)” respectively if participants have confirmed that they drink alcohol or/and use non-prescribed 
drugs. If participants report that they are frequently woken in the night on the initial screening questionnaire, 
this can be discussed further with the participant during the telephone-screening interview. Supervision will 
be used to discuss the eligibility of participants based on the information they provide.  
Inclusion criteria for the OSA group will be as follows:  
• Screens positively for suspected OSA. A positive screen will involve a score equal to or above 2 
when interviewed using the Structured Clinical Interview for DSM-5 Sleep Disorders (SCISD; 
Taylor et al., 2018) and a score equal to or above 3 on the STOP-Bang Questionnaire (Chung et al., 
2008), which has a high sensitivity of 93% (moderate OSA) and 100% (severe OSA) despite low 
specificity (43% and 37% respectively). This screen will also be administered with any potential 
participants with a reported existing diagnosis of sleep apnoea to determine if any treatment or 
lifestyle changes have reduced symptoms below inclusion criteria for this study. 
Whilst information on participant medication will be collected through questions based on the 
demographic questions of the DSI (Edinger et al., 2009) it is anticipated that there will be no significant 
OBSTRUCTIVE SLEEP APNOEA WITH A DIAGNOSIS OF BIPOLAR DISORDER   Version	0.2				26/09/19																																																																																																				
IRAS	PROJECT	ID:	240867																																																																																																						 Page 7 of 25	
difference between medication taken by the control and suspected OSA groups as medication is the first line 
treatment for difficulties diagnosed as BD (NICE, 2014). Therefore, attempting to recruit participants with a 
diagnosis of BD not taking medication, or attempting to control for medication, is likely to be unfeasible and 
unrepresentative (Harvey, Schmidt, Scarnà, Semler & Goodwin, 2005; Harvey, Talbot & Gershon, 2009).  
Materials 
REDCap (Research Electronic Data Capture). REDCap (Harris et al., 2019; Harris et al., 2009) is 
a secure, online software platform for collecting research data. REDCap is liscenced by Lancaster University 
and will be used to host the online aspects of the study.  
Duke Structured Interview Schedule (DSI). The demographic information section of the DSI 
(Edinger et al., 2009) has been adapted to develop initial screening questions that participants will complete 
either online (through REDCap) or on paper following consenting to participate in the study. These 
questions will be used to collect demographic information and further information on factors that could 
impact sleep, informing the questions asked during the later telephone-screening interview. The following 
information will be collected using questions adapted from the DSI: name, date of birth, biological sex, 
information around current employment, travel and living arrangements, use of prescribed and non-
prescribed medications/substances and information around parasomnias. Where information will not be used 
to screen participants for eligibility, it will be used to characterise the participant groups and inform of 
potential confounding variables and limitations following data collection. For instance, if a significant 
difference in prescribed medication use is found between the OSA and control group, this will need to be 
recognised as a confounding variable as medication can affect sleep (Eidelman, Talbot, Gruber, Hairston & 
Harvey, 2010).  
Alongside questions adapted from the DSI (Edinger et al., 2009), participants will be asked questions 
around their BD diagnosis to further characterise the participant groups, and questions around their most 
recent experience of an extreme of mood to inform questions during the telephone-screening interview. 
Participants will also be asked to provide their preferred contact details and their address for 
postage/delivery of the actigraph equipment.  
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STOP-Bang Questionnaire. Participants will be asked to complete the STOP-Bang Questionnaire 
(Chung et al., 2008) as part of screening for eligibility for either the OSA or control group as it is cited as 
one of the best screening tools for OSA (Amra et al., 2018; Vana, Silva & Goldberg, 2013).  
Pittsburgh Sleep Quality Index (PSQI) and Epworth Sleepiness Scale (ESS). Participants will 
also be asked to complete the PSQI (Buysse, Reynolds, Monk, Berman & Kupfer, 1989) and ESS (Johns, 
1991) to further characterise the groups. These scales are two of the most frequently used subjective 
measures of sleep quality (Buysse et al., 2008) and each have been used to characterise groups with 
confirmed OSA (Epstein et al., 2009; Tufik, Santos-Silva, Taddei & Bittencourt, 2010; Vana, Silva & 
Goldberg, 2013), but not for people with a BD diagnosis (Soreca, Buttenfield, Hall & 2015). Therefore, 
characterisation of the groups in the current study using these measures will newly contribute to the 
literature around OSA in people with a BD diagnosis.  
7 Up 7 Down Inventory. Participants will also be asked to complete the 7 Up 7 Down Inventory 
(Youngstrom, Murray, Johnson & Findling, 2013) as it is a brief measure of the severity of experiences 
relating to a diagnosis of BD which will therefore provide a baseline characterisation of this for each group. 
Mini International Psychiatric Interview (MINI). The MINI (Sheehan, 2016) sections A and C 
will be used as part of the telephone-screening interview for all participants to confirm that their past 
difficulties are consistent with the DSM-V (American Psychological Association, 2013) criteria for BD, but 
also that participants are currently “inter-episode” in terms of their difficulties and not currently 
experiencing pervasive extremes in mood. Moreover, Sections I and J of the MINI will be used to assess for 
“alcohol use disorder” and “substance use disorder (non alcohol)” respectively if participants have 
previously confirmed that they drink alcohol or/and use non-prescribed drugs through the initial screening 
questions.  
Structured Clinical Interview for DSM-5 Sleep Disorders (SCISD). The Obstructive Sleep 
Apnoea section of the SCISD (Taylor et al., 2018) will also be administered during the telephone-screening 
interview as part of screening for eligibility for either the OSA or control group as is it consistent with the 
current DSM-V (American Psychological Association, 2013) criteria for OSA.  
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WatchPATTM Oximeter. Whilst the gold standard assessment for OSA is polysomnography 
(Jordan, McSharry & Malhorta, 2014), evidence supports the use of an oximeter in detecting OSA when 
polysomnography is not possible (Mulgrew, Fox, Ayas & Ryan, 2007; Vázquez et al, 2000). An oximeter is 
a device that can be operated at home rather than in a laboratory. The WatchPATTM 200U device (Itamar 
Medical, 2015) measures Peripheral Aterial Tone (PAT), oxygen saturation of the blood and movement 
through a probe worn on the finger connected to a device worn on the wrist while sleeping. Through 
recording these variables, the device calculates a Respiratory Disturbance Index (RDI) according to the 
number of times the variables indicate that the sleeper stopped breathing, had suppressed breathing, or 
experienced a respiratory effort related arousal from sleep, per hour of sleep. The device also estimates the 
person’s Apnoea-Hypopnoea Index (AHI) score, which is a measure of OSA severity comparable with 
polysomnography results. Diagnosis of OSA using WatchPATTM has been found to have good sensitivity 
and specificity for detecting OSA that was then confirmed with polysomnography (Ayas, Pittman, 
MacDonald & White, 2003; Kenny, Christine & David, 2007; Yuceege, Firat, Demir & Ardic, 2013).  
It is possible to assess a subset of nine participants (maximum number possible utilising available 
resources) in the OSA group with the WatchPATTM 200U over night. This will be done to gain a RDI 
measurement for nine participants to further characterise the OSA group. Participants asked will be those 
geographically closest to Lancaster University to reduce necessary time and cost of delivery and collection 
as the chief investigator will deliver the oximeter in order to demonstrate how to fit and use the device and 
answer any questions. The device also comes with clear demonstration card and there is also step by step 
tutorials of how to fit the device online: https://www.youtube.com/watch?v=rckaIg8PHJA. 
GENEActivTM actigraph. Sleep variability will be objectively measured through actigraphy. An 
actigraph is a light, waterproof, watch-like device worn on the non-dominant wrist that monitors movement 
through an acceleration sensor. Research has shown that actigraphy is able to estimate the following sleep 
variables with reasonable accuracy compared to polysomnography (Martin & Hakim, 2011): total sleep time 
(TST), sleep efficiency (SE, percentage of time in bed actually spend asleep) and wake after sleep onset 
(WASO, time spent awake during the night between initially falling asleep and finally waking up), which are 
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relevant variables to OSA monitoring. Participants will be posted (or delivered, depending on geographical 
location) an actigraph device (GENEActivTM Original model (Activinsights, 2017)) and asked to wear it 
continually for a period of two weeks (15 nights) before returning the device. The data collected through the 
actigraphs will provide estimates of variability in TST, SE and WASO for each participant across the two 
weeks of data collection.  
Positive and Negative Affect Scale (PANAS). Participants will be asked to record affect twice on a 
daily basis using the PANAS (Watson, Clark & Tellegen, 1988). The PANAS askes participants to rate how 
much they identify with 10 positive affect adjectives and 10 negative affect adjectives on a scale of 1-5 (1 
being “very slightly/not at all” and 5 being “extremely). The PANAS has been shown to have good 
psychometric properties and has been used in previous research measuring sleep and affect variability in 
participants with a diagnosis of BD (Gershon et al, 2012). 
Participants will be asked to answer the PANAS based on how they feel currently, once in the 
morning (before 13:00) and once in the afternoon/evening (between 13:00 and 24:00). They will be able to 
complete the PANAS online using a computer, laptop, tablet or mobile phone, and will receive an email 
containing the link to each questionnaire. Alternatively, participants can complete the PANAS using a paper 
booklet that they will receive with their actigraph.  
Alongside the PANAS completed in the morning, participants will also be asked to answer three 
questions about their sleep the night before: the time the estimate falling asleep, the time they estimate 
waking up, and to rate the quality of their sleep. Research suggests that the combination of an objective 
measure through actigraphy, corroborated with a subjective, self-report measure, is the most reliable way to 
measure sleep (Kushida et al., 2001). Moreover, estimated sleep and wake times are the two variables 
required by the data analysis software to corroborate the actigraph data and increase the validity of 
interpretations. The three sleep questions will be presented to participants before the morning PANAS 
questions in the paper questionnaire booklet and online. It is expected that each PANAS questionnaire, 
including answering the questions on sleep will take two minutes to complete.  
Procedure 
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Recruitment. Participants will be recruited through advertisement of the study through social media 
(using a dedicated Twitter account @AmyBrow68300074), through emails sent to the Spectrum Connect 
database held by the Spectrum Centre at Lancaster University, and through a poster advertisement placed in 
the premises of the Lancashire Care NHS Foundation Trust (LCFT) Community Mental Health Team 
(CMHT). Clinicians within LCFT CMHT will be contacted by the chief investigator and provided 
information on the study to share, as is felt appropriate, with people eligible for the study that they are 
currently working with.  
All methods of advertising the study will provide participants with an email address for the chief 
investigator and a QR code and link to the online participant information sheet (www.tinyurl.com/OSA-
BDresearch). It will be advertised that participants can email the chief investigator to request a paper copy of 
the participant information sheet to be sent to them in the post if they prefer. Clinicians wit LCFT CMHT 
will be provided with paper participant information sheets to provide to participants if they are interested. 
Both online and paper information sheets inform potential participants of a video version of the information 
sheet that they can watch instead of reading the participant information sheet: https://youtu.be/yFb1jPqsvso. 
Participants are encouraged throughout the information given through the participant information sheet and 
video to email the chief investigator if they have any questions regarding the study.  
Consent. Participants can consent to participate in the study online through clicking through from the 
participant information sheet and completing an online consent form (using a desktop or laptop computer 
only) or through completing a paper consent form and returning to the chief investigator using a pre-stamped 
envelope, depending on their preference. Once participants have consented to take part, they will be invited 
to take part in Step 1 of the study.  
Step 1. Step 1 of the study begins once participants have consented to take part in the study and 
comprises of answering demographic and initial screening questions, the STOP-Bang questionnaire, PSQI, 
ESS and 7 Up 7 Down Inventory. It is anticipated that answering all questions will take participants twenty 
minutes in total.  
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Participants who consent to take part in the study online will be immediately navigated to the first 
page of online questions. Participants can save their progress and return to the online questions later at a time 
that is convenient for them.  
Participants who would prefer a paper copy of the initial questionnaires will be posted these with a 
pre-stamped envelope to return. 
Step 2. Following receiving their responses to the questions asked in Step 1, participants will be 
contacted by the chief investigator (using their preferred method of contact they provide in Step 1) to arrange 
a telephone-screening interview at a time that is convenient for them. Wherever possible, telephone 
interviews will be conducted over Zoom (https://www.zoom.us/) or Skype to minimise telephone costs. 
Zoom is a video conferencing software like Skype that will allow face to face contact with participants, if 
they consent to use the video function, which will enable the chief investigator (who will be conducting the 
telephone interviews) to be more aware of any signs of distress from the participant during the interview and 
able to adapt the process accordingly. If participants opt out of the video function on Zoom, the software acts 
like a telephone call. Zoom requires participants to have access to a smart phone, tablet, computer or laptop 
with at least a microphone if not also a camera. Participants will receive a link via email and will not require 
login credentials to use the software. However, Skype calls can be conducted if participants would prefer. If 
participants would prefer to be contacted telephone, the interview will be conducted using a landline 
telephone in a private room at Lancaster University. These interviews will be offered during the day or early 
evening to fit around participants’ commitments.  
During the telephone-screening interview, participants may be asked to clarify answers that they 
provided to questions during Stage 1 if their answers suggest they may not be eligible for the study. All 
participants will be interviewed using Section A and C of the MINI and the Obstructive Sleep Apnoea 
Syndrome section of the SCISD. If a participant’s responses during Step 1 indicate that they drink alcohol 
and/or take non-prescribed substances, sections I and/or J of the MINI will also be administered accordingly. 
Participants will also be invited to ask any questions about the study that they may have. Telephone-
screening interviews should take no longer than 45 minutes.  
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Following the telephone-screening interview, the chief investigator will seek supervision around any 
potential participants for whom it is unclear if they are eligible to participate based on the information they 
have provided. The chief investigator will then contact participants using their preferred method of contact, 
either to make arrangements for Step 3 of the study or to explain that the responses they have given suggest 
that they are not eligible to continue participating in the study. Everyone who is not able to continue 
participating in the study will be invited to leave an email or postal address to be sent a non-scientific report 
of the study once the study is completed and will be given the option to withdraw their data. People 
continuing to participate will be told which group they have been assigned to based on their responses.  
Step 3. Nine participants in the OSA group who are geographically closest to Lancaster University 
will be invited to undergo the overnight oximeter test. If the participants who are geographically closest 
decline, then the next closest participants will be invited to undergo the test if it is still feasible for the chief 
investigator the deliver and collect the oximeter to the participants’ homes. For participants who undergo the 
overnight test, the chief investigator will deliver the oximeter to the participant’s home, at a time suitable for 
them, and provide instructions on how to operate it. The chief investigator will then leave the oximeter with 
the participant and return the next day to collect it at a convenient time for the participant. Participants will 
then be given their actigraph by the chief investigator to begin wearing for two weeks (15 nights), along with 
the paper questionnaire booklet if they wish to use this to complete the twice-daily questionnaires.  
Participants not completing the overnight test will either be posted their actigraph to a convenient 
location for them or delivered it by the chief investigator (depending on geographical location). Participants 
will be asked to begin wearing their actigraph once they receive it and to begin completing the twice-daily 
questionnaires the next morning. The actigraphs will be programmed to be already measuring movement 
when participants receive them so that participants do not need to do anything more than put them on. Data 
collection will begin from the night preceding the first morning questionnaire that participants’ complete and 
end after 15 nights in total, all other data will be deleted.  
Once participants have worn their actigraphs for two weeks (15 nights), the chief investigator will 
contact them using the preferred method of contact to arrange either collection or free postage of the 
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actigraph from where they collected it (depending on how they received the actigraph). At the end of the 
final afternoon questionnaire, participants are invited to leave any comments or feedback on the study. All 
participants will be invited to leave an email or postal address to receive a non-scientific report of the study 
findings.  
Prize draw. The prize draw for a £50 Amazon voucher will be conducted once all participants have 
completed the study. All participants who wear the actigraph for two weeks (15 nights) and complete at least 
the first morning questionnaire will be entered. A name will be drawn at random by the chief investigator 
and that person will be contacted to arrange receipt of their prize. Should the winner not be contactable 
within a reasonable amount of time, names will continue to be drawn until the prize is accepted.  
Analysis. Preliminary analyses of between group comparisons based on demographic and clinical 
data collected at baseline will be conducted using descriptive statistics and parametric tests (e.g. t-tests) or 
appropriate non-parametric tests if data is not normally distributed. This will be to determine if there are 
significant differences between the groups at baseline that may have impacted on sleep and affect variability.  
Descriptive/exploratory analyses will also be conducted to evaluate average characteristics of the 
sleep (subjective and objective) and affect data collected for each group. Actigraph data will be analysed 
using GGIR package in R (van Hees et al., 2019). 
Measures of instability in sleep and affect recordings will be calculated using the mean squared 
successive difference (MSSD; Jahng, Wood & Trull, 2008) index as done by Gershon and colleagues 
(2012), based on recommendations for use of this index in prospective measurement of affect for people 
with a diagnosis of a mood cycling condition such as BD (Ebner-Priemer, Eid, Kleindienst, Stabenow & 
Trull, 2009). MSSD differences between groups will be explored using generalised multilevel modelling 
(Jahng, Wood & Trull, 2008). 
The probability of acute change (PAC; Jahng, Wood & Trull, 2008) index, which is similarly 
recommended for use in capturing affect instability for people with a diagnosis of a mood cycling condition, 
will be calculated and explored between groups using generalised multilevel modelling.  
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MSSD and PAC indices are recommended as measures of affect instability as they account for both 
variability and temporal dependency in a time series and have been found to capture affective instability 
better than other indices (Jahng, Wood & Trull, 2008).  
Analysis will be conducted using R software (van Hees et al., 2019) and SPSS. 
Dissemination. It is intended that the findings will be submitted for publication in an academic 
journal (e.g. Bipolar Disorders or Journal of Affective Disorders) and that findings may potentially be 
presented at a peer review conference. The chief investigator will produce a free, non-scientific report of the 
findings that will be available for anyone who is interested and those participants who have said they would 
like to receive one. The study findings will also be disseminated during the thesis presentation day organised 
by the Lancaster Doctorate in Clinical Psychology course. 
Consultation with Experts by Experience 
A panel of three experts by experience (people with a bipolar disorder or manic depression 
diagnosis), organised through the Spectrum Centre at Lancaster University, were consulted on the 
advertisement materials, participant information sheet and methodology of the study. The advertisement 
materials and participant information sheet have been adapted according to feedback. This involved 
specifying more clearly the expected time commitment of participants in each step and highlighting the 
benefits that participating in research can have. All three experts by experience felt that the design of the 
methodology of the study was acceptable and that they would participate in the study if they met the 
requirements.  
Practical Issues 
The Lancaster University Doctorate in Clinical Psychology department has accepted application for 
the funds necessary to complete the study. Permission for use of copyrighted measures has been sought 
where necessary. The licences for all the necessary statistical analyses and for the online platform to deliver 
questionnaires electronically (REDCap) are already available through Lancaster University.  
Ethical Considerations 
Risk to participants 
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It is hoped that the study may support people of moderate to high risk of OSA to recognise this and 
to seek advice from their GP. When participants are identified as having suspected OSA, they will be made 
aware of this and encouraged to see their GP. They will be provided with a letter to show to their GP that 
explains a little about the study and why the person is suspected to have OSA. Whilst it is considered that the 
study should pose little to no risk to participants, contact numbers and websites are provided to participants 
in case of distress. It is recognised that the study requires a twice-daily commitment from participants for 
two weeks in addition to the screening measures. Completion of all twice-daily measures during the two 
weeks is not mandatory and all participants who wear the actigraph for two weeks (15 nights) and complete 
at least the first morning questionnaire will be entered into the prize draw.  
Risk to researcher 
The chief investigator will need to visit participants at home to deliver and explain how to use the 
oximeter and deliver actigraphs. The LCFT lone worker policy will be followed in order to ensure the safety 
of the chief investigator. This will involve the details of the visit (e.g., participant, date, time, location) being 
shared with one of the two supervisors within the research team. They will telephone or text the supervisor 
of the team when the visit is concluded. If this telephone call/text does not take place, attempts will be made 
to contact the chief investigator. If contact cannot be made, the appropriate authorities will be informed. 
Risk to equipment  
The equipment being provided to participants is expensive. Where actigraphs are posted this will be 
done using signed for delivery using a private courier. Participants will be asked to confirm that they are 
prepared to take care of the equipment and return it at the end of the data collection period. However, it is a 
recognised risk that equipment may be damaged or lost. In the event that equipment is damaged or lost, 
participants will be assured that this is a recognised risk and their participation will not necessarily be 
affected. The study has access to 40 actigraphs in total but it is the intention that not all actigraphs will be 
used at once to ensure that there are replacements available to participants in the event of the equipment not 
working or accidental loss or damage. Participants will not be held liable for any unintended loss or damage 
of the equipment.  
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Confidentiality and Anonymity 
The personal information that participants provide will be kept confidential. The data collected for 
this study will be stored securely and only the researchers conducting this study will have access to 
the raw data.  
• Personal data will be kept separately from all other data. REDCap marks personal data to ensure that 
is not transferred when data is exported from REDCap to data analysis software (e.g. SPSS), 
replacing it instead with a participant ID assigned in REDCap.  
• Paper copies of questionnaires will be kept in a locked cabinet at Lancaster University for 10 years or 
10 years from publication, whichever is the longer, and then destroyed.  
• Consent forms and anonymised data will be kept for 10 years after the study has finished and will 
then be deleted or destroyed.  
• Online consent forms and questionnaires will collect and initially store data through the secure data 
collection platform, REDCap, which only the researchers conducting the study have access to.  
• Electronic personal data will be later be kept securely on the university secure network.  
• Personal contact details will be kept for 6 months following the study finishing and they will then be 
deleted or destroyed. Files held on the computer will be encrypted (meaning no one other than the 
researchers can access them) and the computer itself will be password protected.  
Approximate Timescale 
July 2019: Submit ethical application and HRA application  
 
September 2019 – February 2020: Recruitment and data collection  
 
March 2020 – May 2020: Data analysis and write up 
 
May 2020:  Submit project as part of DClinPsy thesis (it is intended that the project will be ready for 
submission in May 2020, however if there are unforeseeable delays in the project it is possible that the 
submission deadline can be extended until August 2020). 
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May 2020 – August 2020: Dissemination of findings  
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PARTICIPANTS NEEDED FOR A STUDY OF OBSTRUCTIVE SLEEP APNOEA 
AND MOOD FOR PEOPLE WITH A BIPOLAR DISORDER DIAGNOSIS 
 
• A quarter (1/4) of people with a bipolar disorder diagnosis may have obstructive 
sleep apnoea, a condition where breathing stops during the night, interrupting sleep. 
• Obstructive sleep apnoea might increase mood changes for people with a bipolar disorder 
diagnosis. If we find this, this could lead to better diagnosis and treatment of obstructive 
sleep apnoea for people with a bipolar disorder diagnosis, improving people’s lives. 
• Some signs of obstructive sleep apnoea are loud snoring, night time snorting/gasping and 
feeling very tired in the day. However, some people do not know they have sleep apnoea. 
• Risks of obstructive sleep apnoea include being: male, over 40 and overweight. 
 
 You are invited to participate if you: 
• Have a diagnosis of bipolar disorder or manic depression 
• Are between 30 and 60 years old 
• Live in North West England 
 
You DO NOT need to have sleep apnoea. Participants will be asked questions through 
questionnaires and a brief phone conversation to see if they might have obstructive sleep 
apnoea. We are hoping to recruit 20 people who might have obstructive sleep apnoea, or 
already know they have, and 20 people who are not likely to have obstructive sleep apnoea.  
 
Nine people will be invited to take part in an overnight test to look for signs of sleep apnoea.  
 
You will be asked to wear a watch-like device to monitor movement and sleep for two weeks.  
You will also be asked to answer a short questionnaire twice a day for two weeks using your 
phone/tablet/computer or a paper diary. The questionnaire asks how you feel and about your 
sleep the night before (morning only) and should take you around 2 minutes to complete. 
 
Prize draw to win a £50 Amazon voucher for participants completing the study. 
 
For more information, or to take part, go to: www.tinyurl.com/OSA-BDresearch 
 
Or, please contact Amy Brown, Chief Investigator on a.brown21@lancaster.ac.uk 
 
This study has been sponsored by the Lancaster University Faculty of Health and Medicine Research Ethics Committee and has been 
reviewed and approved by the NHS Research Ethics Service, part of the Health Research Authority. IRAS project ID: 240867. If you wish to 
make a complaint or raise any concerns about this research and do not want to speak to the Chief Investigator, please contact Dr Ian Smith, 
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Participant Information Sheet 
 
Title of research: 
Impact of obstructive sleep apnoea for people 
with a bipolar disorder diagnosis 
 
 
My name is Amy Brown and I am conducting this research at Lancaster University, 
Lancaster, UK, as part of training to become a clinical psychologist.  
 
This page aims to give you the main information about the study. Please take your time to 
read and understand the information, and discuss it with others if you wish.  
 
You can watch an online video of me explaining the information on this page using the 
following link: https://youtu.be/yFb1jPqsvso 
 
It is important that you understand why the research is being done and what it would 
involve from you before deciding whether you would like to take part in the study. 
 
 If you have any questions, please email me on a.brown21@lancaster.ac.uk. 
 
What is the study about? 
 
This study hopes to find out if obstructive sleep apnoea might be increasing changes in 
mood for people with a bipolar disorder diagnosis.  
 
A quarter (1/4) of people with a bipolar disorder diagnosis may have obstructive sleep 
apnoea, a condition where breathing stops during the night, interrupting sleep. 
 
If we find that obstructive sleep apnoea is linked to increased mood changes for people 
with a bipolar disorder diagnosis, this could lead to better diagnosis and treatment of 
obstructive sleep apnoea for people with a bipolar disorder diagnosis, improving people's 
lives.  
 
This research is being conducted with help from services within Lancashire Care NHS 
Foundation Trust who work with people with a bipolar disorder diagnosis in the hopes that 
the findings will help inform the support that people are given.  
 
What is obstructive sleep apnoea? 
 
Obstructive sleep apnoea is a condition where the throat muscles relax during sleep, 
narrowing the air way and stopping breathing for 10 seconds or more.  
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The sleeper wakes up a bit to start breathing again. However, the sleeper usually does not 
wake up enough to remember this.  
 
Some people do not know they have obstructive sleep apnoea but might be told that they 
snore loudly, gasp or snort in their sleep.  
 
People with obstructive sleep apnoea are likely to feel very tired during the day and some 
might sweat a lot at night and/or wake up a lot to go to the toilet. 
 
Some things that put people at risk of obstructive sleep apnoea are if they:  
• are overweight  
• are male 
• are over 40 years old 
• have a neck 43cm/17 inches or larger (41 cm/16 inches for women) 
• take medications that make them sleepy 
• smoke 
• drink alcohol (especially at night) 
 
For more information on obstructive sleep apnoea, including risk factors and 




Why research obstructive sleep apnoea and people with a bipolar disorder 
diagnosis? 
 
How well we sleep impacts on our mood. People with obstructive sleep apnoea are often 
very tired during the day and can feel low in mood. 
 
People with a bipolar disorder diagnosis are believed to experience more changes in how 
well they sleep as well as more changes in their mood compared to people without a 
bipolar disorder diagnosis.  
 
It is likely that people with a bipolar disorder diagnosis and obstructive sleep apnoea will 
experience even more changes in their mood, but no research has looked at this so far.  
 
Learning more about how obstructive sleep apnoea might impact changes in mood for 
people with a bipolar disorder diagnosis will hopefully be helpful to them and the people 
who support them. 
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Research findings may lead to more people with a bipolar disorder diagnosis being found 
to have obstructive sleep apnoea. This could mean they can be supported to sleep better 
to decrease changes in their mood.  
  
The study is not looking at solutions to snoring problems. 
 
Who can take part in the study? 
 
We are looking for volunteers who have a bipolar disorder diagnosis (or a manic 
depression diagnosis), who are between 30 and 60 years old and who live in North West 
England. 
 
You do not need to have obstructive sleep apnoea to take part. 
 
We are hoping to recruit 20 people who may have, or know they have, obstructive sleep 
apnoea, and 20 people who do not.  
 
People taking part need to start when they are not currently feeling really high or low in 
mood. 
 
People who have more than one mental health/psychiatric diagnosis can take part if they 
feel that bipolar disorder is their primary diagnosis (this means that it is the diagnosis given 
to the experiences that you find to be most noticeable, distressing or disabling).  
 
Does anything mean I cannot take part? 
 
You cannot take part if you:  
• work night shifts 
• regularly travel overseas 
• are currently jet-lagged 
• are likely to be disturbed at night (e.g. live with a child under 1 year old) 
• have had a brain injury 
• have a neurodegenerative condition (e.g. dementia or Parkinson's) 
• have received treatment for obstructive sleep apnoea and no longer have symptoms 
(e.g. you no longer gasp at night and/or don't usually feel tired during the day) 
 
• drink alcohol or caffeine or take drugs in a way that may impact on your sleep - you 
will be asked to give information on your alcohol/caffeine/drug intake 
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• are taking part in a drug trial  
• are unable to move most of your body  
 
If you have any questions about whether you can take part, please don't hesitate to ask me 
on a.brown21@lancaster.ac.uk 
 
Do I have to take part? 
 
No. It's completely up to you to decide whether or not you take part. Your decision will have 
no negative effect on any care that you are receiving now or may receive in the future. 
 
If you decide to take part in the study, you may stop taking part in the study at any point, 
but this DOES NOT mean your data will be withdrawn.  
 
If you would also like to withdraw your data from the study, please email me on 
a.brown21@lancaster.ac.uk to request that your data is withdrawn. It will be possible to 
withdraw your data for at least 10 days following the end of your participation in the study. 
 
If you become unwell during the study and you are considered to lose capacity to consent 
to continue to take part, you will be withdrawn from the study but your data collected up 
until that point will be kept.  
 
What will I be asked to do if I take part? 
 
Step 1  
 
If you consent to take part, you will be asked to provide some information about yourself 
and complete 4 questionnaires. You will only have to answer these questions once. 
 
You can complete these questionnaires online using a desktop computer or laptop. 
Unfortunately you cannot complete these questionnaires using a tablet or mobile 
phone.  
 
Paper copies can be posted to you with a stamped envelope to return them if you prefer.  
 
Answering all the questions should take up to 20 minutes and can be done from home at 
a time that is suitable for you. You do not have to answer all the questions at once, you can 
save your answers and come back another time. 
 
The questions will ask you about your sleep, your mood, and your risk of obstructive sleep 
apnoea. In order to work out your risk of obstructive sleep apnoea, you will be asked to 
give your height (in feet and inches), weight (stone and pounds) and neck measurement 
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Step 2  
 
I will contact you (using your preferred method of contact) to arrange a call over the phone, 
Skype or Zoom.  
 
Skype and Zoom are online ways of making calls for free. Zoom is like Skype but easier as 
you do not need a login, username, or need to download any software. To use Zoom, you 
can just click on a link that is emailed to you to start the conversation, which is then like a 
telephone/Skype call. 
 
If you prefer, I can call you using Skype or on the phone using your landline/mobile 
number. 
 
During the call I will ask you about your mood and experiences relating to your bipolar 
disorder diagnosis (or manic depression diagnosis), and also about any symptoms of 
obstructive sleep apnoea that you might have.  
 
This call should last no more than 45 minutes, and can be held at time that is most 
convenient for you. 
 
Shortly after this call, I will contact you to confirm if it is possible for you to continue with the 
study. If it is not, this will be because information you have provided matches one or more 
of the reasons why people cannot take part. You will be invited to leave your contact 
details to be emailed a non-scientific report of the study findings. You will also be asked if 
you are happy for us to keep the information that you have provided so far, which will be 
anonymised and therefore not be identifiable to you.   
  
Step 3  
 
If it is possible for you to continue take part, you will be asked to wear a watch-like device 
called an actigraph for 2 weeks (15 nights). The actigraph measures movement to decide if 
you are asleep or awake.  
 
An actigraph has no screen and you will not need to charge it or learn how to use it. 
Depending on where you live, I will either deliver an actigraph to you or post it to a local 
collection point where it is convenient for you to collect.   
 
Once you have received the actigraph, all you will need to do is wear it on your non-
dominant wrist (the wrist of the hand you do not write with). Actigraphs are completely 
waterproof so do not need to be taken off to play sport, shower, bath or go swimming. We 
ask that you do not remove the actigtaph for two weeks, including to go to sleep. 
 
Whilst you are wearing the actigraph, you will be asked to complete one short 
questionnaire, two times a day. The questionnaire will ask you how you feel and 
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(morning questionnaire only) what time you think you fell asleep the night before and what 
time you think you woke up that morning.  
 
The questionnaire should take you 2 minutes to complete. These questionnaires can be 
completed on your computer, mobile phone or tablet, or using a paper questionnaire 
booklet.  
 
You will be emailed a link to complete the questionnaires online, and a paper diary will be 
delivered along with your actigraph so you can choose how to complete the 
questionnaires. Please complete the questionnaires in the same way throughout the two 
weeks.  
 
You do not have to complete all the questionnaires. If you miss a questionnaire, this does 
not matter, and you will be asked not to fill out missed questionnaires at a later point. If you 
complete the questionnaires online, the links will expire after a certain number of hours. 
 
What happens after two weeks? 
 
After two weeks (15 nights), you will either be asked to return your actigraph (and your 
paper questionnaire booklet if you completed it) to the collection point to post it back for 
free, or I will collect it from you.  
 
Then you will have completed the study! 
 
What if the information I provide suggests I might have obstructive sleep 
apnoea? 
 
I will let you know if you may have obstructive sleep apnoea. This will be based on the 
information you will have provided in steps 1 and 2.  
 
One of the online questionnaires will automatically tell you whether you are at low, 
moderate or high risk of obstructive sleep apnoea based on the answers you provide. 
 
If it looks like you may have obstructive sleep apnoea, you will be given a letter explaining 
this to show to your GP.  
 
The researchers of this study are not qualified to diagnose obstructive sleep 
apnoea. 
 
If it is considered in this study that you may/may not have obstructive sleep apnoea (based 
on the information that you provide), there is no guarantee that you do/do not have 
obstructive sleep apnoea, or that this might not change in the future. 
  
The overnight test 
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9 people who may have obstructive sleep apnoea will be invited to do an over night test 
using a device called an oximeter.  
 
This means wearing a plastic tube on the end of one of your fingers, and a small, flat, 
microphone on your chest, over night. The finger tube and chest microphone are attached 
by thin wires to the oximeter device which you wear like a watch.  
 
The oximeter device monitors the oxygen levels in your blood over night using infrared 
light. The microphone detects snoring and/or gasping.  
 
If your blood oxygen levels regularly dip during the night and you snore and/or gasp loudly, 
this suggests you might have obstructive sleep apnoea. 
 
The test does not involve needles. The equipment is comfortable to wear and the oximeter 
does not make any noise.  
 
You do not have to have an overnight test with the oximeter. Not everyone will be invited to 
do the overnight test due to there being limited equipment. 
 
If you are invited to do the overnight test and are happy to do so, I will deliver and collect 
the oximeter to and from your home at times convenient for you. 
 
I will show you how to use it and also give you written instructions. There are also videos 
online to help you. Please use this link to see a video about using an oximeter: 
www.youtube.com/watch?v=NG0bhGBVWYA. 
 
If you do the overnight test, I will share the results with you and let you know if they 
suggest you might have obstructive sleep apnoea or not. Again, you will not receive a 
diagnosis of obstructive sleep apnoea from the researchers of this study but may be 
advised to see your GP if you haven't already. 
 
You will be invited to do the overnight test between step 2 and step 3 of the study. 
Whatever the results of the overnight test, you will be invited to continue to step 3 of the 
study. 
 
What if the information I provide suggests I don't have obstructive sleep 
apnoea? Or what if I do not do the over night test? 
 
If the information you have provided does not suggest that you have obstructive sleep 
apnoea, you will not be invited to do the overnight test. Due to limited equipment, not 
everyone who may have obstructive sleep apnoea (based on their information) will be 
invited to do the over night test. 
 
If you do not do the overnight test for whatever reason, you will be invited to continue to 
step 3 of the study. 
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Are there any benefits to taking part? 
 
Taking part in the study will mean contributing to potentially improving understanding and 
support of difficulties experienced by people with a bipolar disorder diagnosis.  
 
It is hoped that the findings may lead to increased diagnosis and treatment of obstructive 
sleep apnoea for people with a diagnosis of bipolar disorder, improving people's lives. 
 
Participants who complete the full study will also be entered into a prize draw for a £50 
Amazon voucher. The draw will happen when all participants have finished taking part in 
the study and the winner will be contacted using their preferred contact information that 
they provided for the study.  
 
All participants, including people who consent to participate but are told that they cannot 
continue participating, can be sent a non-scientific report of the study's findings.  
 
Are there any risks? 
 
There are no expected risks with participating in this study. However, if you experience any 
distress, you are encouraged to inform me (Amy) or someone on the research team, and 
contact the resources provided at the end of this information sheet. 
 
What will happen to the results? 
 
The results will be analysed and be written into a scientific report for my thesis, which will 
be submitted for examination as part of my final doctorate evaluation. This may also be 
submitted for publication in an academic or professional journal.  
 
I will also write a non-scientific report and can send this to all participants who are 
interested. 
 
Will my data be identifiable? 
 
No. The information you provide is anonymous. No identifiable information (e.g. any 
names, date of birth and other information that might identify you) will be reported in the 
final report.  
 
How will my data be kept? 
 
The data collected for this study will be stored securely and only the researchers 
conducting this study will have access. This means me (Amy) and my supervisors. 
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All your personal data (name, date of birth and address) will be confidential and will be kept 
separately from your questionnaire responses, actigraph data (and oximeter data if 
relevant), making this other information anonymous.  
 
Any personal data on paper will be kept in a secure locked location on the university 
premises. Electronic personal data will be kept securely on the university secure network.  
 
Your personal contact details will be kept for 6 months following the study finishing and 
they will then be deleted or destroyed. Consent forms and anonymised data will be kept for 
10 years after the study has finished and will then be deleted or destroyed. 
 
Lancaster University will be the data controller for any personal information collected as 
part of this study.  
 
Under the GDPR (General Data Protection Regulation) you have certain rights when 
personal data is collected about you.  
 
You have the right to access any personal data held about you, to object to the processing 
of your personal information, to correct personal data if it is inaccurate, the right to have 
data about you erased and, depending on the circumstances, the right to data portability 
(to move your data from one data controller to another).  
 
Please be aware that many of these rights are not absolute and only apply in certain 
circumstances. If you would like to know more about your rights in relation to your 
personal data, please speak to me (Amy, a.brown21@lancaster.ac.uk). 
 
For further information about how Lancaster University processes personal data for 




Who has reviewed this project? 
 
This study has been sponsored by Lancaster University and has been reviewed and 
approved by the NHS Research Ethics Service, part of the Health Research Authority. 
 
How do I consent to take part? 
 
If you decide to take part, you can follow the link at the bottom of this page to an online 
consent form. If you would prefer a paper consent form to be posted to you (with a 
stamped envelope to return) please email a.brown21@lancaster.ac.uk to request this.  
 
If you consent to take part, you will also be asked to provide your preferred contact details 
so that I can contact you for Step 2 of the study. 
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Where can I get further information about the study? 
 




Department of Clinical Psychology 
Furness Building  






If you wish to make a complaint or raise concerns about any aspect of this study and do 
not want to speak to me, you can contact: 
 
Dr Ian Smith 
Tel: +44 (0)1524 592282  
Research Director 
Email: i.smith@lancaster.ac.uk 
Division of Health Research 
Faculty of Health and Medicine  




If you wish to speak to someone outside of project team, you may also contact: 
 
Professor Roger Pickup 
Tel: +44 (0)1524 593746  
Associate Dean for Research 
Email: r.pickup@lancaster.ac.uk 
Division of Biomedical and Life Sciences 
Faculty of Health and Medicine 




Resources in the event of distress  
 
We are not expecting this study to cause you any distress.  
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However, if you do experience distress following your participation in the study, we advise 
you to contact your GP and/or your mental healthcare provider, who can offer guidance 
and advice to best manage this. 
 
Here is a useful resource you can access if you feel distressed:  
 
Mind UK 
You can contact Mind UK via email, phone, text, post or by visiting your local branch. 
Email: info@mind.org.uk 
Telephone: 0300 123 3393 
Text: 86463 
Address: Mind Infoline, Unit 9, Cefn Coed Parc, Nantgarw, Cardiff, CF15 7QQ 




In case you want more information on obstructive sleep apnoea, the NHS website 
has some helpful information: 
 





Thank you for reading this information sheet. Please use this URL if you are 
interested in participating and are happy to proceed online: 
https://tinyurl.com/OSA-BDresearch  
or contact a.brown21@lancaster.ac.uk to request a paper consent form if you 
do not have one already.  
 
If you do proceed online please only do so using a desktop or laptop 
computer, not a mobile phone or tablet.  
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Participant consent form 
 
By signing below, I, (your full name)___________________________________, confirm that: 
 
 Please write your initials in 
each box to confirm you 
understand and agree 
 
1) I have read the information sheet and fully understand what is 
expected of me within this study; 	  
2) I understand that my participation is voluntary and that there are 
no guaranteed rewards for taking part in the study; 
 
 




4) I consent to Lancaster University to keep my anonymised data 
for a period of 10 years after the study has finished; 
 
 
5) I consent to my data being used for these research purposes 
unless I take the necessary 
steps to withdraw my data from the study;  
 
 
6) I understand that I may stop the study at any point, but this does 
not mean that my data will be withdrawn. If I would also like to 
withdraw my data from the study, I will email the main researcher, 
Amy Brown, at a.brown21@lancaster.ac.uk and request to 
remove my data; 
 
 
7) I understand that I must take reasonable care of the study 
equipment and return it at the appropriate time; 
 
 













Please use the addressed and stamped envelope that was enclosed with this 
form to return your completed consent form.  
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Dear [name of participant], 
 
Thank you for participating in our study. 
 
For Step 1 the study, please answer the questions on the following pages.  
 
The first 4 pages ask for some information about you and then there are 4 questionnaires.  
 
There is also a page explaining how to work out your Body Mass Index as one of the 
questionnaires asks about this. If you have any problems with working out your Body Mass Index, 
please don’t hesitate to email me on a.brown21@lancaster.ac.uk. 
 
You do not have to answer all the questions at once. You can answer the questions when it is 
most convenient for you.  
 
Once you have finished answering the questions, please use the enclosed addressed and 
stamped envelope to return your questionnaires and I can then contact you using your preferred 
method of contact once I have received them. 
 
If you have any questions, please feel free to email me on a.brown21@lancaster.ac.uk. 
 
Thank you once again for participating; your time is really appreciated. 
 















Trainee Clinical Psychologist 
Department of Clinical Psychology 








RE: Name of person, address 
 
The above named person has consented to participate in a research study that is investigating the 
impact of obstructive sleep apnoea for people with a bipolar disorder diagnosis. Their responses to 
the STOP-Bang questionnaire and Structured Clinical Interview for DSM-5 Sleep Disorders 
suggest that they may have obstructive sleep apnoea. Their scores were X and X respectively.   
 
[They also underwent an overnight test using an oximeter. The outcome of this test also suggests 
this person may have obstructive sleep apnoea. The test outcomes were an Apnoea-Hypopnoea 
Index (AHI) of X and a Respiratory Disturbance Index (RDI) score of X. The AHI indicates the 
number of apnoeas or hypopnoeas detected per hour and the RDI indicates the number of 
apnoeas, hypopnoeas and any other respiratory disturbance of sleep per hour.] (This paragraph 
will not be applicable for all participants). 
 
More details of the study are available via the online information sheet: 
http://www.tinyurl.com/OSA-BDresearch/.  
 
If you have any queries about the study please do not hesitate to contact me. Alternatively you 








Trainee Clinical Psychologist 
 
Supervised by Dr Guillermo Perez-Algorta 
The Spectrum Centre and Department in Clinical Psychology 
Division of Health Research  
Lancaster University  
LA1 4YW 
g.perezalgorta@lancaster.ac.uk 
